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Systemic lupus erythematosus (SLE) is a chronic autoimmune disease where failure 
to remove apoptotic cells, due to a defect in phagocytic cells, or deficient 
opsonisation, leads to secondary necrosis and the release of DNA and chromatin. The 
nuclear constituents from apoptotic cells are targeted by autoantibodies, which form 
immune complexes. Immune complex-mediated TLR9 activation of plasmacytoid 
dendritic cells (pDCs) and subsequent secretion of interferon (IFN-α) is thought to 
drive inflammation in SLE. It is currently believed that pDCs do not normally 
respond to apoptotic cells, as self-DNA is hidden from TLR9. However, DNA and 
chromatin expressed on membrane bound apoptotic bodies is essential for inducing 
IL-10 secreting regulatory B cells through TLR9 stimulation. The overall objective 
of this thesis was to understand how apoptotic cells influence immune responses in 
health and in patients with SLE.  
 
Splenic mouse pDCs were activated with the synthetic TLR7 agonist R848 and 
TLR9 agonists CpGB and CpGA and were co-cultured with apoptotic cells, or with 
freeze-thawed necrotic cells. PDCs co-cultured with apoptotic cells down-regulated 
the expression of CD40 and CD86. When pDCs were activated by R848 or CpGB, 
IL-10, IFN-γ and IL-6 secretion was significantly induced in the presence of 
apoptotic cells. PDCs so cultured induced T cells to secrete immune-regulatory IL-
10. In contrast, co-culturing apoptotic cells with pDCs activated by CpGA, 
augmented IFN-α secretion. These cytokine responses by pDCs were only stimulated 
by DNA on whole apoptotic cells; not by free nucleic acids derived from necrotic 
cells.  
 
This data demonstrates that the inflammatory context in which pDCs sense whole 
apoptotic cells is crucial to determining the threshold of tolerance to apoptotic self. It 
questions the perception that pDCs see all apoptotic cells and their necrotic cellular 
debris as dangerous and suggests that there may be something intrinsically different 
about SLE apoptotic cells, which causes inflammation. SNPs near ATG5, a protein 




the role of autophagy in SLE pathogenesis is unclear. We hypothesised that 
dysfunctional autophagy is linked to abnormal apoptosis of SLE lymphocytes.  
 
Western blotting revealed that ATG5-ATG12 protein complex expression was 
significantly reduced in SLE lymphocytes and they failed to convert LC3-I to LC3-
II, the hallmark of a functioning autophagy pathway, which caused accelerated 
secondary necrosis. Apoptotic SLE lymphocytes had an impaired ability to stimulate 
IL-10 secreting regulatory B cells and they induced pro-inflammatory cytokine 
secretion by monocyte-derived macrophages. Phagocytosis of apoptotic SLE 
lymphocytes by healthy macrophages was also impaired; however this was 
independent of ATG5 protein expression. The novel findings of this thesis suggest 
SLE apoptotic lymphocytes are intrinsically pro-inflammatory, which may be caused 
by diminished autophagy leading to an inability of lymphocytes to correctly execute 
apoptosis. Furthermore, inefficient clearance of SLE apoptotic cells results from a 



















In our bodies millions of cells die naturally every day by a regulated process called 
apoptosis. Apoptotic cells must package their inner contents, including genetic 
material called DNA and chromatin, in to small membrane enclosed apoptotic 
bodies. This is important to ensure that apoptotic cells are quickly removed by being 
eaten by immune cells called phagocytes, and it is also essential for actively inducing 
immune cells to make proteins called anti-inflammatory cytokines, such as 
interleukin (IL)-10. In the complex disease systemic lupus erythematosus (SLE), it is 
thought that the phagocytes are unable to clear away apoptotic cells. The apoptotic 
cell membrane then breaks apart and the body’s immune system mounts a self-
inflammatory attack against the freely released DNA and chromatin.  
 
A small population of immune cells, the plasmacytoid dendritic cells (pDCs), are key 
drivers of inflammation in patients with SLE. PDCs are specialised to respond to 
genetic material from virus infections by making lots of the pro-inflammatory 
cytokine interferon (IFN)-α. It is considered that pDCs do not usually respond to 
apoptotic cell-derived DNA and chromatin because the receptors required to do so 
are “hidden” inside the cell. However, in SLE, pDCs are activated to make IFN-α by 
self-DNA and chromatin released from apoptotic cells because it is attached to 
antibodies. In this thesis I wanted to find out if and how pDCs normally respond to 
apoptotic cells.  
 
Here I showed that activated mouse pDCs were stimulated to secrete the anti-
inflammatory cytokine IL-10, and they induced immune cells called T cells to 
produce IL-10, in response to DNA from whole apoptotic cells, but not from 
apoptotic cells that were broken apart. Whereas when pDCs were co-activated with a 
viral mimic, the secretion of IFN-α, but not IL-10, was increased by apoptotic cell-
derived DNA. This suggests that the inflammatory environment in which pDCs sense 
apoptotic cells is important for determining the level of tolerance to apoptotic self. 




dangerous, and it suggests that inflammation might be caused by the way that SLE 
cells die. 
 
It is known that the cell survival pathway (called autophagy) is linked to SLE, but it 
is not clear what role autophagy plays in the disease. Here I found that SLE 
lymphocytes (T cells and B cells) isolated from the blood of SLE patients expressed 
less of the essential autophagy protein, ATG5, compared to healthy lymphocytes and 
this resulted in malfunctioning autophagy. As a result, SLE lymphocytes died rapidly 
and the cell membrane quickly began to break apart. SLE phagocytes had the same 
ability as healthy phagocytes to eat healthy apoptotic cells; however the ability of 
both healthy and SLE phagocytes to eat SLE apoptotic cells was significantly 
reduced. This indicates that the elimination defect in SLE may originate from the 
apoptotic cells, rather than as a result of dysfunctional phagocytes. Although less 
SLE apoptotic cells were eaten, they induced a pro-inflammatory response by the 
phagocytes. 
 
The data in this thesis suggests that pDCs can generate an anti-inflammatory 
response to apoptotic cell-derived DNA, but this is prevented in the context of 
inflammatory stimuli. SLE lymphocytes die abnormally, and this appears to be 
caused by a defect in the autophagy pathway. Importantly, although SLE phagocytes 
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Chapter 1: Introduction 1 
Chapter 1 Introduction 
The immune system has evolved a complex network of cells consisting of the innate 
(nonspecific) and adaptive (specific) arms, which work together to remove infectious 
pathogens and restore homeostasis. It is important that immune cells distinguish 
“self” from “non-self” to prevent destructive inflammation. The process of cell death 
by apoptosis is tightly regulated to ensure that the immune system does not respond 
aberrantly to self. For that reason, despite the presence of millions of apoptotic cells 
in the body at any one time, their occurrence normally goes unnoticed due to the safe 
packaging of self antigens onto membrane bound apoptotic bodies, their rapid 
disposal, and the anti-inflammatory immune response that ensues. Yet, certain 
chronic inflammatory disorders, such as systemic lupus erythematosus (SLE), occur 
in response to apoptotic cells. SLE is caused by a combination of complex genetic 
and environmental interactions, and it is considered that the failure to remove 
apoptotic cells before they become secondarily necrotic is key to driving this 
autoimmune disease. The current understanding of immune regulation induced by 
apoptotic cells in health and in SLE and conflicting ideas are discussed in more detail 
in this chapter. 
 Apoptotic cell death 1.1
 Morphology of apoptotic cells 1.1.1
Apoptosis, first described by Kerr et al. in 19721, is a process of programmed cell 
death, which is essential for development, cell turnover, and maintaining immune 
homeostasis. In the 1990s it was discovered that apoptosis is an active process, 
requiring energy in the form of adenosine triphosphate (ATP)2-5. The energy-
dependent morphological changes that distinguish apoptotic cells include cell 
shrinkage, chromatin condensation, DNA fragmentation, and maintenance of cell 
membrane integrity1. During the final stages of apoptosis the cell clusters its 
intracellular material, including DNA and ribonucleoproteins (RNP), on to the cell 
surface and subsequently dismantles, releasing these packages as small apoptotic 
bodies6. This is in contrast to necrotic cell death, where the organelles become 
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enlarged and the membrane becomes permeable, allowing the release of intracellular 
components in an inflammatory way7. 
 Extrinsic and intrinsic apoptotic pathways 1.1.2
There are two mechanisms of apoptosis initiation, the extrinsic (death receptor) 
apoptotic pathway and the intrinsic (mitochondrial) apoptotic pathway (Reviewed in 
reference8). These pathways involve apoptosis-associated caspases that either initiate 
(caspases 8 and 9) or execute (caspases 3, 6, and 7) cell death. Since caspases are 
initially produced as proenzymes, their proteolytic function is exerted following a 
cascade of molecular events that trigger caspase activation (Figure 1.1). 
 
The initiator pro-caspases contain a pro-domain, such as the caspase recruiting 
domain (CARD) in caspase 9 and the death effector domain (DED) in caspase 8, 
which interact with polyprotein complexes required for their clustering and 
activation8. The death-inducing signalling complex (DISC) is formed following 
ligation of the extrinsic death receptors, such as Fas receptor by FasL, or TNFR1 by 
TNF-α, which form a trimer leading to the recruitment of adaptor proteins FADD 
and TRADD, respectively, and association with pro-caspase 88. Following activation 
of the intrinsic pathway the apoptosome is assembled when cytochrome c released 
from mitochondria binds to apoptotic protease-activating factor 1 (Apaf-1) and 
associates with pro-caspase 98. 
 
The Bcl-2 family of proteins regulate the mitochondrial apoptosis pathway by 
controlling mitochondrial outer membrane permeabilisation (MOMP)9. These 
proteins interact via the Bcl-2 homology (BH) domains BH1-4. Pro-apoptotic 
proteins that contain only the BH3 domain, Bim, Bid, and Bad, are activated by 
stimuli such as DNA damage9. Bid is also activated by caspase 8, thereby linking 
death receptor pathway activation and the mitochondrial pathway10. The BH3-only 
proteins incite cell death by binding to the anti-apoptotic Bcl-2 family proteins, such 
as Bcl-2, Bcl-XL, Bcl-W. This triggers the release of the sequestered activated pro-
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apoptotic Bax and Bak11,12, which induce MOMP thus permitting the escape of 
cytochrome c and committing the cell to dying.  
 
Following maturation of the initiator caspases they cleave and activate the 
executioner (effector) caspases. Once activated, executioner caspases can cleave and 
activate other executioner caspases, hence resulting in positive feedback and 
maturation of all apoptosis-associated caspases irrespective of the initial stimulus8. 
Many intracellular targets linked to the unique morphology of apoptotic cells are 
cleaved by active caspases 3 and 7. DNA fragmentation occurs when the effector 
caspases cleave the inhibitor of caspase-activated DNase (CAD) thus releasing CAD 
and allowing it to translocate to the nucleus13. Chromatin condensation and cell 
rounding is caused by caspase-mediated cleavage of p21 activated protein kinase 2 
(PAK2)14,15. Caspase-activated Rho-associated kinase 1 (ROCK-1) facilitates 
contraction of the actin-myosin cytoskeleton thus initiates cell membrane 
blebbing16,17.  
 
Another key identifier of apoptotic cells is the extracellular exposure of the 
membrane phospholipid phosphatidylserine (PS), which is constitutively internalised 
on viable cells. Transfer of PS from the cytoplasmic leaflet of the plasma membrane 
to the external side was initially described as a caspase-independent event18. 
However, recently it has been shown that PS exposure requires caspase-mediated 
inactivation of phospholipid flippase, which normally transfers PS from the outer to 
the inner leaflet19.  
 
After the transient process of cell membrane blebbing and in an independent event, 
apoptotic cells disassemble into apoptotic bodies, which are released from the dying 
corpse. It has recently been discovered that blocking pannexin channels in the 
membrane of T cells and monocytes results in the release of a string of apoptotic 
bodies, termed apoptopodia20,21. Interestingly the nuclear contents were excluded 
from the apoptopodia released from monocytes by this mechanism21. Breaking apart 
of the nuclear contents involves cytoskeleton remodelling16,22, yet it is not known 
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how cells package intracellular contents, including DNA and chromatin, into 
membrane-bound apoptotic bodies. Furthermore, it is not completely understood 
why apoptotic cells release small bodies from their corpse, although it is speculated 
that this may increase the efficiency of apoptotic cell clearance23. 
 
 
Figure 1.1. The extrinsic and intrinsic apoptosis pathways.  
An overview of the caspase-activation cascade triggered following activation of 
death receptors (extrinsic pathway) and mitochondrial release of cytochrome c 
(intrinsic pathway). Activation of the initiator caspases 8 and 9 leads to activation of 
the effector caspases 3 and 7, which cleave many proteins to induce chromatin 
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 Apoptotic cells regulate the immune response 1.1.3
1.1.3.1 Phagocytosis of apoptotic cells 
Around a billion cells die by apoptosis in the body each day, yet apoptotic cells are 
rarely seen in healthy tissue histology24 because professional phagocytes, such as 
macrophages, and local phagocytes, such as neighbouring epithelial cells, rapidly 
remove apoptotic cells from the environment. Apoptotic cells actively promote their 
own clearance, in addition to inducing a non-phlogistic response by the phagocytes 
that engulf them. This is essential for maintaining self-tolerance.   
 
Apoptotic cells release “find-me” factors and produce “eat-me” signals in order to be 
located and recognised by professional mononuclear phagocytes25 (Figure 1.2). The 
“find-me” chemotactic factors include the nucleotides ATP and UTP26, the lipids 
lysophosphatidylcholine (LPC)27 and sphingosine-1-phosphate (S1P)28, and the 
classical chemokine CX3CL1 (fractalkine)29. Apoptosis effector caspases mediate the 
release of LPC from the membrane through activation of phospholipase A227, 
ATP/UTP through pannexin-1 membrane channels30, and CX3CL129. These 
attractants then signal through G-protein coupled receptors on the phagocytes; the 
nucleotides signal through P2Y226, LPC ligates G2A27, and CX3CL1 acts through its 
receptor CX3CR129. 
 
Neutrophils are also professional phagocytes and they are the critical first line innate 
defence for mounting an inflammatory attack against invading pathogens31. 
However, although neutrophils can respond to the “find-me” chemoattractants, they 
are rarely found at sites of apoptotic cells in vivo7. This is because apoptotic cells 
also secrete the “keep out” signal, lactoferrin, an anti-inflammatory protein that binds 
to specific receptors on neutrophils32. Thus, apoptotic cells preferentially attract 
monocytes and macrophages to avoid inflammatory responses. 
 
After the appropriate phagocytes are recruited, apoptotic cells are tethered to their 
surface then engulfed. This is facilitated by the “eat-me” signals that decorate the 
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apoptotic cell surface. There are many “eat-me” signals (Reviewed in 
references25,33,34) including the expression of oxidised low-density lipoprotein 
(oxLDL)-like sites, which bind to the scavenger receptor CD3633. The most 
commonly studied “eat-me” signal is PS, which can be recognised by phagocytes 
directly through T cell immunoglobulin mucin domain (TIM)-4, or stabilin 225. PS is 
also indirectly recognised via bridging molecules, such as milk fat globule EGF-
factor 8 (MFG-E8), or Gas-6, which bring the apoptotic cells to appropriate 
engulfment receptors on phagocytes, such as αvβ3/5, and MER, respectively25. 
Furthermore, complement proteins and antibodies opsonise apoptotic cells to mediate 
phagocytosis. For example, binding of the classical complement pathway protein 
C1q to the apoptotic membrane35-37, or to IgM that has bound to the membrane38 
triggers phagocytosis through the C1q receptor, the CD91-calreticulin complex33. 
Although PS is essential for apoptotic cell uptake, knockout mouse studies have 
demonstrated that the combination of PS with other “eat-me” components is required 
to initiate phagocytosis25.  
 
An additional measure to flag up that apoptotic cells should be phagocytosed is the 
loss of “don’t eat me” signals that are expressed on viable cells. This includes the 
loss CD47, which normally interacts with macrophages by binding signal regulatory 
protein-α (SIP-α), and inactivation of CD31, which subsequently binds to phagocyte-
expressed CD317. 
 
Following receptor-mediated uptake, phagocytes must degrade the apoptotic cell 
cargo by step-wise maturation of phagosomes involving acidification and fusion with 
lysosomes (reviewed in reference39). It has recently been demonstrated that apoptotic 
cell opsonins regulate the intracellular processing of phagocytosed apoptotic 
cells40,41. C3 delays phagosome maturation by prolonging apoptotic cells in 
endosomes and consequently enhances antigen loading on to major 
histocompatibility complex (MHC) class II for presentation to CD4+ T cells40. 
Whereas, MFG-E8 mediates phagosome trafficking to lysosomes thus avoiding 
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apoptotic fragments outwith lysosomes being cross-presented by MHC class I to 




Figure 1.2. “Find-me” and “eat-me” signals that mediate apoptotic cell 
phagocytosis.  
An overview of the chemotactic factors released by apoptotic cells to attract 
mononuclear professional phagocytes. The phagocytes then engulf the apoptotic cells 
following interactions directly with the ligands displayed on the apoptotic cell 
surface, such as phosphatidylserine (PS) and oxLDL-like sites, or indirectly via 
adaptor proteins, such as Gas-6, MFG-E8, IgM, and C1q, that have bound to the 
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1.1.3.2 Anti-inflammatory responses induced by apoptotic cells 
Apoptotic cells induce an anti-inflammatory phenotype in macrophages, which is 
reported to require cell contact and is independent of phagocytosis43. Contact with 
apoptotic cells inhibits the synthesis of pro-inflammatory cytokines, for example 
tumour necrosis factor (TNF)-α and interleukin (IL)-1β, in response to inflammatory 
stimuli, such as lipopolysaccharide (LPS)44,45. This is likely to occur following the 
secretion of anti-inflammatory transforming growth factor (TGF)-β secretion46. TGF-
β is a multifunctional cytokine, which is initially secreted in latent form through 
association with two proteins, latent TGF-β-binding protein and latency-associated 
protein. It is activated in response to apoptotic cell interactions with the αV 
containing integrins during phagocytosis.  
 
Through binding to TGF-β receptor II (TGF-βRII), TGF-β regulates the proliferation 
and differentiation of many innate and adaptive immune cells, including promoting 
the survival of natural regulatory T cells47. Additionally, TGF-β inhibits the 
expression of the co-stimulatory molecules CD86 and CD40 48, which are normally 
upregulated on phagocytes following the uptake and processing of antigens onto 
MHC. Consequently, T cells that recognise apoptotic cell-derived peptide-MHC 
complexes in the absence of co-stimulation are induced into an anergic state, or into 
regulatory T cells (Tregs)48. 
 
Macrophages located in the marginal zone (MZ) of the spleen are stimulated to 
secrete the anti-inflammatory tryptophan catabolising enzyme indoleamine 2,3 
dioxygenase (IDO) by apoptotic cells being filtered from circulating blood49. 
Furthermore, although apoptotic (and necrotic) human neutrophils are commonly 
found at sites of inflammation, these dying cells release anti-inflammatory alpha-
defensins to inhibit pro-inflammatory macrophages50. This mechanism is important 
for restoring the inflammatory environment back to normal, as indicated by alpha-
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Apoptotic cells also interact with non-phagocytic cells to induce regulation. For 
example, the innate-like, weakly self-reacting MZ and B1 B cells express high levels 
of TIM-151, a PS-binding glycoprotein from the same family as TIM-4. In mice, 
when apoptotic cells bind to TIM-1 this induces anti-inflammatory signalling 
resulting in the secretion of IL-10 52, which has been shown to reduce the severity of 
experimental autoimmune encephalomyelitis (EAE), the mouse model of multiple 
sclerosis53. TIM-1 potentially has regulatory function in human B cells too54. IL-10-
secreting MZB and B1 B cells are also induced following TLR9 activation by 
apoptotic cell derived DNA55. Regulatory B cells induced in this way protect mice 
from developing severe collagen-induced arthritis (CIA) through the induction of IL-
10 secreting antigen specific CD4+ T cells55,56. 
 
IL-10 is a potent immunosuppressive cytokine, which signals through a 
heterodimeric receptor (IL-10Rα and β). It acts by down regulating inflammatory 
cytokine production by many cell types including T helper cells, monocytes, and 
neutrophils, and it inhibits antigen presentation by monocytes and DCs57.  
 Apoptotic cells prevent autoimmunity 1.1.4
In a healthy immune system, the response to apoptotic cells maintains homeostasis 
during the extensive turnover of cells and resolves inflammation to minimise tissue 
damage. The anti-inflammatory reaction induced by apoptotic cells is not always 
beneficial to the host, as apoptotic cells can promote tumour progression58. 
Nevertheless, the importance of the immunosuppressive response is clearly 
demonstrated when the removal of apoptotic cells is faulty. This causes chronic 
inflammation in the lungs of patients with chronic obstructive pulmonary disease 
(COPD)59, whereas the excess of apoptotic cells in genetically susceptible people 
causes SLE, an autoimmune disease affecting multiple tissues and organs. In this 
thesis I was particularly interested in comparing immune regulation induced by 
apoptotic cells from healthy donors and patients with SLE.  
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 Systemic lupus erythematosus 1.2
 Symptoms and serology 1.2.1
SLE is a chronic multisystem autoimmune disease with a female to male ratio of 9:1, 
predominantly affecting females of childbearing age. The symptoms and organ 
presentation can vary greatly between patients, ranging from mild, such as the 
characteristic butterfly rash across the face, alopecia, and joint pain and swelling, to 
more severe where inflammation causes potentially life-threatening damage to the 
kidneys, heart, or brain. 
 
Autoreactive B cells secrete anti-nuclear IgG autoantibodies (ANA), which are 
characteristic of SLE and are detected in sera during diagnostic tests. ANA include 
anti-dsDNA, chromatin, RNP, Smith (Sm; recognise the core units of small nuclear 
RNP), Ro and La antibodies. Although anti-DNA and anti-Sm antibodies are specific 
to SLE, anti-Ro and anti-La antibodies are commonly found in Sjogren’s syndrome 
(SS), a closely related autoimmune disease affecting the exocrine glands, which can 
develop in combination with SLE. The anti-phospholipid antibodies, lupus anti-
coagulant and anti-cardiolipin, are also found in approximately half of SLE patients, 
which may cause thrombosis and complications during pregnancy. Furthermore, the 
presence of antibodies specific for the first component of the classical complement 
pathway, anti-C1q antibodies, has long been associated with lupus nephritis60-62. 
 
The aetiology of SLE is still unknown, but the onset of disease is most likely caused 
by a combination of genetic and environmental factors63. Environmental factors that 
are linked to SLE include exposure to ultraviolet (UV) light and virus infections 63. 
For example, antibodies generated against Epstein-Barr virus (EBV) derived protein 
EBV nuclear antigen (EBNA)-1 cross-react with the autoantigens Ro and Sm64, 
indicating a role for molecular mimicry in SLE. The concordance rate of SLE in 
monozygotic twins is ten-fold higher than dizygotic twins65, suggesting that there is a 
genetic cause. Genome-wide association studies (GWAS) have identified more than 
50 genes associated with SLE (reviewed in reference66). These can be sub-divided 
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into groups of genes associated with lymphocyte activation (including PTPN22, 
STAT4, and BANK1), cross-talk between leukocytes (such as HLA-DR2, HLA-
DR3, and OX40L), innate immune signalling (such as IRAK1 and IRF7), and 
removal of apoptotic cells (in particular C1q and FcRs)66. Recently, single nucleotide 
polymorphisms (SNPs) in genes associated with the autophagy pathway, including 
Atg5, have been linked to SLE67 and the relevance of this will be discussed later in 
this chapter (section 1.4). 
 Treatment of SLE 1.2.2
Like many other autoimmune diseases there is no cure for SLE, therefore drugs are 
used to control the aberrant inflammation. Depending on how severe the symptoms 
are, SLE patients are currently treated with non-steroidal anti-inflammatory drugs 
(NSAIDs), corticosteroids, disease modifying anti-rheumatic drugs (DMARDs), such 
as hydroxychloroquine (HCQ) and methotrexate, and/or immunosuppressants, such 
as azathioprine, and mycophenolate mofetil. These available treatments are useful for 
controlling SLE symptoms by non-specifically dampening the inflammatory immune 
response. Due to the complex and heterogeneous nature of this autoimmune disease, 
it has proved difficult to develop new specific therapies. 
 
Recently, belimumab has become the first FDA approved drug since the 1950s, and 
currently the only approved biologic therapy, for SLE treatment68 following the 
results of two independent, but similarly designed phase III, double-blind, placebo-
controlled trials69,70. Belimumab is a monoclonal antibody that targets B lymphocyte 
stimulator (BLyS; also termed B cell activating factor, BAFF), an essential factor for 
B cell survival and maturation. Therefore, neutralisation of soluble BLyS by 
belimumab induces the reduction in B cells, potentially eliminating autoreactive B 
cells, which rely more greatly on BLyS for survival71. Belimumab-treated SLE 
patients with active disease showed a significant improvement in clinical symptoms 
and fewer disease flares compared to those treated with placebo69,70. Belimumab 
therapy additionally resulted in a greater number of SLE patients being able to 
reduce their steroid dosage69,70.  However, more than 40% of the SLE patients in the 
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clinical trials failed to respond to BLyS neutralisation72 indicating that B cells are not 
the main influence of disease activity in a high proportion of cases. Furthermore, it 
remains to be investigated if belimumab is beneficial, or even safe, to treat patients 
with lupus nephritis or central nervous system lupus, as this subset of patients with 
severe SLE was excluded from the phase III trials.  
 
Other promising biologics mainly targeting pro-inflammatory cytokines involved in 
SLE pathogenesis are discussed in section 1.2.4. Nevertheless, it would be ideal to 
specifically address the underlying cause of the disease, but this is not clearly known. 
 The current paradigm of SLE pathogenesis 1.2.3
1.2.3.1 Apoptotic cells are the primary antigen source in SLE 
It is well established that apoptotic cells encompass the source of autoantigens to 
which SLE autoantibodies are targeted. Nuclear components, including DNA and 
RNP, and negatively charged phospholipids, such as PS, are exposed in clusters on 
the surface of apoptotic cells and bodies6,73,74 and are the ligands for ANA and anti-
phospholipid antibodies, respectively. Additionally, C1q bound to the surface of 
apoptotic cells is the ligand for anti-C1q antibodies75. Therefore, it is not surprising 
that apoptosis-inducing events, such as virus infection and exposure to sunlight, are 
associated with flares of disease symptoms. 
 
Apoptotic cells are considered to become immunogenic in SLE due to the failure to 
rapidly remove the dying cells; therefore they eventually break apart, increasing the 
exposure of the accumulated nuclear components to the immune system76. It is 
reported that macrophages from SLE patients have an impaired ability to 
phagocytose apoptotic neutrophils77 and apoptotic T cells78. The phagocyte defect 
may be caused by genetic alterations in phagocytic receptors. For example SNP 
rs1143679 in integrin-alpha(M) (ITGAM; CD11b), a component of complement 
receptor (CR)3 (CD11b/CD18), is a strong genetic risk factor (odds ratio 1.76) 
associated with SLE67,79,80. Heterozygous expression of this SNP, which is most 
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common in SLE patients, impairs CR3-mediated uptake of iC3b opsonised particles, 
including apoptotic cells by professional phagocytes81.  
 
Mouse models of SLE complement the reports that phagocytosis is dysfunctional in 
patients. Peritoneal macrophages from MRL/Mp and New Zealand black/white 
(NZB/W) F1 mice have defective phagocytosis of sterile inflammation-induced 
accumulation of apoptotic neutrophils82. Yet, clearance of IgG1 opsonised mouse 
RBCs was efficient, indicating that the defect was specific to the phagocytosis of 
apoptotic cells82. Conversely, the accumulation of systemically injected apoptotic 
cells in wild type mice is reported to induce the non-pathogenic generation of anti-
ssDNA and anti-cardiolipin IgG antibodies, but not anti-dsDNA or other ANA83. 
This provides evidence that an accumulation of apoptotic cells is required in 
combination with disease-modifying genes in order for SLE to develop. 
 
In addition to intrinsic defects in the phagocytic cells, the loss of opsonisation is also 
associated with impaired removal of apoptotic cells in SLE. The development of 
glomerulonephritis and an excess of apoptotic bodies in mice deficient in C1q 
demonstrates the importance of efficient removal of apoptotic cells by phagocytosis 
to prevent inflammation84. The severity of autoimmunity was influenced by C1q-
deficiency on a 129/C57BL6 background84, which express SLE susceptibility loci on 
chromosome 185. This further supports the need for genetic risk factors to allow the 
break in tolerance to self-nucleic acids. In fact, although very rare, the majority of 
individuals who have inherited deficiencies in early components of the classical 
complement pathway, in particular C1q, develop SLE (reviewed in reference86).  
 
Innate-like B cells (B1a and MZB subsets) express self-reactive BCRs and are 
activated to secrete natural IgM antibodies with specificities for apoptotic cell 
surface components, such as dsDNA, independently of T cell help57. In health, 
despite being self-reactive, innate-like B cells maintain tolerance to apoptotic cells 
through the secretion of anti-inflammatory IL-10 (discussed in section 1.1.3.2) and 
the protective role of natural IgM antibodies bound to apoptotic cells, which recruit 
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C1q thus promoting phagocytosis38,57. Self-tolerance is breached in SLE due to 
failure at conventional B cell tolerance checkpoints (reviewed87). Circulating 
CD27high plasma cells, which become autoreactive following somatic hypermutation, 
are elevated in SLE88. It is then assumed that reduced disposal of apoptotic cells, 
such as in the absence of C1q, causes the increased exposure of intracellular 
antigens, which are immunogenic to the autoreactive B cells89.  
1.2.3.2 Immune complexes in SLE 
In the absence of effective removal, apoptotic cells become secondarily necrotic 
thereby switching what should be an anti-inflammatory response to an inflammatory 
response. Secondary necrosis is considered to result in the inflammatory release of 
danger associated molecular patterns, such as DNA and chromatin90. Furthermore, 
the binding of IgG autoantibodies to their nuclear autoantigens released from the 
broken apart apoptotic cells results in the formation of immune complexes, which are 
found circulating in SLE patient blood and are considered to drive inflammation. 
 
Immune complexes deposit in the skin, joints and organs, where they cause 
inflammation through activation of the classical complement cascade. The C1 
complex is activated when C1q binds to IgG in the immune complex and 
subsequently initiates activation of the C1r and C1s. The C1s enzyme then cleaves 
C2 and C4 into fragments that generate the C3 convertase (C4bC2a), which cleaves 
C3 to produce C3a and C3b. C3b acts as an opsonin, thus renders antigen susceptible 
to phagocytosis, and it also forms the C5 convertase by interacting with C4bC2a to 
cleave C5 into C5a and C5b91.  C3a and C5a mediate inflammation by increasing 
vascular permeability and recruiting inflammatory macrophages, neutrophils and 
lymphocytes to the site of immune complexes91. The final step of the complement 
cascade is the formation of the membrane attack complex92, a disruptive pore in the 
plasma membrane which is initiated by sequential binding of C5b to C6, C7, C8 and 
up to 16 C9 molecules91.  Immune complex deposition in the glomeruli of the kidney 
is particularly detrimental, as this leads to nephritis and may result in irreversible 
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kidney damage. A low level of C3 and/or C4 in SLE patients is characteristic of an 
activated complement cascade and active disease92.  
 
RNP-IgG immune complexes also drive inflammation in SLE by activating 
neutrophils through FcγRIIa and TLR7 to undergo NETosis, a specific form of 
caspase-independent, reactive oxygen species (ROS)-dependent cell death93. 
NETotic neutrophils extrude DNA and decondensed chromatin mixed together with 
granular proteins such as the antimicrobial peptide LL37, in large web-like structures 
called neutrophil extracellular traps (NETs)94. Although these structures are an 
important component of innate immunity for entrapping and destroying pathogens95, 
in recent years it has been discovered that NETs play a pathogenic role in SLE. 
NETs are normally destroyed by serum DNase1, yet this mechanism to rapidly 
remove a source of self-antigens does not function in some SLE patients and anti-
dsDNA autoantibodies form immune complexes with the NETs, which deposit in 
kidney glomeruli96. Hence impaired clearance of NETotic neutrophils provides an 
additional source of immune complexes in SLE.  
 
Previous investigations revealed that a circulating component of SLE patient blood 
was acting as an endogenous inducer of IFN-α secretion by plasmacytoid dendritic 
cells (pDC)97. The inducer of IFN-α could be mimicked by binding anti-dsDNA IgG 
antibodies to CpG-DNA98. It is now known that nucleic acids in complex with 
autoIgG made by B cells, or LL37 released by NETotic neutrophils activate pDCs to 
secrete IFN-α. FcγRII-mediated endocytosis is required for the induction of pDC 
IFN-α  secretion by apoptotic cell-derived nucleic acids found in immune complexes 
with IgG99-101. Immune complexes also induce pDCs to secrete IL-693 and other pro-
inflammatory cytokines including TNF-α and IL-12102. It is specifically SLE immune 
complexes that induce activation of pDCs due to the presence of self-DNA and RNP, 
as immune complexes found in the serum of other rheumatic diseases, such as RA, 
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Figure 1.3. The current paradigm of SLE pathogenesis. 
It is currently considered that impaired phagocytosis caused by dysfunctional 
phagocytes and loss of opsonisation results in the accumulation of apoptotic cells, 
which progress to secondary necrosis. The intracellular components that are 
normally clustered on the surface of apoptotic cells are released following secondary 
necrosis. Autoreactive B cells, which have escaped self-tolerance checkpoints, are 
stimulated by nuclear contents released from secondarily necrotic cells and 
differentiate into IgG antinuclear autoantibody (ANA)-secreting plasma cells. The 
binding of the ANA to nuclear antigens forms immune complexes, which stimulate 
pDCs to secrete IFN-α. This requires Fc receptor-mediated uptake to allow the self-
nuclear components to reach TLR7 and TLR9. By the same mechanism, immune 
complexes also induce neutrophils to undergo NETosis thus releasing more self 
DNA available for ANA to bind, or already in complex with LL37, further driving 
IFN-α secretion by pDCs. 
 
1.2.3.3 Are apoptotic cells really a danger signal? 
It is accepted that the failure of phagocytes to quickly and efficiently remove 
apoptotic cells is detrimental due to the accumulation of secondary necrotic cells. 
Though it seems counterintuitive why a cell that has invested energy into dying by 
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apoptosis would naturally progress to becoming pro-inflammatory. However the data 
that supports this is inferred from studies that report on the pro-inflammatory nature 
of late apoptotic/necrotic cells utilising tumour cells103, which are likely to express a 
fundamentally different complement of danger signals to primary cells. In addition 
studies using primary necrotic cells, that have not first undergone programmed cell 
death will release the danger signal high mobility group box 1 (HMGB1), in contrast 
to secondarily necrotic primary cells, in which HMGB1 is tightly associated with 
chromatin104.  
 
In fact it was published many years ago that late apoptotic cells fail to induce 
inflammatory responses105,106, and early and late apoptotic cells induce the same 
signalling in macrophages, which is distinct from necrotic cells107. MZB and B1 B 
cells are induced to become anti-inflammatory in response to DNA expressed on 
early and late apoptotic cells, even in the presence of inflammatory PAMPs, such as 
LPS and PGN55. Therefore, it is unlikely that apoptotic cells and secondary necrotic 
cells are inflammatory in a healthy immune system. Perhaps in SLE, cells 
undergoing apoptotic death act as a danger stimuli due to an intrinsic defect caused 
by the underlying complex genetic nature of the disease. 
 IFN-α and the type I IFN signature 1.2.4
A high serum level of IFN-α compared to healthy individuals is reported in some 
SLE patients and this has been associated with disease activity108. However, elevated 
serum IFN-α is also found in healthy first degree relatives of SLE patients indicating 
that it might be a heritable trait that increases SLE susceptibility108. Nevertheless, it 
is considered that the immunomodulatory effects exerted by IFN-α are central to the 
pathogenesis of SLE. This is supported by reports of the development of reversible 
SLE symptoms in some patients administered with long-term IFN-α therapy to fight 
against viral infections and certain forms of malignancies109,110.  
 
There are 12 functional subtypes of IFN-α, which is part of the type I IFN family 
also including IFN-β, IFN-ε, IFN-κ and IFN-ω108. All type I IFNs signal through the 
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same receptor composed of two subunits, IFNAR1 and IFNAR2, yet they induce 
distinct biological responses due to different binding affinities111. IFNAR signals 
through Janus kinase (Jak)1 and tyrosine kinase (Tyk)2 with the subsequent 
formation of the signalling transducer and activation of transcription (STAT)1-
STAT2 heterodimer. This is recruited to the nucleus where it binds to interferon 
regulatory factor (IRF)9 thus forming the IFN-stimulated gene factor 3 (ISGF3) 
complex, which induces the transcription of hundreds of IFN-inducible genes by 
interacting with IFN-stimulated response elements. A subset of patients with severe 
SLE have a type I IFN “signature”, which is defined by up-regulated expression of 
IFN-α-induced genes in peripheral blood mononuclear cells (PBMC)112,113. 
 
However, the type I IFN signature in the autoimmune setting is not unique to SLE, as 
it is also correlated with disease activity and autoantibody levels in the closely 
related disease SS (reviewed in reference114). Furthermore, a small study has 
reported that an elevated baseline of type I IFN-induced genes in the peripheral 
blood of rheumatoid arthritis (RA) patients is associated with non-responders to 
rituximab therapy115. Conversely, the type I IFN signature in RA neutrophils 
indicates a good response to inhibitory TNF-α therapy116. Gene expression meta-
analysis of SLE, SS, and RA studies found that these three connective tissue diseases 
share common type I IFN-induced genes117. Therefore, it suggests that the type I IFN 
signature may represent active disease activity. 
 
IFN-α is an important anti-viral pleiotropic cytokine, which acts by directly 
interfering with virus replication and survival, in addition to linking innate and 
adaptive immunity. IFN-α induces the differentiation of monocytes into 
inflammatory antigen-presenting DCs118, promotes B cell survival by inducing BAFF 
expression, and stimulates the differentiation of B cells into plasmablasts119. IFN-α 
also feeds back on neutrophils further driving NETosis and the release of immune 
complexes93. Therefore there is a positive feedback loop developed between immune 
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During virus infections, the IFN signature is normally transient due to tight 
regulation of IFN-α responses120. However, in SLE it is considered that chronic 
inflammation is driven by the excessive production of IFN-α by immune complex 
activation of pDCs and inadequate regulation due to genetic variations in 
components of IFN-α production, such as the transcription factor IRF7, and 
signalling, for example Tyk2108. 
 
Mouse models of SLE demonstrate that the role of IFN-α in disease pathogenesis is 
inconclusive. MRLlpr/lpr mice that do not express IFNAR1 develop worse disease121, 
indicating that IFN-α signalling is protective. Conversely, deficiency of the IFNAR 
prevents autoantibody production and limits the severity of glomerulonephritis in the 
genetically susceptible SLE prone NZB mice122, and the pristane-induced SLE-like 
disease123. Although pristane-induced SLE is the only model with an associated IFN 
signature124, it is intriguing that the major source of IFN-α production in this model 
is not pDCs, but inflammatory (Ly6Chigh) monocytes responding in a TLR7-
dependent and immune complex-independent way125.  
 
Inhibiting IFN-α signalling either by targeting IFN-α or the IFNAR with biologics 
has been the subject of recent clinical trials (reviewed in reference126). A phase I 
clinical trial of the anti-IFN-α monoclonal antibody, sifalimumab, reported that it did 
not significantly improve clinical activity compared to placebo127. Similarly, a phase 
II trial of rontalizumab, a humanised antibody to IFN-α, failed to meet its primary 
and secondary endpoints128. Conversely, the anti-IFN-α humanised antibody AGS-
009, resulted in partial reduction in type I IFN-induced genes during a small phase I 
trial126. The anti-IFNAR1 monoclonal antibody MEDI-546, almost completely 
inhibited the expression of type I IFN-induced genes in systemic sclerosis patients 
and is currently undergoing trials in SLE126. An additional mechanism is to broadly 
target IFN-α using an IFN-α kinoid, which is a complex of recombinant IFN-α and 
the immunogenic protein keyhole limpet haemocyanin129. In a recent phase I/II trial, 
IFN-α kinoid successfully induced T cell-dependent production of neutralising IFN-α 
antibodies and the reduction in the type I IFN signature, but did not benefit clinical 
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disease activity129. Long-term depletion of IFN-α may increase the risk of viral 
infections. 
 
The disappointing results reported from clinical trials targeting IFN-α might be 
explained by a recent study, which found that the IFN signature associated with SLE 
is extremely complex and is not solely induced by IFN-α, but also by IFN-β and the 
type II IFN, IFN-γ130. Therefore, future studies will have to take into account the 
previously unidentified contribution of IFN-γ to SLE pathogenesis.  
1.2.4.1 Other inflammatory cytokines in SLE 
In addition to IFN-α, other inflammatory cytokines including IL-6, IL-17, and IL-18 
are elevated in SLE patient serum and also contribute to the inflammatory 
pathogenesis. IL-6 is most commonly thought of as pro-inflammatory, yet in certain 
situations it exerts anti-inflammatory responses. For example, although IL-6 
promotes inflammatory arthritis, it also induces IL-10 secreting regulatory B cells to 
subsequently dampen the inflammation131. In the context of SLE, IL-6, which is 
secreted by pDCs following TLR stimulation, may stimulate IgG autoantibody 
secretion by plasma cells differentiated by IFN-α119. In the MRLlpr/lpr mouse model 
of SLE, the absence of IL-6 delays the development of severe renal disease, 
indicating that IL-6 may be a promising therapeutic target132, although the results of 
two recent phase II clinical trials using anti-IL-6 monoclonal antibodies, sirukumab 
and PF-04236921, have showed varying outcomes, with the severe risk of infection a 
major challenge133. 
 
The role of IL-17 in SLE has gained interest in the last few years due to reports that 
it is elevated in SLE serum, though there is currently no evidence to suggest that it 
correlates with disease activity134. CD4+ T helper (Th)17 cells and double negative 
CD3+ T cells, which are both elevated in SLE patient PBMCs, may be the source of 
IL-17 in SLE (Reviewed134). Differentiation of human Th17 cells requires IL-6, 
TGF-β, and IL-1β, whilst their maturation into pro-inflammatory cells is induced by 
IL-23135. Interestingly, TLR7-stimulated pDCs secrete IL-1β and IL-23, in addition 
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to IFN-α and IL-6, which promotes Th17 differentiation and maturation136. 
Furthermore, a pDC depletion study has reported that they regulate Th17-mediated 
inflammation in EAE by an unknown mechanism137.  
 
An additional source of IL-17 might be released from NETotic neutrophils in SLE 
skin lesions138. This is the predominant mechanism of IL-17 release in psoriasis139, 
an autoimmune disease, which like SLE, is driven by immune complex-mediated 
induction of IFN-α by pDCs140. IL-17 plays a role in the immune response against 
extracellular pathogens by stimulating the secretion of antimicrobial peptides, pro-
inflammatory cytokines, and chemokines to attract neutrophils. These functions, in 
addition to IL-17 stimulating autoreactive B cells to differentiate into antibody 
secreting plasma cells may contribute to inflammation in SLE134. IL-17 targeted 
therapy has not been investigated in SLE. However, blocking this cytokine with anti-
IL-17 monoclonal antibodies (secukinumab and ixekizumab), or anti-IL-17 receptor 
monoclonal antibody (brodalumab) has been successful in other autoimmune 
diseases, in particular psoriasis134.  
 
Unlike IL-6 and IL-17, the secretion of the pro-inflammatory cytokines IL-1β and 
IL-18 requires two activation steps: the first signal (NFκB activation) stimulates the 
production of precursor proteins whilst the second signal (inflammasome 
stimulation) activates the caspase 1-mediated cleavage of the precursors to make 
active IL-1β and IL-18141,142. Inflammasomes are multiprotein innate immune 
receptors composed of NOD-like receptors (NLRs; such as NLRP3), or absent in 
melanoma  (AIM)2, which contain a pyrin domain  (PYD). The PYD interacts with 
apoptosis-associated speck-like protein containing CARD (ASC), which 
subsequently recruits and activates caspase 1142.   
 
There is an emerging role of the inflammasome in SLE pathogenesis (reviewed143). 
In a healthy immune system, C1q bound to phagocytosed apoptotic cells represses 
NLRP3 inflammasome activation144. Whereas in SLE, C3a released during immune 
complex-mediated complement activation (discussed in section 1.2.3.2), may 
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enhance NLRP3 activation in stimulated monocytes by mediating ATP release145. 
Additionally, healthy monocytes are stimulated to produce IL-1β in response to 
NLRP3 inflammasome activation by nuclear constituents, including U1-small 
nuclear ribonucleoprotein146 and self-DNA147, which form immune complexes with 
SLE autoantibodies. LL37 extruded in NETs also stimulates IL-1β and IL-18 
secretion by SLE macrophages by activating NLRP3, with IL-18 subsequently 
triggering more NETosis148. A pathogenic role of inflammasomes in SLE is indicated 
by reports that disease is reduced in experimentally-induced SLE mouse models 
deficient in caspase-1 149 and IL-1β150. 
 Plasmacytoid dendritic cells 1.3
PDCs are considered to be the key source of elevated IFN-α in SLE. PDCs are a 
small population (<1%) of lineage-negative, bone-marrow derived circulatory cells 
of the innate immune system151. Human pDCs can be distinguished by their 
expression of blood dendritic cell antigen (BDCA)-2, BDCA-4, CD4, FcγRII, 
CD123 (IL-3Rα) and MHC Class II151. Mouse pDCs do not express CD123, but do 
express plasmacytoid DC antigen (PDCA)-1, B cell marker B220, and at low levels 
CD11c151. PDCs were originally identified as natural interferon-producing cells 
(IPC) due to their rapid secretion of vast quantities of Type I IFN152. Additionally, 
pDCs were also initially termed plasmacytoid T cells, as these CD4+ cells were 
found in abundance in the T cell rich regions of lymphoid organs153. In 1999, 
investigations of these cells converged when IPC were found to be equivalent to 
plasmacytoid T cells154.  
 
Human and mouse pDC populations develop from both the myeloid and lymphoid 
pathways, with the latter expressing Ig heavy chain V-J rearrangements155,156. PDC 
development is under the control of the transcription factor E2-2157,158, which is 
induced by Fms-like tyrosine kinase 3 (Flt-3) and STAT3 signalling102. Immature 
pDCs have a B cell morphology, but upon maturation, they develop a similar 
morphology to conventional dendritic cells (cDC)159, yet these dendritic cells are 
functionally distinct. Mature cDCs are professional antigen presenting cells, as they 
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have the unique ability to present antigen to prime naïve CD4+ T cells160. 
Conversely, activated pDCs are professional type I IFN secreting cells, but have a 
limited ability to prime CD4+ T cells compared to cDCs102,161. This is likely due to 
the continuous turnover of MHC class II-peptide in pDCs, unlike activated cDCs 
which accumulate MHC class II complexes expressing the same antigen162. 
Furthermore, the continual loading of MHC class I with intracellular antigens renders 
pDCs efficient at priming anti-viral CD8+ cytotoxic T cells163.  
 Plasmacytoid DCs are specialised to sense nucleic 1.3.1
acids 
Toll-like receptors (TLR) are a family of ten human and twelve mouse germline-
encoded, transmembrane pattern recognition receptors (PRR), which have 
extracellular leucine rich repeats (LRR) specific for various conserved pathogen-
associated molecular patterns (PAMPs)164,165. Most of these receptors are expressed 
on the cell surface membrane. However, viral and bacterial nucleic acid-specific 
receptors, TLR3, TLR7/8, and TLR9, are distinguished from other TLRs by their 
location on intracellular membranes166,167. These intracellular receptors respectively 
recognise double-stranded (ds)RNA, single-stranded (ss)RNA, and cytosine-
phosphate-guanine (CpG) sequences in DNA168. Unlike other immune cells, 
immature pDCs selectively express TLR7 and TLR9. 
 
Upon stimulation with the appropriate ligand, TLRs dimerise and TLR7 and TLR9 
translocate from the endoplasmic reticulum (ER) to endosomes with help from the 
ER membrane protein UNC93B169 and chaperone protein gp96170. Acidification of 
the endosome and proteolytic cleavage of TLR7 and TLR9 is required for receptor 
activation and interactions between the cytosolic Toll-IL-1 resistance (TIR) domains 
of the TLR and the TIR-containing signalling adaptor protein, MyD88165,171. 
TLR/MyD88 association activation induces the phosphorylation of IL-1 receptor-
associated kinase (IRAK)4, which activates TNF receptor associated factor 
(TRAF)6. This MyD88-dependent signalling pathway is shared with all TLRs, 
except TLR3, which is TRIF-dependent, and upon activation ultimately leads to 
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NFκB-mediated secretion of pro-inflammatory cytokines, such as TNF-α and IL-6. 
Activation of intracellular TLRs in pDCs induces an additional signalling pathway, 
whereby MyD88-dependent activation of IRAK1 and TRAF3 results in IRF7-
mediated transcription of IFN-α and other type I IFNs (Figure 1.4). 
 
Unlike most PAMPs, which are pathogen-specific, nucleic acids are also components 
of mammalian cells. Tolerance to self-DNA was initially considered to occur by 
TLR9-specificity for unmethylated CpG motifs found in microbial DNA, but not 
methylated CpG motifs in mammalian DNA161. This view was challenged when it 
was reported that the deoxyribose backbone was important for TLR9 activation172. 
Re-localisation of chimeric TLR9 to the cell surface revealed endosome acidification 
is important for distinguishing microbial DNA from self-DNA166. Therefore, it is 
currently considered that intracellular compartmentalisation of TLR7 and TLR9 is 
vital for maintaining tolerance to self, as this enables regulation of the source of 
ligands that can reach the TLR166.  
 
The specialised ability of pDCs to respond to nucleic acids and rapidly secrete IFN-α 
is owed to the selective expression of TLR7 and TLR9 and constitutive expression of 
IRF7173. Although other cells can make IFN-α in response to virus infections this 
response is limited compared to the rapid and vast secretion of IFN-α by pDCs. 
PDCs are therefore important in the first line of defence against systemic virus 
infections, such as murine cytomegalovirus (MCMV) and herpes simplex virus 
(HSV)-1 while the other cells come in to play later in infection102. The importance of 
pDC-derived IFN-α to provide protection against virus infections is demonstrated 
when this response is lost, such as severe influenza A infection in IRF7-deficient 
humans174. Conversely, the 129 mouse strain develops detrimental influenza virus-
induced inflammation caused by excessive IFN-α secretion by pDCs175, indicating 
that this key anti-viral response is pathogenic on the autoimmune 129 genetic 
background. The nucleic acid-induced IFN-α response that is specialised for anti-
viral immunity associates pDCs with the loss of tolerance to self-nuclear components 
and pathogenesis in SLE patients.  
 
	  




Figure 1.4. Toll-like receptor 7 and 9 signalling in plasmacytoid DCs. 
An overview of the signalling pathways that stimulate the transcription of IFN-α, 
pro-inflammatory cytokines, and activation markers following TLR7 and TLR9 
engagement in pDCs. Adapted from Gilliet et al. (2008)161 
 
 Plasmacytoid DCs are tolerogenic 1.3.2
PDCs are primarily recognised for playing a central role in anti-viral IFN-α 
responses, yet evidence suggests that they are also important in promoting tolerance. 
Immature pDCs always induce tolerance, whilst activated pDCs can induce tolerance 
or immunity depending on the environmental context162. PDCs help regulate central 
tolerance in the thymus; in humans this is reported to occur through the induction of 
IL-10 secreting FoxP3+ natural Tregs by activated thymic pDCs176,177, whereas in 
mice the recruitment of antigen-presenting peripheral pDCs induces deletion of self-
reactive T cells178.  
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Peripheral T cell tolerance to tumour cells, alloantigens, and allergens is also 
regulated by pDCs through IL-10 producing Tregs179,180 most commonly induced by 
pDC expression of IDO181-184. Following activation, pDCs upregulate the expression 
of inducible co-stimulator ligand (ICOS-L), which also drives IL-10 secreting 
Tregs185. Furthermore, peripheral T cell tolerance to self-antigens in the autoimmune 
setting of RA may be regulated by mouse and human pDCs through IDO-induced 
IL-10 secreting Tregs186,187. Yet, although the inflammatory response of pDCs to 
apoptotic cell-derived self nucleic acids has been described in the context of 
autoimmune disease, it is not fully understood if pDCs induce tolerance to apoptotic 
cells in a healthy immune setting. Research using a mouse model of apoptotic cell-
induced allogeneic hematopoietic cell engraftment reported macrophage-derived 
TGF-β was necessary for pDCs to indirectly induce immune suppression to apoptotic 
cells188. However there are no reports that direct pDC-apoptotic cell interactions are 
immunoregulatory. 
 
The expression of TLR7 and TLR9, which are responsible for potent IFN-α 
production in response to nucleic acids from viruses and SLE immune complexes, 
may indicate that pDCs should ignore apoptotic cells to maintain homeostasis in 
health. However, it has previously been demonstrated that pDCs induce regulation in 
response to stimulation through TLR9 using the synthetic ligand CpGB by 
promoting naïve T cell differentiation in to Foxp3+ Tregs 189. This has been 
supported by additional evidence that pDCs promote TLR9-dependent, IDO-
mediated T cell suppression and differentiation into Tregs 181,190. Additionally, recent 
evidence established that DNA complexes on the surface of apoptotic cells stimulate 
TLR9-dependent differentiation of IL-10-secreting regulatory B cells55. Therefore, it 
is conceivable that DNA expressed by apoptotic cells may activate pDCs through 
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This suggests there are two distinct pathways of TLR9 activation depending on the 
source of ligand; a protective inflammatory response can be generated in response to 
pathogens, whereas tolerance to self-DNA is maintained. The concept of a regulatory 
role for TLR9 is further supported by evidence that TLR9-deficient lupus-prone mice 
develop accelerated disease191. On the other hand, TLR7-deficient mice are protected 
from generating severe SLE191. TLR9 was shown to regulate the antibody and IFN-α 
response produced by TLR7 ligation192,193. This suggests that TLR7 and TLR9 play 
opposing roles in SLE. Additionally, lupus-prone BXSB mice that carry the Y-linked 
autoimmune acceleration (Yaa) gene have augmented progression of SLE-like 
disease.194 The Yaa gene was discovered to cause duplication and overexpression of 
TLR7195, due to translocation of the telomeric end of the X chromosome to the Y 
chromosome. Similarly, elevated expression of TLR7 in humans is associated with 
increased risk of SLE in males, further implicating this receptor in the loss of 
tolerance to self 196. 
 Do plasmacytoid DCs sense apoptotic DNA in a healthy 1.3.3
immune system? 
The current paradigm of SLE suggests that the stabilisation of self nucleic acids in 
immune complexes facilitates their delivery to TLR7 and TLR9 thus breaching 
tolerance161. However, the induction of IL-10-secreting regulatory B cells by 
apoptotic cells is dependent on TLR9 stimulation by DNA and chromatin exposed on 
the apoptotic cell membrane55. This occurs in response to antigen recognition and 
internalisation by self-reactive BCRs, which triggers the redistribution of TLR9 from 
the ER to endosomes55. Hence it is likely that TLR7 and TLR9 traffic to endosomes 
as a means to function optimally197, rather than as a mechanism to avoid interacting 
with mammalian chromatin. Despite the important role of pDCs in tolerance (section 
1.3.2), there is currently no evidence to suggest that in health they sense apoptotic 
cell-derived DNA and chromatin in a similar regulatory way to B cells. The main 
issue is how, in a healthy person, who does not have IgG ANA, would self-DNA 
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The same question arises as to how pDCs sense viral DNA and RNA, since they are 
rarely infected by viruses198 and they do not require productive viral replication to 
make IFN-α. However, pDCs respond to other infected cells. Direct contact with 
hepatitis C virus (HCV)-infected hepatocytes, but not free virus, induces IFN-α 
secretion by human pDCs199 resulting from the release of exosomes containing HCV 
RNA200. Similarly, contact with hepatitis A virus (HAV)-infected cells, or HAV 
enveloped within host cell membrane, but not free virions, stimulates human pDCs to 
produce IFN-α, though this occurs via uptake by as yet unidentified PS receptors201. 
It is also interesting that human pDCs can phagocytose fragments from HIV-infected 
apoptotic cells, which are then cross-presented to T cells202, but it was not 
determined if IFN-α was also induced. 
 
Therefore, pDCs sense virus nucleic acids from infected cells, indicating that the 
same antibody-independent mechanisms could be used to sense self-DNA on 
apoptotic cells. However, it is essential that if this occurs in health IFN-α is not 
produced. In fact, human pDCs express inhibitory cell surface receptors including 
the type II C-type lectin receptor BDCA-2 and immunoglobulin-like transcript 
(ILT)7, which associate with immunoreceptor-based tyrosine activation motif 
(ITAM)-containing γ-chain of FcεRI161. Mouse pDCs express Siglec-H, which is 
associated with ITAM-containing adaptor DAP12161. Activation of these receptors 
stimulates a BCR-like signalosome including LYN, SYK, B cell linker (BLNK), and 
B cell adaptor protein (BCAP), which regulates TLR7 and TLR9 signalling to inhibit 
IFN-α secretion203-205. These regulatory receptors might function to control the 
threshold of TLR activation, hence prevent an inflammatory response by pDCs 
exposed to self-DNA.  
 
PDCs also express on their surface the receptor for advanced glycation end-products 
(RAGE)206, which recognises the ligands HMGB1207, C1q208, and PS209.  
Contradicting studies report that free HMGB1 inhibits TLR9-mediated IFN-α 
production by pDCs206, whereas HMGB1-DNA complexes augment IFN-α 
secretion210. Nevertheless, although it is published that human pDCs endocytose 
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apoptotic bodies211 it has not been determined if pDCs can phagocytose apoptotic 
bodies via uptake by RAGE, or even low level expression of TIM-1212. 
 Autophagy 1.4
In addition to impaired phagocytosis of apoptotic cells it is emerging that autophagy 
may play a role in SLE. 
 The autophagy pathway 1.4.1
The term autophagy (from the Greek auto “self” and phagy “to eat”) was founded by 
Christian de Duve over 50 years ago and it describes a mechanism that functions to 
promote cell survival and maintain tissue homeostasis213. Three types of autophagy 
exist: microautophagy, macropautophagy, and chaperone-mediated autophagy. The 
common link between these pathways is the transport of a cell’s own long-lived 
cytoplasmic proteins and organelles to the lysosome for degradation and recycling. 
Microautophagy involves lysosomal membrane invagination to directly engulf cell 
components (reviewed in reference214), whereas chaperone-mediated autophagy 
selectively tags proteins, which then cross the lysosome membrane to be degraded 
(reviewed in reference215). The main autophagy pathway is macroautophagy (herein 
referred to as autophagy), which is characterised by cytoplasmic constituents 
enclosed in double membrane vesicles that fuse with lysosomes213. This catabolic 
process is constitutively active at basal levels in most cell types, and is upregulated 
in response to need.  
 
Cell stress, such as nutrient or energy depletion, induces non-selective autophagy of 
cytosolic components, which are degraded and recycled to provide the cell with 
essential nutrients. Selective, or cargo-specific, autophagy occurs to remove specific 
organelles that are damaged or in excess by degradation in the autophagosome. 
Several selective autophagy pathways are known, including ribophagy to remove 
ribosomes, xenophagy to eliminate pathogens, and mitophagy to selectively degrade 
mitochondria. Mitophagy occurs during the development of red blood cells to 
remove all mitochondria and to selectively remove mitochondria from sperm in a 
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fertilised egg to allow for inheritance of maternal mitochondrial DNA. It is also an 
essential quality control process required to maintain normal cell homeostasis by 
removing damaged or excessive mitochondria.  
 
Autophagy involves a complex pathway of many proteins, which work together 
during the three stages of the process, initiation, elongation and closure, and 
maturation (Figure 1.5). The pathway is initiated when inhibition of the mammalian 
target of rapamycin (mTOR) causes dephosphorylation and activation of components 
of the ULK complex (consisting of ULK1 and ULK2 interacting with FIP200, 
autophagy-related (ATG)13 and ATG101), and the beclin-1-associated protein, 
AMBRA1216,217. The ULK complex activates the beclin1 complex (composed of 
beclin-1, ATG14 and the class III PI3K Vps34), which is essential for promoting 
activation of Vps34218. Vps34 phosphorylates phosphatidylinositol generating PI3P, a 
phospholipid crucial for generating the isolation membrane called the phagophore213, 
which is formed from one of multiple membranes sources, such as the ER219,220, 
plasma membrane221, and mitochondrial outer membrane222. 
 
The next step of elongation and closure of the membrane involves two ubiquitin-like 
conjugation systems. Firstly, the E1-like enzyme ATG7 activates ATG12, which is 
then transferred to the E2 enzyme ATG10 before finally conjugating to ATG5213. 
ATG5-ATG12 dimerise and subsequently ATG5 interacts with a dimer of ATG16, 
enabling ATG5-ATG12 to associate with the phagophore membrane213. In the 
second pathway, LC3-I is conjugated to the membrane lipid 
phosphatidylethanolamine (PtdE) to form LC3-II. This involves activation of 
cytosolic LC3 by ATG4 to make LC3-I, which then associates with ATG3 to be 
lipidated by PtdE. The ATG12-ATG5-ATG16 conjugate acts as an E3-ligase by 
promoting the transfer of LC3 from ATG3 to PtdE223. LC3-II forms a stable 
interaction with the outer and inner membrane, which mediates the recruitment of 
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Autophagosomes then fuse with lysosomes, a process that is mediated by several 
molecules including PLEKHM1, an adaptor protein that binds to LC3 on the 
autophagosome, and the small GTPase, Rab 7, on the lysosome224. This recruits the 
homotypic fusion and protein sorting (HOPS) complex which also interacts with the 
SNARE, syntaxin (Stx)-17225,226. The final step of the pathway is the degradation of 






























Figure 1.5. The autophagy pathway. 
1. Initiation of the autophagy pathway involves generating the isolation membrane 
(phagophore) to enclose the cargo. 2. The double membrane is then elongated and 
fused, forming the autophagosome. This requires the conversion of LC3-I to LC3-II 
by binding of phosphatidylethanolamine (PE). 3. The cargo is degraded following 
fusion of the autophagosome with lysosomes to form the autolysosome. 
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 Role of autophagy in systemic lupus erythematosus 1.4.2
Autophagosomes were first hypothesised to be linked to SLE by Weissmann in 1964 
when he suggested that SLE lysosome membranes were more fragile than healthy 
individuals227. In recent years it has become clear that there is an association between 
deregulated autophagy and SLE. It is published that SLE CD4+ T cells from 
MRLlpr/lpr and NZB/W F1 SLE-prone mice and a small number of SLE patients 
contain more autophagosmes compared to healthy controls228. This corresponds with 
data from a human study, which found elevated autophagy in SLE CD19+ B cells in 
addition to CD4+ T cells229. Bone marrow-derived B cells from NZB/W F1 mice 
expressed a particularly elevated number of autophagosomes, even in young mice 
that had not yet developed disease229. These findings suggest that autophagy is 
intrinsically deregulated in SLE lymphocytes to promote the survival of autoreactive 
T cells and B cells228,229. Conversely, it has been reported that CD4+ T cells from 
SLE patients are resistant to both SLE serum- and starvation-induced autophagy, as 
indicated by reduced LC3-II230. 
 
GWAS analyses have identified several SNPs linked with SLE susceptibility in and 
near autophagy-associated gene Atg567,231,232, which encodes an essential component 
of the autophagy pathway that is required for LC3-I conversion to LC3-II (discussed 
in section 1.4.1). Another risk factor for SLE is SNPs near the gene encoding 
damage-regulated autophagy modulator (DRAM)-1233, a lysosome membrane protein 
that is activated by tumour suppressor p53 and induces both autophagy and 
apoptosis234. However, the effect of these SNPs is currently not described. 
 
Although the published literature is still limited, it is clear that autophagy is 
deregulated in SLE patients. The cause of this appears to be unknown and the link 
between autophagy and apoptosis in SLE cells has not been addressed. A key 
unanswered question is, how does dysfunctional autophagy affect SLE pathogenesis? 
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 Cross-talk between autophagy and apoptosis 1.4.3
Autophagy has largely been seen as a survival mechanism by cells to avoid cellular 
apoptosis through the removal of damaged proteins and organelles, yet similarities 
exist between the autophagy and apoptosis processes. Autophagy and apoptosis both 
function to preserve homeostasis, either within the cell or in the whole organism, 
respectively. Whilst autophagy is concerned with the packaging and delivery of 
effete organelles to the lysosomal pathway of the same cell, following apoptosis the 
packaging of intracellular components into apoptotic bodies allows for the delivery 
of cellular corpses to the lysosomal pathway of the phagocytes that ingest them. The 
presence of autophagosomes in dying cells has been noted for many years235, though 
it was taken to indicate either a last attempt to survive, or a form of non-apoptotic 
cell death characterized by a lack of caspase activation and DNA fragmentation236.  
 
It is now recognised that the autophagy and apoptosis pathways share regulatory 
elements (reviewed in237). The proteins Bcl-2 and Bcl-XL not only function to inhibit 
apoptosis, they also have the capacity to prevent autophagy by sequestering Beclin-1 
238. Pro-apoptotic BH3-only proteins, including Bid and Bad, are also pro-autophagic 
by breaking apart the interactions between Bcl-2, or Bcl-XL and beclin-1, leading to 
activation of the PI3K, Vps34237. Likewise, autophagy proteins function in apoptosis 
induction, such as non-conjugated ATG12, which interacts with and inhibits anti-
apoptotic proteins239. In apoptotic cells, the autophagy pathway is inhibited by 
caspase-mediated cleavage of autophagy proteins240-242. However, this converts the 
function of the autophagy proteins into pro-apoptotic proteins. For example caspase-
activated calpain-cleaved ATG5 translocates to the mitochondria, where it induces 
apoptosis through inhibition of anti-apoptotic Bcl-XL243. Additionally, intracellular 
DISC-mediated activation of apoptotic caspase 8 can occur on the autophagosome 
membrane 244,245.  
 
In addition to regulating the initiation of apoptosis, autophagy also influences how 
other cells respond to apoptotic cells. The activation of autophagy prior to apoptotic 
cell death is important for the release of the “find me” signals, LPC and ATP246, 
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which subsequently recruit phagocytes. In addition a number of recent studies have 
identified the importance of autophagy proteins in the heterophagy of apoptotic 
corpses by phagocytes247-249. Binding of PS to the TIM-4 receptor stimulates 
autophagy proteins, such as ATG5, ATG7, and LC3-II, expressed by the phagocytic 
cells to mediate the lysosomal degradation, but not uptake, of apoptotic cells247. This 
process, termed LC3-associated phagocytosis (LAP), is distinct from the canonical 
autophagy pathway since a double membrane is not formed and it proceeds 
independently of ULK1247,250.  Therefore, autophagy proteins are connected with the 
anti-inflammatory removal of apoptotic cells, which was discussed in section 1.1.3. 
 Autophagy regulates inflammation 1.4.4
Autophagy also plays a role in eliminating infectious bacteria and viruses by LAP251, 
or indeed by the canonical autophagy pathway, xenophagy252. PDCs are stimulated 
to make IFN-α in response to certain ssRNA viruses by autophagy-recruited 
endosomes containing TLR7; the antiviral response is inhibited in autophagy-
deficient pDCs253. TLR9 is also recruited to autophagosomes following FcγR 
engagement in pDCs stimulated by DNA-IgG immune complexes254 and B cell 
receptor cross-linking in B cells simultaneously stimulated by CpG DNA255. 
Therefore, the autophagy machinery potentially contributes to SLE pathology by 
enabling TLR signalling, though it remains to be investigated if the autophagy 
proteins are involved in IFN-α secretion induced by TLR7 activation by self-
RNA/RNP-containing immune complexes. 
 
Conversely, the over activation of IFN-α production in response to cytosolic DNA is 
suppressed by autophagy proteins, for example ATG5-ATG12 and ULK1, which 
inhibit signalling of the cytosolic DNA receptors retinoic acid-inducible gene (RIG)-
1 and stimulator of IFN genes (STING), respectively (reviewed in reference256). 
Aberrant NLRP3 inflammasome activity is additionally prevented via the removal of 
damaged mitochondria by mitophagy to prevent the release of endogenous agonists, 
such as mitochondrial ROS and DNA257. Autophagy machinery also degrades the 
components of activated NLRP3 and AIM2 inflammasomes258. Furthermore, 
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autophagy is required in combination with superoxide production for neutrophils to 
undergo NETosis259. 
 
In addition to the important role of autophagy proteins in regulating innate immune 
responses to infection, they also influence adaptive immunity256. For example, the 
loading of pathogen antigens onto MHC class II for presentation to T cells is 
reported to require the autophagy machinery260,261. Equally, autophagy is essential 
for processing self-antigens onto MHC class II, which is critical in the thymus to 
avoid the development of T cells with self-reactive receptors; mice with Atg5-
deficient thymi develop autoimmune colitis262. Autophagy also plays a role in 
humoral immunity by regulating the development of plasma cells and secretion of 
antibodies229,263. Thus, autophagy is intricately involved in the immune system. 
 Hypothesis 1.5
In summary, SLE is a complex and heterogeneous inflammatory disease driven by 
the loss of tolerance to apoptotic cell-derived nuclear constituents. This goes against 
the anti-inflammatory response that is normally induced by apoptotic cells. In a 
healthy immune system it is currently considered that pDCs do not respond to self 
nucleic acids due to the intracellular compartmentalisation of TLR7/9. However, the 
IgG ANA produced by autoreactive B cells in SLE generate immune complexes with 
nucleic acids released from apoptotic cells that have become secondarily necrotic 
due to failure in phagocytosis mechanisms. These immune complexes enable their 
transport into pDCs thus stimulating IFN-α production through TLR7/9 activation. 
Yet it is known that in health, stimulation of innate-like B cell TLR9 by apoptotic 
DNA/chromatin induces IL-10 secretion and immune regulation. Although a 
tolerogenic role of pDCs is defined, it has not been described if pDCs in health can 
respond directly to apoptotic DNA in a similar way as innate-like B cells.  
 
Many defects have been associated with SLE, including impaired function of 
phagocytes, loss of apoptotic cell opsonisation, and unchecked development of 
autoreactive B cells. More recently, genetic and cellular defects in autophagy have 
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emerged as potentially contributing to SLE. Autophagy was originally discovered as 
a pathway to promote cell survival, but it is now known to play a significant role in 
regulating apoptosis, apoptotic cell removal, and innate and adaptive inflammation. 
However, it is not clear how, or if, the published autophagy defects are related to cell 
death in SLE. 
 
The over-arching hypothesis of this thesis was, in health apoptotic cells induce 
regulatory immunity through pDCs whereas in SLE there is an intrinsic defect in the 
apoptotic lymphocytes that contributes to inflammatory immunity. To address this 
hypothesis, the results chapters assessed the following specific aims: 
 
1. Establish if apoptotic cells induce cytokine secretion by TLR-stimulated pDCs in 
healthy subjects. 
2. Analyse the cell death kinetics of SLE lymphocytes. 
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Chapter 2 Materials and Methods 
 Ethical approval 2.1
All work involving mice was covered by Dr Mohini Gray’s Project Licence granted 
by the UK Home Office under the Animals (Scientific Procedures) Act 1986. 
Locally, this was approved by the University of Edinburgh Ethical Review 
Committee. Permission was granted by the Lothian SAHSC BioResource (Ref QF-
TGU-A-SAMREQA) to collect samples of blood from consenting adults. Samples of 
healthy donor blood were collected from the CIR blood resource approved by 
AMREC (Ref 15-HV-013). 
 Mice 2.1.1
Wild type Balb/c and DO11.10 TCR mice, and wild type C57BL/6 and C57BL/6 
background TLR9-/- and C1q-/- mice were bred and maintained under pathogen-free 
conditions at the animal facilities at the University of Edinburgh, UK. DO11.10 mice 
were kindly provided by Professor Jürgen Schwarze (University of Edinburgh, UK). 
TLR9-/- mice were generously provided by Professor Shizuo Akira (Hyogo College 
of Medicine, Nishinomiya, Japan). C1q-/- mice were a kind gift from Professor 
Marina Botto (Imperial College London, UK). In all experiments mice were age and 
sex matched and used aged 6-12 weeks 
 Patients 2.1.2
SLE patients were recruited from the Western General Hospital, Edinburgh 
following informed consent and ethical approval. The mean age of the patients was 
47 (range 19 – 77), with a female:male (F:M) ratio of 7.2:1. Patient characteristics 
and the figure number(s) where the samples were used are listed in appendix A table 
A.1. Prerana Hudder calculated the safety of estrogens in lupus erythematosus 
national assessment – SLE disease activity index (SELENA-SLEDAI) scores where 
the patient details were available to her during her medical elective. Healthy controls 
were recruited from the Centre for Inflammation Research, University of Edinburgh, 
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and non-SLE patient controls were recruited from the Western General Hospital, 
Edinburgh following informed consent and ethical approval. The mean age of 
controls was 40 (range 19 – 77) with a F:M ratio of 3.9:1. Characteristics of the non-
SLE patients are listed in appendix A table A.2. 
 
 Media 2.2
 Mouse cell culture media 2.2.1
IMDM (Gibco) supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 2 µΜ 2−mercaptoethanol was used in the majority of experiments. 
Where cells were purified from C1q-deficient mice, the culture medium was X-
VIVO™ 15 (Lonza) supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin.  
 Human cell culture media 2.2.2
RPMI (Gibco) supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml 
penicillin, and 100µg/ml streptomycin. Human monocytes and macrophages were 
cultured in IMDM (Gibco) supplemented with 100 U/ml penicillin, 100µg/ml 
streptomycin, and 10% serum (pooled from ten healthy donors). 
 Starvation media 2.2.3
HBSS containing calcium and magnesium (Life Technologies) and supplemented 
with 100 U/ml penicillin, and 100µg/ml streptomycin. 
 
 Cell isolation and purification 2.3
 Peripheral blood mononuclear cells (PBMCs) 2.3.1
40 ml of venous blood from healthy donors and SLE patients was collected into 50ml 
Falcon tubes (BD Biosciences) containing 4ml 3.8% sodium citrate to prevent 
clotting. The blood was centrifuged at 350xg for 20 min at room temperature prior to 
aspirating the top layer consisting of platelet-rich plasma in to 10ml glass tubes. 
200µl 1M calcium chloride was added per 10ml and the plasma was incubated in a 
37°C water bath for a minimum of 1 h. The serum was removed from the platelet 
plug and was retained to include in cell culture medium, or it was stored at -30°C. 
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6ml of 6% Dextran 500 (Pharmacosmos) was added to the remaining blood cell layer 
then filled to 50 ml with NaCl. Following sedimentation of the red blood cells for 20 
min at room temperature, the leukocyte-rich top layer was aspirated in to a new 50ml 
Falcon tube and centrifuged at 350xg for 6 min at room temperature. A stock of 90% 
Percoll (GE Healthcare) was used to create a gradient in a 15ml Falcon tube (BD 
Biosciences) by layering 3ml 81%, 3 ml 68%, and 3ml 55% percoll (containing cells 
from the leukocyte-rich layer). The Percoll gradient was centrifuged at 720xg for 20 
min then the peripheral blood mononuclear cells (PBMCs, top layer) was collected, 
washed and counted. PBMCs that were not used immediately in an experiment were 
frozen at 10x106/ml in FCS containing 10% DMSO and stored in liquid nitrogen. 
Neutrophils (bottom layer) were also collected, washed, and counted. 
 
To generate macrophages, PBMCs (2x106/ml) were cultured for 1 h in serum-free 
human monocyte medium in a 24-well plate (Corning) to allow the monocytes to 
adhere to the plastic. The non-adherent cells (lymphocytes) were then removed and 
replaced with human monocyte medium containing 10% healthy donor serum. The 
monocytes were cultured for seven days, or where stated three days, and the medium 
was removed and replaced half way through the culture period. 
 CD19+ B cells 2.3.2
Single-cell suspensions of mouse spleen and human PBMCs were incubated with 5µl 
(mouse), or 10µl (human) anti-CD19 microbeads (Miltenyi Biotec) in 45µl (mouse), 
or 40µl (human) autoMACS buffer (Miltenyi Biotec) per 107 cells for 15 min at 4oC. 
The cells were then washed in autoMACS buffer and centrifuged at 300xg for 10 
min. While the cells were being washed, an LS column (Miltenyi Biotec) attached to 
a quadroMACS magnet (Miltenyi Biotec) was rinsed with 3ml autoMACS buffer. 
The cells were resuspended in 500µl autoMACS buffer per 108 cells and allowed to 
flow through the LS column followed by three washes with autoMACS buffer, with 
the CD19-negative cells collected in a 15ml greiner tube for further use. To collect 
the CD19-positive cells, the column was removed from the magnet and flushed 
through with 5ml autoMACS buffer using the plunger provided with the column.  
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 Plasmacytoid dendritic cells 2.3.3
Mouse plasmacytoid dendritic cells (pDCs) were enriched from single-cell 
suspensions of red cell lysed spleen by depleting B cells using anti-mouse CD19 
microbeads (Miltenyi Biotec), as described in 2.4.2, and were further sorted using a 
FACSAria cell sorter (BD Biosciences) to generate a highly purified population. To 
block non-specific binding of antibodies the CD19-negative splenocytes were 
resuspended at 40x106 per ml and incubated with anti-mouse CD16/CD32 antibody 
(BioLegend) for 10 min at 4oC. The cells were then stained with anti-mouse PDCA-
1, B220, Ly6C, CD3, and CD11b antibodies described in Table 2.1 for 20 min at 4oC 
and then immediately flow sorted. 
 
Where stated, human pDCs were enriched by negative selection using the pDC 
isolation kit II (Miltenyi Biotec). PBMCs were incubated with 400µl autoMACS 
buffer and 100µl of Non-pDC biotin antibody cocktail II per 108 cells for 10 min at 
4oC. The cells were then washed in autoMACS buffer and centrifuged at 300xg for 
10 min. The pellet was then resuspended in 400µl autoMACS buffer and incubated 
with 100µl Non-pDC MicroBead cocktail II per 108 cells for 15 min at 4oC. While 
the cells were being washed and centrifuged at 300xg for 10 min an LS column 
(Miltenyi Biotec) attached to a quadroMACS magnet (Miltenyi Biotec) was rinsed 
with 3ml autoMACS buffer. The cells were resuspended in 500µl autoMACS buffer 
and passed through the LS column followed by three washes with autoMACS buffer, 
with the non-pDCs attaching to the column and the pDC-positive population passing 
through into a 15ml greiner tube. 
 
Where applicable, human pDCs were flow sorted to high purity using a FACSAria 
cell sorter (BD Biosciences). To block non-specific binding of antibodies to the 
PBMCs, the cells were resuspended at 10x106 per 100µl and incubated with 20µl of 
FcR blocking reagent (Miltenyi Biotec) for 10 min at 4oC. The cells were then 
washed and resuspended at 40x106 per ml in FACS buffer (PBS, 1% FCS) and 
stained with anti-human CD304, CD123, CD19, CD3, and CD14 antibodies 
described in Table 2.1 for 20 min at 4oC. 
 
	  









































































Table 2.1. Fluorescently conjugated antibodies used to flow sort pDCs. 
 CD4+ T cells 2.3.4
CD4+ T cells were sorted from mouse spleen and lymph nodes and human PBMCs 
using 5µl (mouse), or 10µl (human) anti-CD4 microbeads (Miltenyi Biotec) in 45µl 
(mouse), or 40µl (human) MACS buffer per 107 cells for 15 min at 4oC. The cells 
were isolated using magnetic separation as described in 2.3.2. 
 
 Cell lines 2.4
The NIH 3T3 (mouse embryonic fibroblast) and the C127 (mouse mammary 
epithelial) cell lines, which were kindly provided by Professor Peter Ghazal (DIPM, 
University of Edinburgh), were maintained in culture flasks in DMEM (Gibco) 
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supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin at 37oC 5% CO2. The wild type (WT) and Atg5-/- immortalised baby 
mouse kidney epithelial (iBMK) cell lines were gifted from Professor Eileen White 
(Rutgers Cancer Institute of New Jersey), and were maintained in culture flasks in 
DMEM/F-12 + GlutaMAX™ (Gibco) supplemented with 10% FCS, 100 U/ml 
penicillin, and 100 µg/ml streptomycin at 37oC 5% CO2. 
 
These adherent cell lines were passaged every 3-4 days when they were 70-80% 
confluent. To split the cells, the media was removed and replaced with PBS to wash 
the cells. The washed cells were incubated in Trypsin-EDTA (ThermoFisher 
Scientific) for 5 min at 37oC to detach them from the flasks. Double the volume of 
culture medium (containing 10% FCS) was then added to neutralise enzymatic 
activity of trypsin. The cells were transferred into a 50ml Greiner tube and 
centrifuged at 300xg for 5min. After discarding the supernatant, the cell pellet was 
gently resuspended in culture medium and added at a ratio of 1:10 to new flask 
containing fresh medium. 
 
 Viruses 2.5
The Influenza A virus (H1N1) used in this thesis was derived from frozen stocks of 
known titre generated by Dr Simon Talbot (DIPM, University of Edinburgh).  
 
Murine cytomegalovirus (MCMV) was kindly provided by Prof Peter Ghazal 
(DIPM, University of Edinburgh). To prepare a seed stock of MCMV to use in this 
thesis, twenty 15cm culture dishes (Corning) of 3T3 cells were grown to 70-80% 
confluence in DMEM + 10% FCS + 2 mM L-glutamine (without pen/strep). On the 
day of infection, 3T3 cells were detached and pooled into a single tube, centrifuged 
at 300xg for 5 min, then resuspended in 5ml of media. After counting the cells they 
were infected with MCMV at a multiplicity of infection (MOI) 0.001 by incubating 
for 1 h at 37oC 5% CO2 and gently mixing the tube every 15 min. 5ml of media was 
added to make up to total volume 10ml of infected cells, which was split evenly 
between two 500 ml bottle of media. After mixing well, 25ml of cells in media was 
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pipetted in to 15cm plates (40 plates in total) and incubated at 37oC 5% CO2 for 4 
days, when the infected cells had become rounded. The cells were then harvested 
using a cell scraper and pooled into 250ml centrifuge tubes. 
 
To concentrate the MCMV bulk stocks, the supernatant was centrifuged at 7,500xg 
at 4oC for 20 min in a high-speed centrifuge (Beckman). The supernatant was poured 
into new 250ml centrifuge tubes and kept on ice while the pellets were resuspended 
in a total of 10ml medium. The cell pellet was disrupted using a 40ml glass 
homogeniser then centrifuged at 3,600xg at 4oC for 20 min to remove cell debris. 
The supernatant was added to the 250ml tube kept on ice and the pellet was 
discarded. To pellet the virus stock, the supernatant was centrifuged at 35,000xg at 
4oC for 3 h with no brake. After discarding the supernatant the pellets were 
resuspended in residual fluid and pooled. The virus suspension was disrupted using a 
25ml glass homogeniser and then it was slowly pipetted onto 20% Sorbitol (Sigma-
Aldrich) in 30ml tubes (10 parts sorbitol for 1 part virus suspension). This was 
centrifuged at 35,000xg at 4oC for 3 h and the supernatant was aspirated. 500µl of 
ice-cold 20% Sorbitol was added to resuspend the virus pellet and then topped up to 
2ml, homogenised, aliquoted, and stored at -80oC. 
 
To determine the viral titre of the MCMV stock, a plaque assay was performed. 3T3 
cells were cultured to 80-90% confluence by adding 4x104 cells per ml per well in a 
12-well plate (Corning). The medium was removed and the concentrated virus was 
added at dilutions 0, 10-2, 10-3, 10-4, 10-5, 10-6, 10-7, and 10-8. After incubating at 
37oC 5% CO2 for 1 h, the cells were overlaid with 1ml 2.5% agarose (Invitrogen) to 
immobilise newly produced virions and placed back in the incubator for 4 days. 1% 
formalin solution was added to the cells and they were fixed by incubating overnight 
at 4oC. The formalin was poured off and the wells washed with tap water to remove 
the agarose media plugs and then the plaques were stained overnight with 0.1% 
toluidine blue solution. Using a light microscope, the number of visible plaques per 
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 Induction of apoptosis 2.6
To generate apoptotic thymocytes, single-cell suspensions of murine thymi were 
exposed to UVB-irradiation (100 mJ/cm2) then incubated in mouse medium at 37oC 
5% CO2 for 4 h prior to coculture. Mouse CD19+ B cells were induced to become 
apoptotic by the same method described for thymocytes. Apoptotic human 
lymphocytes were generated either by UVB-irradiation (100 mJ/cm2), or by LEAF™ 
purified anti-human CD95 (FAS) antibody, 10µg/ml (BioLegend) followed by 4 h 
incubation at 37oC 5% CO2. Necrotic cells were generated from apoptotic cells by 
performing five cycles of freezing on -80oC dry ice and thawing in 37oC water bath. 
C127 cells were induced to become apoptotic by UVB-irradiation (100 mJ/cm2) and 
iBMK cells became apoptotic after 6 h culture in starvation medium. 
 
The proportion of apoptotic cells was measured by flow cytometry by staining 
0.5x106 cells in 50µl of the cell membrane impermeable DNA-intercalating stain 
propidium iodide (PI) and surface expression of PS using Annexin V (AnV) 
conjugated to FITC or AF647 (1:200; BioLegend). The 20 min staining period and 








Table 2.2. Annexin V Binding Buffer. 
 
 In vitro cultures 2.7
Cells were treated with the following TLR ligands: TLR7 ligand R848, 1µg/ml 
(InvivoGen); mouse TLR9 ligands, CpGB 10µg/ml for pDCs and 1µg/ml for B cells 
(CpG ODN 1826, Eurofins MWG Operon) and, CpGA 20 µg/ml (CpG ODN 1585, 
InvivoGen); human TLR9 ligands, CpGA 3µg/ml (CpG ODN 2216, InvivoGen) and 
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CpGB, 2µM (CpG ODN 2206, Eurofins MWG Operon); TLR4 ligand LPS, 5ng/ml 
(human) and 5µg/ml (mouse, Sigma-Aldrich); mouse TLR2 ligand PGN 10µg/ml 
(InvivoGen). 
 
Where stated, the following components were added to culture medium: DNase, 
50µg/ml (Roche, UK. Added each day of the culture period); Box A from HMGB1, 
20µg/ml (IBL International); OVA323-339, 4µg/ml (Albachem).  
 Mouse cell cultures 2.7.1
PDCs (104), or CD19+ B cells (2x105), were co-cultured with apoptotic thymocytes 
(106), or apoptotic CD19+ B cells (2x105) and where stated CD4+ WT or OVA-T 
cells (105), in 96-well round bottom plates in mouse medium at 37oC 5% CO2 for the 
duration of the assay. In transwell experiments, pDCs (4x104) were cultured in the 
lower part of the transwell and apoptotic cells (4x106) located in the upper transwell 
insert (permeable membrane 0.4µm pore size) in 24-well plates.    
 Human cell cultures 2.7.2
PBMCs (106) were co-cultured with healthy CD4+ T cells (106), whereas CD19+ B 
cells (2x105) were co-cultured with healthy or SLE apoptotic lymphocytes (0.5x106) 
in 96-well round bottom plates in human cell culture medium at 37oC 5% CO2 for 
the duration of the assay. Day seven macrophages were co-cultured with healthy or 
SLE apoptotic lymphocytes (106) in 96-well flat bottom plates in IMDM (10% 
healthy serum) at 37oC 5% CO2 for the duration of the assay. 
 
 Flow Cytometry 2.8
All antibody staining and wash steps were performed in FACS buffer (PBS, 1% 
FCS) unless otherwise stated. Single stain controls of each fluorochrome and isotype 
controls were used to determine appropriate compensation and gating, respectively. 
Samples were analysed using the LSR Fortessa (BD Biosciences) or the 
FACSCalibur (BD Biosciences) and analysed using FlowJo Software (version 10.0). 
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 Mouse pDC activation markers 2.8.1
Mouse pDCs (1x104) were incubated in 50µl FACS buffer containing anti-mouse 
CD40, CD86, and MHC Class II antibodies described in Table 2.3. After 20 min at 
4oC, the cells were washed and resuspended in 300µl of FACS buffer to be analysed 
immediately. 
 Intracellular IL-10 cytokine staining 2.8.2
Cells were taken on day three and day seven of culture and re-suspended at 1x106 per 
ml in fresh medium with added PMA, 20ng/ml (Sigma-Aldrich) and Ionomycin, 
1µg/ml (Sigma-Aldrich). After 1 h, brefeldin A, 1µg/ml (Sigma-Aldrich) was added 
to block secretion of cytokines and the cells were incubated for an additional 3 h. 
The cells were then surface-stained (PDCA1-APC and B220-Percp), followed by 
fixation and permeabilisation (BD Biosciences) before intracellular cytokine staining 
with PE rat anti-mouse IL-10 (1:100; BD Pharmingen) or PE rat IgG2b isotype 
control (1:100; BD Pharmingen). 
 IL-10 secretion assay 2.8.3
The mouse IL-10 secretion assay was performed in accordance with the 
manufacturer’s instructions (Miltenyi Biotec) with a few minor changes. On day 
seven of culture, cells were washed and re-suspended in mouse medium containing 
IL-10 catch reagent and incubated on ice for 5 min. The cells were then continuously 
rotated for 4 h at 37oC prior to washing and staining with PE-conjugated mouse IL-
10 detection antibody (Miltenyi Biotec) and anti-mouse CD4-FITC (1:100; 
BioLegend). 
 TLR9-/- mouse T cells and B cells 2.8.4
1x106 WT and TLR9-/- mouse splenocytes were incubated with anti-mouse 
CD16/CD32 antibody (1:400; BioLegend) for 10 min at 4oC to block non-specific 
binding. The cells were then stained in 100µl with anti-mouse CD3, CD19, CD21, 
and CD23 antibodies described in Table 2.3 for 20 min at 4oC, washed and then 
analysed on the flow cytometer.  
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 HMGB1 staining 2.8.5
UV-irradiated thymocytes (0.5x106) were resuspended in 50µl and incubated with 
anti-HMGB1 antibody (1:100; ThermoFisher Scientific) for 20 min at 4oC. After 
washing the thymocytes, they were incubated in 50µl with secondary antibody goat 
anti-rabbit IgG AF647 (1:200; Life Technologies) for 20 min at 4oC. The cells were 
washed and analysed immediately.  
 Intracellular TLR9 staining 2.8.6
The human pDC/TLR9 kit (Imgenex) was used in accordance with the 
manufacturer’s protocol to assess TLR9 expression in pDCs within PBMCs. 10µl of 
human lineage marker antibody mix (anti-CD3, CD14, CD16, CD19, CD20, and 
CD56 antibodies conjugated to FITC, and anti-HLA-DR antibody conjugated to 
PerCPCy5.5) and 5µl of anti-CD123 conjugated to AF647 was added to 1x106 
PBMCs in 100µl for 20 min at 4oC. The cells were washed twice in cold 1x staining 
buffer and centrifuged for 10 min at 1,200xg. After removing the supernatant and 
resuspending the pellet, 300µl of 1x fixation buffer was added and the cells were 
briefly vortexed and incubated for 20 min at 4oC. To wash, 2ml of 1x 
permeabilisation buffer was added and the cells were centrifuged for 10 min at 
1,200xg. The supernatant was removed and the pellet resuspended in 1ml 1x 
permeabilisation buffer for 10 min at 4oC, then washed with 2ml of 1x 
permeabilisation buffer. 5µl of anti-human TLR9 antibody conjugated to PE was 
added to the cells in 100µl residual buffer. The cells were vortexed to mix, incubated 
for 25 min at 4oC then washed twice with 2ml of 1x permeabilisation buffer. The 
samples were stored overnight in 300µl of 1x staining buffer at 4oC in the dark and 
were analysed the following morning. 
 Human inflammatory cytokines 2.8.7
Quantification of human IL-6, IL-12p70, TNF-α, and IL-1β protein in supernatant 
was measured in a single sample using the cytometric bead array (CBA) human 
inflammatory cytokines kit (BD Biosciences). In a 96-well plate, 50µl per well of 
capture beads were added to all wells and 50µl of a serial two-fold dilution of 
cytokine standard (0-5,000 pg/ml) and 50µl of sample supernatant were added in 
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duplicate wells. The human inflammatory cytokine PE detection reagent was added 
to all wells at 50µl. The plate was incubated in the dark for 3 h and then centrifuged 
at 300xg for 5 min to pellet the beads. After carefully aspirating the supernatant, the 
wells were washed twice with 250µl of wash buffer. The pellets were resuspended in 
100µl of wash buffer and acquired on the FACSArray (BD Biosciences). 
 Human B and T cell subsets 2.8.8
To assess B cell and T cell subsets in healthy and SLE PBMCs non-specific binding 
of antibodies was blocked by resuspending 1x106 cells in 50µl and incubating with 
10µl of FcR blocking reagent (Miltenyi Biotec) for 10 min at 4oC. The cells were 
then washed and resuspended at 1x106 cells in 100µl FACS buffer (PBS, 1% FCS) 
and stained for B cells with anti-human CD20, CD38, CD24, CD27, IgD, IgM, and 
CD1c antibodies, or T cells with anti-human CD3, CD4, and CD8 antibodies 
described in Table 2.3. After 20 min at 4oC, the cells were washed and resuspended 
in 300µl FACS buffer to analyse immediately. 
 Mitochondrial membrane integrity 2.8.9
Human lymphocytes (0.5x106) were incubated in 50µl with nonylacridine orange 
(NAO) at a final concentration of 100nM at 37oC for 15 min in the dark. The cells 
were then washed twice, resuspended in 300µl, and analysed immediately.  
 Caspase 3 and caspase 7 activation 2.8.10
Apoptosis in human lymphocytes was detected using the FAM-FLICA® in vitro 
Caspase-3/7 Detection kit (ImmunoChemistry Technologies), which fluorescently 
labels activated caspase 3 and caspase 7. Cells were resuspended at 2x106 per ml and 
290µl was pipetted into a FACS tube with 10µl of 30X FLICA solution. After 15 h, 
the cells were washed twice with 2ml of 1X apoptosis wash buffer by centrifuging at 
230xg for 6 min. The cells were resuspended in 300µl of 1X apoptosis wash buffer 
and analysed immediately.  
 Autophagy detection 2.8.11
Autophagic vacuoles in healthy and SLE lymphocytes were analysed using the Cyto-
ID® Autophagy detection kit (Enzo Life Sciences). 1x106 cells were resuspended in 
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250µl 1X assay buffer and 250µl Cyto-ID green stain (1µl of Cyto-ID green 
detection reagent diluted in 1ml 1X assay buffer). The samples were mixed well and 
incubated at 37°C in the dark for 30 min, then washed twice with 1ml 1X assay 
buffer and centrifugation at 300xg for 5 min. The cells were resuspended in 300µl of 
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Figure 2.3. Antibodies used for staining cells for flow cytometric analysis. 
  Cytokine ELISA 2.9
The concentration of human and mouse IL-10 and IL-6, mouse IFN-γ and IL-12, and 
human TNF-α and IL-1β (R&D Systems), and human IFN-α (eBioscience) were 
measured using standard ELISA with minor changes to the manufacturer’s protocol. 
96-well EIA/RIA plates (Corning) were coated overnight at room temperature with 
capture antibody and then washed three times with PBS (0.05% Tween-20) and 
patted on paper towel to remove excess fluid. The wells were blocked for 1 h at room 
temperature by adding 150µl ELISA block (1% BSA, 5% sucrose, 0.2% azide in 
PBS). After washing and drying the wells, a two-fold serial dilution of standard 
protein was performed in duplicate and cell culture supernatants were added to wells 
in triplicate in a final volume of 50µl per well. Dilutions of the standard and samples 
were performed in 1X reagent diluent (R&D Systems). The plates were incubated at 
room temperature for 1.5 h, then washed and incubated with 50µl of the detection 
antibody for 1 h at room temperature. After washing and drying the wells, 50µl of 
streptavidin horseradish peroxidase (HRP; 1:200) was added for 30 min at room 
temperature. The wells were then washed and dried prior to adding 50µl SureBlue™ 
Reserve TMB Microwell Peroxidase substrate (KPL Inc.). When the top standard 
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turned dark blue (10-15 min), the enzymatic reaction was stopped by adding 50µl 
0.6N sulphuric acid.  
 
The VeriKine mouse IFN-α ELISA kit, which detects all 13 IFN-α subtypes, was 
used to quantify the concentration of IFN-α in accordance with the manufacturer’s 
protocol (PBL Interferon Source). A seven-point standard curve (6.25-400 pg/ml) 
was created by two-fold serial dilution in Sample Buffer and culture supernatant 
samples were diluted appropriately in Sample Buffer. Per well, 100µl of standard or 
sample were added to wells from the pre-coated microtiter plate followed by 50µl 
Antibody Solution. The plates were sealed and incubated at room temperature for 1 h 
with shaking at 450rpm and then incubated for a further 24 h at 4°C without shaking. 
After washing the wells four times with Wash Solution, 100µl of HRP solution was 
added per well and the plate was incubated at room temperature for 2 h with shaking 
at 450rpm. The wells were then washed four times and 100µl of TMB solution was 
added per well for 15 min followed by 100µl of Stop solution. 
 
The Human IL-18 Instant ELISA (eBioscience) was used to detect human IL-18 in 
accordance with the manufacturer’s instructions. In duplicate, two-fold serial 
dilutions of standard (78-5,000 pg/ml), or 100µl dH2O plus 50µl of sample were 
added to pre-coated microwell strips. Following incubation at room temperature for 3 
h with shaking at 400rpm, the wells were washed six times with PBS (0.05% Tween-
20) then incubated with 100µl TMB substrate solution. When the highest standard 
turned dark blue, 100µl of Stop Solution was added immediately per well. 
 
Absorbance values were read at 450nm on a Synergy HT plate reader (Biotech, 
Winnoski, U.S.A) using Gen5 (version V.1.01.14) software from BioTek. 
Absorbance readings from the standard curve were used to calculate the appropriate 
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  Intracellular calcium flux 2.10
CD19+ WT and C1q-/- cells were resuspended at 10x106 per ml in cation-free HBSS 
(PAA Laboratories) and incubated with 2µM fura-2/AM for 30 min at 37oC. The 
cells were washed twice and incubated in cation-free HBSS for 10 min for optimal 
de-esterification then resuspended at 2x106 per ml in HBSS with divalent cations. 
Changes in fluorescence upon addition of 10µg/ml anti-mouse IgM (Southern 
Biotec) were determined using the LS5OB luminescence spectrometer (Perkin 
Elmer) with dual wavelength excitation (340nm and 380nm) and emission at 510nm, 
and FLWinLab Software. To obtain the maximal fluorescence (Rmax), 10% Triton X-
100 was added to induce cell lysis and subsequent release of intracellular calcium. 
When this fluorescence became constant, the minimal fluorescence (Rmin) was 
obtained by adding 250mM of the calcium chelator EGTA. The concentration of 
intracellular Ca2+, [Ca2+]i was calculated from the relationship [Ca2+]i = Kd.(R – 
Rmin)/(Rmax – R).b, where R is the ratio of fluorescence obtained at 340nm and 
380nm in the cuvette before calibration, Rmax is the fluorescence ratio under 
saturating intracellular Ca2+, Rmin is the fluorescence ratio in the absence of Ca2+, Kd 
is the dissociation constant for fura-2/AM (taken as 224nm at 37oC), and b is the 
fluorescence ratio at 340nm of cells in the absence and presence of Ca2+. 
 
  Purification of serum IgG 2.11
IgG was purified from the serum of four SLE patients and three healthy blood donors 
using 100µl Protein G Sepharose beads (Sigma-Aldrich) per sample. Protein G beads 
were washed three times in 1ml PBS and centrifuged at 10,000xg for 5 min prior to 
mixing with 1ml of serum. Following continuous rolling for 30 min at room 
temperature the tubes were centrifuged at 10,000xg for 5 min and the serum 
discarded. IgG-Protein G beads were washed three times as before. 500µl 0.1M 
glycine (pH 2.7) was added to dissociate the beads from IgG, then the pH was 
neutralised with 1M Tris HCl (pH 9.0). The IgG-containing supernatant was added to 
dialysis high retention seamless membrane tubing (Sigma-Aldrich) and submerged in 
5L of PBS with constant stirring at 4°C for 24 h, with the PBS replaced three times. 
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Centricon 100kDa centrifugal filter devices (Millipore) were used to concentrate the 
IgG antibody.  
 
Total protein was quantified using DC protein assay reagents (Bio-Rad 
Laboratories). The protein standard was generated by diluting BSA (Europa 
Bioproducts) in PBS to 5mg/ml (top standard) and doing a two-fold dilution series in 
a 96-well plate (Corning). In triplicate wells, 5µl of sample or standard was added 
followed by 25µl of working reagent A (20µl of reagent S per 1 ml reagent A) and 
200µl of reagent B. The plate was incubated for 15 min at room temperature on a 
plate shaker. Absorbance was read at 750nm using the Synergy HT plate reader and 
Gen5 software (version V.1.01.14). Absorbance readings from the protein standard 
were plotted against the known protein concentrations and the resulting line equation 
was used to calculate the protein concentration of the samples. 
 
Additionally, the concentration of total IgG antibody was quantified by the Human 
IgG total Ready-SET-Go® ELISA (Affymetrix eBioscience) in accordance with the 
manufacturer’s protocol. Capture antibody was added to 96-well EIA/RIA plates 
(Corning) and incubated overnight at 4°C. The wells were washed twice with wash 
buffer (PBS + 0.05% Tween-20) and patted on paper towel to remove excess fluid 
then 250µl of blocking buffer was added per well for 2 h at room temperature. After 
washing the wells, two-fold serial dilutions of the standards with assay buffer A was 
performed in duplicate and serum samples diluted 1:100,000 in assay buffer A were 
added to wells in triplicate. The plate was incubated at room temperature for 2 h on a 
microplate shaker at 400 rpm. 100µl of detection antibody was added to the washed 
wells and incubated at room temperature for 1 h on a microplate shaker at 400 rpm 
prior to washing and adding 100µl of Substrate Solution per well. After 15 min, 
adding 100µl Stop Solution to each well terminated the reaction and the plate was 
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  TdT-mediated dUTP Nick-End Labeling (TUNEL) 2.12
Fragmented DNA in human lymphocytes was detected by confocal microscopy using 
the DeadEnd™ Fluorometric TUNEL system (Promega). 1x106 cells were added to 
96-well round-bottom plates (Corning) and fixed in 200µl 4% PFA for 25 minutes at 
4oC. The cells were then washed twice with PBS and centrifuged at 300xg for 5 min 
at room temperature. To permeabilise the cells they were incubated with 200µl 0.2% 
Triton-X 100 in PBS for 5 min. After washing twice with PBS, 200µl of 
equilibration buffer was added to the wells and incubated for 10 min at room 
temperature. The plate was centrifuged at 230xg for 6 min and the buffer was 
removed and replaced with TdT incubation buffer (per reaction: 180µl equilibration 
buffer, 20µl nucleotide mix, and 4µl rTdT enzyme) for a further 60 min in the dark at 
37oC. Adding 2x SSC buffer for 15 min at room temperature terminated the reaction. 
The cells were washed three times prior to counterstaining with DAPI (1:10,000), 
and adhered to slides by cytospin (300xg for 3 min). Coverslips were attached to the 
slides using ProLong gold antifade reagent (Invitrogen). Images were acquired on a 
Leica TCS SP5 (Leica Microsystems) confocal laser scanning microscope with a 
fixed stage inverted microscope DMI6000CS, equipped with a HCX PL APO 
63x/1.33 NA oil immersion objective. Images were acquired using LAS AF software 
(Leica Microsystems) and fluorescence was measured using ImageJ software. 
 
  Scanning Electron Microscopy 2.13
The cells were fixed in a solution of 3% glutaraldehyde in 0.1 M sodium cacodylate 
buffer (pH 7.3) for 2 h.  They were then washed in 3 x 10 min changes of 0.1 M 
sodium cacodylate buffer. Stephen Mitchell (Electron Microscopy Facility, School of 
Biological Sciences, University of Edinburgh, UK) prepared the fixed samples for 
viewing as follows:  cells were post-fixed in 1% osmium tetroxide in 0.1 M sodium 
cacodylate buffer for 45 min.  A further 3 x 10 min washes were performed in 0.1 M 
sodium cacodylate buffer. Dehydration in graded concentrations of acetone (50%, 
70%, 90%, and 3 x 100%) for 10 min each was followed by critical point drying 
using liquid carbon dioxide.  After mounting on aluminium stubs with carbon tabs 
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attached, the samples were sputter coated with 20nm gold palladium. The cells were 
then viewed using a Hitachi S-4700 scanning electron microscope.   
 
  Transmission Electron Microscopy 2.14
Cells were fixed in 3% glutaraldehyde in 0.1M Sodium Cacodylate buffer, pH 7.3, 
for 2 h then washed in three 10 min changes of 0.1M Sodium Cacodylate. Stephen 
Mitchell (Electron Microscopy Facility, School of Biological Sciences, University of 
Edinburgh, UK) prepared the fixed samples for viewing as follows: Cells were post-
fixed in 1% Osmium Tetroxide in 0.1M Sodium Cacodylate for 45 min, then washed 
in three 10 min changes of 0.1M Sodium Cacodylate buffer.  These samples were 
then dehydrated in 50%, 70%, 90% and 100% normal grade acetones for 10 min 
each, then for a further two 10-miN changes in analar acetone. Samples were then 
embedded in Araldite resin.  Sections, 1µm thick were cut on a Reichert OMU4 
ultramicrotome, stained with Toluidine Blue, and viewed in a light microscope to 
select suitable areas for investigation.  Ultrathin sections, 60nm thick were cut from 
selected areas, stained in Uranyl Acetate and Lead Citrate. The cells were viewed in 
a Philips CM120 Transmission electron microscope and images were taken on a 
Gatan Orius CCD camera. 
 
  Western Blotting 2.15
  Cell lysis 2.15.1
A stock of 2X RIPA buffer (Table 2.4) was diluted to 1X immediately prior to use by 
mixing 500µl 2X RIPA buffer with 300µl dH20 and 200µl Complete mini protease 
inhibitor cocktail (Roche, Sigma-Aldrich). 50µl 1X RIPA buffer was added to each 
cell pellet following washes in cold PBS and centrifuging at 300xg for 5 min. The 
pellet was then vortexed and incubated on ice for a total of 30 min, vortexing every 
10 min. The lysate was centrifuged at 12,000xg for 15 min at 4oC and the 
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Reagent Concentration  





Sodium deoxycholate 1% 
Triton-X 100 2% 
Glycerol 20% 
Table 2.4 2X RIPA Buffer 
  Quantification of protein concentration 2.15.2
Cell lysates were thawed slowly on ice and then quantified using the DC protein 
assay reagents (Bio-Rad Laboratories) as described in section 2.11. The protein 
standard was generated by diluting BSA (Europa Bioproducts) in RIPA buffer to 
5mg/ml (top standard) and doing a two-fold dilution series in a 96-well plate.  
  SDS-PAGE and Transfer 2.15.3
20µg of protein samples were prepared for gel electrophoresis by adding 5x Laemmli 
buffer to obtain a 1x dilution. To further denature proteins, the samples were heated 
to 95oC for 5 min followed by brief centrifugation. The samples were loaded onto a 
12% gel (Table 2.5 and 2.6) alongside SeeBlue Plus2 pre-stained protein standard 
(Invitrogen) for determination of band molecular weight. The gel tank (Bio-Rad) was 
filled with running buffer (25mM Tris, 192mM glycine, 0.1% SDS in dH2O) and run 
at 170V for 5 min, or until the samples had moved out of the wells, then 130V for 
approximately 90 min. Proteins were then transferred onto a PVDF membrane (GE 
Healthcare) using the semi-dry transfer method. Membranes were pre-soaked in 
methanol before being equilibrated in transfer buffer (25mM Tris, 192mM glycine, 
10% methanol in dH2O). Gels were rinsed in transfer buffer and layered on top of the 
membrane and the gel/membrane was sandwiched between blotting paper in a Trans-
Blot semi-dry (Bio-Rad). After running at 30V for 45 min, membranes were blocked 
in 1x TBST (20 mM Tris, 150 mM NaCl. 0.1% Tween-20; pH 7.4) containing 5% 
milk for 1 h at room temperature. Membranes were immunoblotted overnight at 4oC 
in 1x TBST/5% milk with the relevant antibodies stated in the results chapter at 
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dilutions stipulated in Table 2.7. The membranes were washed 4x for 15 min in 1x 
TBST then incubated in goat anti-rabbit HRP-conjugated secondary antibody 
(1:3000; Santa Cruz Biotechnology) for 45 min at room temperature with rotation. 
After washing for 2 h with 1x TBST replaced every 15 min, the blots were developed 
with WestFemto enhanced chemiluminescent substrate (ThermoFisher Scientific). 
 
Reagent Volume (mL) for one gel 
dH20 3.3 
30% acrylamide mix 4.0 
1.5 M Tris (pH 8.8) 2.5 
10%SDS 0.1 
10% ammonium persulfate 0.1 
TEMED 0.004 
Table 2.5. 12% Resolving Gel 
 
Reagent Volume (mL) for one gel 
dH20 2.7 
30% acrylamide mix 0.67 
1.0 M Tris (pH 6.8) 0.5 
10%SDS 0.04 
10% ammonium persulfate 0.04 
TEMED 0.004 
Table 2.6. 5% Stacking Gel 
 
Antibody  Host Source Dilution 





Anti-ATG3 Rabbit Abcam 1:1000 
Anti-β−actin Rabbit Abcam 1:5000 
Table 2.7. Antibodies used for western blotting 
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  RNA extraction  2.16
 Chloroform/Isopropanol Method 2.16.1
1x106 cells cells were washed in PBS and centrifuged at 300xg for 5 min. 100µl TRI 
Reagent (Ambion) was added to the cell pellet, which was then mixed by gently 
pipetting to lyse the cells and incubated at room temperature for 5 min. 30µl 
chloroform (Sigma-Aldrich) was added per 100µl TRI Reagent and the tubes were 
vortexed for 15 sec, incubated on ice for 5 min, and then centrifuged at 12,000xg for 
15 min at 4°C. The upper aqueous phase containing RNA was carefully collected and 
transferred to a new tube. To precipitate RNA, 50µl isopropanol (Sigma-Aldrich) 
was added per 100µl TRI Reagent originally used, and 1µl glycogen (Invitrogen) was 
added to enhance RNA sedimentation. The samples were subsequently incubated for 
10 min at room temperature and then centrifuged at 12,000xg for 10 min at 4°C. The 
supernatant was carefully removed and 100µl of 75% ethanol was added to the 
remaining RNA pellet. After briefly vortexing and incubating for 10 min at room 
temperature, the samples were then centrifuged at 5000xg for 5 min at 4°C. The 
supernatant was removed and the RNA pellet was air-dried for 15 min on ice. To 
DNase treat the RNA, the pellet was resuspended in 8µl RNase-free water, mixed 
with 1µl RQ1 DNase 10X reaction buffer and 1µl RQ1 RNase-Free DNase 
(Promega) then incubated for 30 min at 37°C. The reaction was stopped by adding 
1µL RQ1 Stop Reaction Buffer (Promega) and incubating for 10 min at 65°C. 30µl 
RNase-free water (Ambion) and 55µl isopropanol was then added to the RNA and 
incubated for 10 min at room temperature. The RNA was centrifuged at 12,000xg for 
15 min at 4°C. After removing the supernatant 100µl 75% ethanol was added, the 
sample was incubated for 15 min at room temperature, and centrifuged at 12 000xg 
for 5min, 4°C. The ethanol was removed and the pellet was air-dried for 15 min on 
ice. RNA was re-suspended in 15µl RNase-free water. RNA concentration was 
measured by the NanoDrop 1000 spectrophotometer (Thermo Scientific). 
 Qiagen RNeasy Mini Kit Method 2.16.2
2x106 cells were washed in PBS and centrifuged at 300xg for 5 min then the pellet 
was lysed in 250µl TRI Reagent (Ambion), as described in 2.16.1. 30µl chloroform 
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(Sigma-Aldrich) was added per 100µl TRI Reagent and the tubes were vortexed for 
15 sec, incubated at room temperature for 2-3 min, and then centrifuged at 12,000xg 
for 15 min at 4°C. The upper aqueous phase containing RNA was carefully collected 
and transferred to a new collection tube. Per 100µl of aqueous phase, 350µl of cold 
buffer RLT and 250µl of cold 100% ethanol were added. The sample was vortexed, 
pipetted into an RNeasy Mini column with a 2ml collection tube, and centrifuged at 
12,000xg for 15 sec at room temperature. After discarding the flow through, on-
column DNase digest was performed as follows. 500µl of buffer RW1 was pipetted 
in the column and centrifuged at 12,000xg for 15 sec. The column was then added to  
a new collection tube and DNase 1 mix (10µl DNase with 70µl of buffer RDD) was 
pipetted directly onto the centre of the column for 15 min at room temperature. 500µl 
of buffer RW1 was added to the column and centrifuged at 12,000xg for 15 sec. The 
collection tube was changed and 500µl of buffer RPE was pipetted in the column and 
centrifuged at 12,000xg for 15 sec. The flow through was then discarded and 500µl 
of buffer RPE was pipetted in the column and centrifuged at 12,000xg for 2 min. To 
remove the last drops of buffer the column was added to a new collection tube and 
centrifuged at maximum speed for 2 min with open an open lid. To recover the RNA 
in the flow through, 12µl RNase-free H2O was pipetted directly onto the centre of the 
column, incubated for 2 min at room temperature, and centrifuged at 12,000xg for 1 
min. RNA concentration was measured by the NanoDrop 1000 spectrophotometer 
(ThermoScientific), and stored at -80oC. 
  Quantitative real-time PCR (qPCR) 2.17
  Reverse transcription of RNA to cDNA 2.17.1
RNA was reverse transcribed to cDNA using the High Capacity cDNA reverse 
transcription (RT) kit (Applied Biosystems/Life Technologies). 1µg RNA was made 
up to 10µl with nuclease-free H20 (Ambion) in 0.6 ml thin-walled PCR tubes 
(Thermo Fisher Scientific) and 10µl 2x RT master mix (Table 2.8) was added. The 
tubes were placed in the iCycler Thermal Cycler (Bio-Rad) and reverse transcription 
was performed using the following conditions: annealing at 25oC for 10 min, 
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extension at 37oC for 120 min, denaturing at 85oC. The cDNA samples were stored 
at -20oC until required. 
 
Component Volume per sample (µl) 
10x RT Buffer 2.0 
25x dNTP mix (100mM) 0.8 
10x RT Random Primers 2.0 
MultiScribe Reverse Transcriptase 1.0 
RNase Inhibitor 1.0 
Nuclease-free H20 (Ambion) 3.2 
Table 2.8. 2X Reverse Transcription master mix 
  qPCR using Taqman assay 2.17.2
20ng of cDNA in a final volume of 10µl was pipetted into duplicate wells in a 
MicroAmp Fast Optical 96-well plate (Applied Biosystems). Per well, 15µl of 
reaction mastermix (12.5µl 2X Taqman Universal PCR Mastermix, 1.25µl 20X 
Taqman probe, 1.25µl Nuclease-free H20) was added. Taqman probes were used for 
analysis of human ATG5 (Hs00169468_m1), ATG3 (Hs00223937_m1), Calpain-1 
(Hs00559804_m1), and Calpain-2 (Hs00965097_m1). In separate wells, the relative 
gene expression between cDNA samples was quantitated using the endogenous 
control gene 18S rRNA. Per well, 2µl of diluted cDNA was added and mixed with 
23µl of reaction mastermix (12.5µl 2X Taqman Universal PCR Mastermix, 1.25µl 
20X Eukaryotic 18s rRNA (FAM/MGB) probe, 9.25µl Nuclease-free H20). The 
plates were sealed with MicroAmp® Optical adhesive film (Life Technologies) and 
centrifuged at 300xg for 30 sec. Plates were run on a 7900HT Fast-real time system 
using SDS software version 2.4.1 (Applied Biosystems) with PCR amplification 
cycle: 50°C 2 min 1x cycle, 95°C 10 min 1x cycle, 95°C 15 sec and 60°C 1 min 40x 
cycles. 
 
Resulting threshold cycles (CT) values were obtained from the amplification plot. 
The data was analysed using delta-delta CT, which normalises the fold difference in 
samples to the fold difference in the respective 18S reference gene. 
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 SNP Genotyping 2.18
SNP genotyping was performed on genomic DNA from controls (n=23 healthy and 
n=15 control patients) and SLE patients (n=42). The donors were matched for age 
(control 45 [24-77]; SLE 47 [21-71]) and sex F:M (control 5.3:1; SLE 6:1). 
 Isolation of DNA from whole blood 2.18.1
200µl of whole blood extracted from healthy donors, SLE patients, and patient 
controls was pipetted in to a 0.5ml eppendorf tube and snap-frozen on dry ice. The 
frozen blood was stored at -80oC until used. Genomic DNA was isolated from the 
blood using the FlexiGene DNA kit (Qiagen). The frozen blood was thawed quickly 
in a 37oC water bath and transferred to a 1.5ml eppendorf tube. 500µl Buffer FG1 
was added to the blood and mixed by inversion of the tube then centrifuged at 
10,000xg for 20 sec. After discarding the supernatant the tube was inverted on to a 
clean sheet of absorbent paper towel for 2 min. A mixture of 100µl Buffer FG2 and 
1µl Qiagen Protease was prepared, which was added per sample and immediately 
vortexed for 5 sec. The tube was centrifuged briefly and then placed in a heating 
block at 65oC for 5 min to digest the protein. 100µl isopropanol (100%) was added 
and the sample was mixed by inversion until the DNA precipitated. Following 
centrifugation at 10,000xg for 5 min the supernatant was discarded and 100µl ethanol 
(70%) was added and the tube was vortexed for 5 sec. The tube was centrifuged at 
10,000xg for 5 min and the supernatant discarded. After inversion on to a clean sheet 
of absorbent paper towel for 5 min, the DNA was air-dried for 5 min and the DNA 
was dissolved in 200µl Buffer FG3 at 65oC for 1 h. The DNA was quantified using 
the NanoDrop 1000 spectrophotometer (ThermoScientific). 
 Analysing DNA integrity by Agarose Gel 2.18.2
Electrophoresis 
Integrity of gDNA was checked on 2% agarose gels following isolation from blood. 
To make the agarose gel, 1.2g agarose was dissolved in 1X TAE buffer (40mM Tris, 
20mM Acetate and 1mM EDTA) by heating the mixture and adding GelRed™ 
nucleic acid gel stain (1:10,000; Biotium). When it had cooled the gel was poured 
into a mini-sub cell GT tank (Bio-Rad) with a 15-lane comb. 10µl of gDNA sample 
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was mixed with 2µl blue/orange 6X loading dye (Promega) and loaded in to the lanes 
alongside Quickload 100bp DNA ladder (New England BioLabs). The gel tank was 
filled with 1X TAE buffer and run at 80V for 1 h and then imaged using a U:Genius3 
(Syngene).  
 Taqman SNP Genotyping Assay 2.18.3
13.75µl of reaction mix (12.5µl 2X Taqman Genotyping Mastermix and 1.25µl 20X 
predesigned SNP genotyping assay) was pipetted into each well in MicroAmp Fast 
Optical 96-well plate (Applied Biosystems). gDNA was diluted to 10ng in nuclease-
free H2O to a final volume of 11.25µl and then added to wells in duplicate. The 
plates were sealed with MicroAmp® Optical adhesive film (Life Technologies) and 
briefly centrifuged. Each assay contained two Taqman MGB probes with different 
reporter dyes at the 5’ end to distinguish the two alleles (Allele 1/Allele 2) at the SNP 
site. VIC dye was linked to allele 1 and FAM dye was linked to allele 2. The 











ATG16L-1 rs2241880  
CCCAGTCCCCCAGGACAATGTGGAT(A/G)CTCATCCTGGTTCTGGTAAAGAAGT 
 
Plates were run on a 7900HT Fast-real time PCR system using SDS software version 
2.4.1 (Applied Biosystems). An allelic discrimination pre-read run was performed to 
record the background fluorescence of each well. The amplification run was 
performed using the thermal profile: 2 min at 50°C, 10 min at 95°C followed by 40X 
cycles each of 15 sec at 95°C and 1 min at 60°C. An allelic discrimination post-read 
run then recorded the fluorescence of each well and subtracted the pre-read run 
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values to obtain the fluorescence that was caused by the PCR amplification. Taqman 
Genotyper Software was used to analyse the raw data.  
 
  Phagocytosis Assays 2.19
For visualisation of apoptotic cells, healthy and SLE lymphocytes, and non-adherent 
iBMK cells were re-suspended at 10x106 cells per ml in serum-free IMDM and 
labelled with cell membrane tracker (CM) green, or orange, 1µg/ml (Invitrogen), for 
15 min at 37oC. Fluorescently labelled cells were washed in serum-containing 
medium and induced to become apoptotic by UV irradiation (100mJ/cm2) at 1x106 
cells per ml. Apoptotic cells were used in the phagocytosis assay at a ratio of 5:1 
(apoptotic cell: macrophage). Zymosan A (S. cerevisiae) bioparticles conjugated to 
AF594 (Molecular Probes, Life Technologies) were used in the phagocytosis assay at 
a ratio of 8:1 (zymosan: macrophage) as described previously247. After 1 h at 37oC 
5% CO2 macrophages were washed twice with PBS to remove apoptotic cells and 
zymosan bioparticles that had not been phagocytosed. 
 Confocal microscopy 2.19.1
For measuring phagocytic index by confocal microscopy, macrophages on coverslips 
were fixed with 4% PFA for 20 min, stained with DAPI (1:10,000) for 5 min and 
mounted on to slides using ProLong gold antifade reagent (Invitrogen). Images were 
acquired on a Leica TCS SP5 (Leica Microsystems) confocal laser scanning 
microscope with a fixed stage inverted microscope DMI6000CS, equipped with a 
HCX PL APO 63x/1.33 NA oil immersion objective. Images were acquired using 
LAS AF software (Leica Microsystems) and analysed using ImageJ software. The 
phagocytic index was defined as the product of the percentage of macrophages 
positive for phagocytosis and the number of apoptotic cells/zymosan bioparticles per 
macrophage, as previously described45. 
 Flow cytometry 2.19.2
To detect phagocytosis by flow cytometry, macrophages were detached from the 
well by adding 500µl Accutase® cell detachment solution for 15 min at room 
temperature. HMDMs were stained with anti-human CD14 AF647 clone HCD14 
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(BioLegend) and BMDMs were stained with anti-mouse F4/80 APC clone BM8 
(eBioscience; performed by Katherine Miles) for 20 min at 4oC then acquired using 
the LSR Fortessa (BD Biosciences). 
 
  LC3-associated phagocytosis (LAP) assays 2.20
Healthy and SLE monocytes were cultured on coverslips at 2x106/ml for three days, 
as described in section 2.3.1. CM-green labelled healthy donor CD4+ lymphocytes 
were UV irradiated (100mJ/cm2) at 1x106 per ml, and incubated overnight (500µl per 
well in a 24-well plate) to become apoptotic. The apoptotic CD4+ lymphocytes were 
counted and added to the macrophages on coverslips at 1.5x106 per well in 250µl for 
60 min. All healthy and SLE day macrophages were fed CD4+ lymphocytes from the 
same healthy donor. The zymosan bioparticles were added as described in section 
2.19. After the incubation period, coverslips were washed twice with PBS to remove 
free apoptotic cells and zymosan bioparticles. To permeabilise the macrophages and 
release non-membrane bound LC3, the coverslips were incubated in digitonin, 
100µg/ml (Sigma-Aldrich) in PBS containing 1% PFA for 2 min on ice. After 
washing in TBS (20mM Tris/100mM NaCl) + 0.01% Tween-20, the macrophages 
were fixed in 4% PFA (Sigma-Aldrich) for 20 min at room temperature. The 
coverslips were briefly washed then incubated in TBS containing 1% BSA, 0.3M 
glycine, and 0.05% Tween-20 for 30 min at room temperature to block non-specific 
antibody binding. 250µl of primary polyclonal antibody, anti-LC3, (1:300; MBL 
International) in TBS/1% BSA was added to coverslips in 24-well plates overnight at 
4°C. The coverslips were washed for five repeats of 5 min then incubated for 1 h at 
room temperature with secondary antibody, goat anti-rabbit AF647 (1:400; Life 
Technologies) for macrophages cultured with apoptotic cells, and goat anti-rabbit 
AF488 (1:400; Life Technologies) for macrophages cultured with zymosan 
bioparticles. The coverslips were washed for five repeats of 5 min then stained with 
DAPI (1:10,000) for 5 min and mounted on to slides using ProLong gold antifade 
reagent (Invitrogen). Images were obtained by confocal microscopy as described in 
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  Statistical analysis 2.21
All statistical analysis was performed using GraphPad Prism 6. Where appropriate, 
results are reported as the mean of n experiments ± standard error of the mean 
(SEM). Comparisons between two groups were assessed by Student’s t-test and for 
data containing more than two groups the analysis of variance (ANOVA). A paired t-
test was performed if the comparison was between matched samples (i.e. untreated 
compared to treated). SNP genotype frequencies and distribution between controls 
and SLE patients was tested using 3 x 2 contingency tables and the χ2 test, and the 
allele frequencies were tested using the Fisher’s exact test stating odds ratio (OR) 
and 95% confidence interval (95% CI). P values less than 0.05 were considered 
significant to reject the null hypothesis.  
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Chapter 3 Apoptotic cells induce differential 




The innate immune pDC is best known for its ability to secrete large amounts of type 
I IFN in response to viral infection152. The selective expression of TLR7 and TLR9, 
and constitutive expression of IRF7, leads to the rapid production of type I IFN and 
downstream effector molecules, which ensures that pDCs are rarely infected 
themselves with virus198. Rather, they sense virally infected host cells, many of 
which have undergone apoptosis201,264. Following infection-induced apoptosis, 
complexes containing viral particles and host nucleic acids are expressed on the 
surface of apoptotic cells and smaller apoptotic bodies265.  
 
Once engulfed within the pDC, viral particles are trafficked to endosomes where 
they encounter TLRs. Here single stranded RNA is recognised by TLR7, whilst 
double-stranded DNA stimulates TLR9. Synthetic immuno-stimulatory 
oligonucleotide sequences (ISS) include the TLR9 ligands CpGA, CpGB and the 
TLR7 ligand R848. CpGA forms multimeric complexes that are held up in the early 
endosomes, stimulating MyD88-IRF7 and leading to type I IFN secretion266,267. In 
contrast, monomeric CpGB homes to the late endosomal lysosomal pathway, 
stimulating MyD88-NF-κB and the secretion of IL-6, TNF-α and pro-inflammatory 
chemokines268,269. This size-mediated intracellular trafficking is believed to explain 
the differential effect on cytokine production102.  
 
To carry out immune surveillance, pDCs circulate through the blood entering 
secondary lymphoid organs via high endothelial venules, where they gather in the T 
cell regions and the marginal zone of the spleen270. They are also recruited to 
damaged tissues where they encounter apoptotic cells within an inflammatory 
milieu102,140. PDCs are therefore in a prime position to interact with either healthy or 
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infected apoptotic cells being filtered from the blood into the splenic marginal zone, 
or dying at sites of infection and inflammation271. However, it is generally believed 
that pDCs only recognise late apoptotic/secondarily necrotic cell derived nucleic 
acids in association with high-titre autoantibodies found in SLE272, or bound to the 
antimicrobial peptide LL37, released from NETotic neutrophils93,273. Receptor-
mediated uptake of these immune complexes by pDCs then leads to the secretion of 
IFNα following TLR7/9 activation98-101,272.  
 
Although the nuclear antigens associated with SLE are expressed on the surface of 
apoptotic cells during the normal process of programmed cell death6,73,274, the 
intracellular location of TLR7 and TLR9 is thought to shield the pDC from 
mammalian nucleic acid under normal conditions166. However immature pDCs can 
endocytose antigens from infected275 and apoptotic cells276, suggesting that they 
should be able to interact with and endocytose chromatin complexes expressed by 
apoptotic cells.  Furthermore, TLR9-activated pDCs promote immune tolerance via 
the generation of regulatory T cells189. Currently the literature draws conflicting 
conclusions on the response of pDCs to apoptotic cells.  
 
Aims 
The main hypothesis of this chapter was that pDCs respond to primary apoptotic 
cells, but immunity or tolerance is promoted depending on the context in which they 
are recognised. This was evaluated using the following aims: 
 
• Compare the cytokine response of highly purified pDCs co-cultured with 
synthetic TLR7/9 ligands and apoptotic, or necrotic primary cells. 
• Establish if the co-recognition of apoptotic cells and virus enhances IFN-α 
production by pDCs. 
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 Results 3.2
 Apoptotic cells do not stimulate pDCs in vitro.  3.2.1
PDCs are likely to encounter healthy apoptotic cells in vivo, so I first asked if they 
sensed apoptotic cells as a danger signal. In the absence of other stimuli, highly 
purified murine splenic pDCs (Appendix B Figure 1) were co-cultured for up to three 
days with apoptotic thymocytes. In the presence of apoptotic cells, pDCs did not 
upregulate expression of activation markers CD40, CD86 and MHC Class II (Figure 
3.1.A). They also did not secrete cytokines, including IL-10, IL-6, IFN-γ, IL-12, or 
IFN-α (Figure 3.1.B), even though 30% of apoptotic cells had started to become 
secondarily necrotic within 24 hours (Figure 3.1.C). 
 PDCs that have interacted with apoptotic cells produce 3.2.2
IL-10 or IFN-α depending on the TLR stimulus. 
PDCs rapidly die in vitro unless survival is maintained by additional activation277,278. 
I included the TLR7 ligand R848 in the co-culture with apoptotic cells, which 
upregulated the pDC activation markers CD86, CD40 and MHC Class II, and 
promoted pDC survival (Figure 3.2A-D).  The combination of apoptotic cells and 
R848 induced the pDCs to secrete significantly more IL-10, IL6, and IFN-γ (Figure 
3.3.A-C), but not IL-12, or IFN-α (Figure 3.3.D-E) three days (and seven days, 
Figure 3.3.Aii) following co-culture. A similar pattern of cytokine secretion was seen 
when pDCs were stimulated with the TLR9 ligand CpGB (Figure 3.3.A-E), which 
was shown to bind to the surface of apoptotic cells (Appendix B Figure 2.Ai). In 
contrast, IL-10, IL6, IFN-γ, and IL-12 were not enhanced when pDCs were cultured 
with apoptotic cells and the synthetic TLR9 ligand CpGA (Figure 3.3.A-D), which 
also interacted with the apoptotic cell surface (Appendix B Figure 2.Bi); whereas 
IFN-α secretion was significantly augmented (Figure 3.3.E). To determine if this 
effect was specific to apoptotic thymocytes, TLR-activated pDCs were also co-
cultured with apoptotic splenic B cells, which yielded similar results (Figure 3.3.F-
G). Apoptotic cells that were cultured alone with TLR ligands were not stimulated to 
produce cytokines. The time points and concentration of synthetic TLR ligands were 
selected based on initial time courses and dose responses (Appendix B Figure 3).  
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It is currently believed that pDCs do not produce IL-10 in response to TLR stimuli 
alone279, though it has not been investigated how TLR-stimulated pDCs respond to 
apoptotic cells. I confirmed that IL-10 was being generated by pDCs in co-culture 
using intracellular IL-10 staining. Following three days of co-culture with apoptotic 
cells and R848, a mean of 12.5% pDCs expressed IL-10 protein and this was still 
evident seven days later in a mean of 9% of the pDCs (Figure 3.4.A-B). Intracellular 
IL-10 was not detected in R848-stimulated pDCs in the absence of apoptotic cells 
(Figure 3.4.A), or in more than 2% of the apoptotic cells (Figure 3.4.C).  
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Figure 3.1. Apoptotic cells do not stimulate pDCs in vitro. 
Beginning on the previous page, (A) pDCs were cultured alone (No AC) and with 
106 UV-irradiated apoptotic thymocytes (+ AC) for one and three days. The cells 
were harvested and analysed by flow cytometry using the markers PDCA1 and B220 
to select for pDCs, and the activation markers CD86, CD40, and MHC Class II.  (B) 
The secretion of IL-10, IL-6, IFN-γ, IL-12, and IFN-α by pDCs cultured alone (No 
AC, black bar) and with 106 UV-irradiated apoptotic thymocytes (+ AC, grey bar) 
was measured in cell supernatants after one and three days in culture. (Ci) 
Representative FACS plots showing annexin V and propidium iodide staining of 
thymocytes 4 h and 24 h after UV irradiation. (Cii) The mean proportion of apoptotic 
(AnV+ PI-) and secondarily necrotic (AnV+PI+) thymocytes 4 h (black bar) and 24 h 
(grey bar) after UV irradiation. Error bars represent SEM of three independent 
experiments. Statistical significance was determined by t test. * P= 0.0303; ** 
P=0.0052. 
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Figure 3.2. TLR7 stimulation by R848 induces pDC activation and survival 
PDCs were cultured for three days alone (D3 pDC) and with R848 (D3 pDC + R848) 
and then analysed by flow cytometry for the expression of (A) CD86, (B) MHC 
Class II, (C) CD40, and (D) annexin V (AnV). FACS plots represent one of three 
independent experiments.  
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Figure 3.3. Apoptotic cells induce pDCs to produce IL-10, or IFN-α depending 
on the TLR stimulus. 
pDCs were unstimulated, or stimulated with R848 (1µg/ml), CpGB (10µg/ml), and 
CpGA (20µg/ml) and were cultured alone (No AC, black bar), or with 106 apoptotic 
thymocytes (+ AC, light grey bar). Apoptotic (AC) thymocytes were cultured alone 
unstimulated, or stimulated with R848, CpGB, and CpGA, which did not result in 
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cytokine production. IL-10 protein was measured in cell supernatants by ELISA after 
(Ai) three days and (Aii) seven days in culture. (B) IFN-γ, (C) IL-6, (D) IL-12, and 
(E) IFN-α protein production were also quantified by ELISA after three days in 
culture. (Fi) IL-10 was measured in the cell supernatants three days and seven days 
after pDCs stimulated with R848 were cultured alone, or with 2x105 apoptotic (AC) 
B cells. CpGA-stimulated pDCs were cultured with and without apoptotic B cells for 
three days then (Fii) IL-10 and (G) IFN-α were quantified in cell supernatant. Data 
are the mean of three to eight independent experiments. Error bars represent SEM. 
Statistical significance was determined by t-test, comparing cytokine responses by 
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(A) PDCs stimulated with R848 and cultured alone (pDC) or with apoptotic B cells 
(pDC + AC) for three days (D3) and seven days (D7) were harvested and stained for 
intracellular IL-10. (i) FACS plots showing the gating strategy to select single cells. 
(ii) FACS plots showing the gating strategy of selecting IL-10-positive pDCs. FACS 
plots are representative of three independent experiments. (B) The mean percentage 
of IL-10 secreting pDCs (PDCA1+ B220+ IL-10+) following culture with apoptotic B 
cells. Error bars represent SEM. (C) Representative FACS plots of intracellular IL-
10 in apoptotic B cells (B220+ PDCA1-) cultured with R848 and pDCs for three and 
seven days. 
 
 PDCs respond to direct contact with whole apoptotic, 3.2.3
but not necrotic cells.  
It has been reported that pDCs secrete IFN-α in response to nuclear material released 
from necrotic cell lines that is in a complex with autoantibodies272. I asked if necrotic 
debris derived from primary cells could also induce pDCs to secrete IFN-α. In 
contrast to whole apoptotic cells, necrotic primary cells did not enhance IFN-
α production by CpGA-stimulated pDCs (Figure 3.5.A). Additionally, IL-10 
production was not induced by pDCs activated with R848 or CpGB if the apoptotic 
cells were made necrotic by freeze-thawing (Figure 3.5.B-C). This shows that TLR-
activated pDCs only respond to intact primary apoptotic cells.  
 
To determine if this occurred through direct pDC-apoptotic cell contact, I separated 
pDCs and apoptotic cells in culture using a transwell insert. Flow cytometric analysis 
of the supernatant revealed that components of apoptotic cells less than 0.4µm in size 
(here called ‘bodies’, as previously described20), but very few viable and apoptotic 
cells could pass through the transwell insert into the well below (Figure 3.6.A). 
Preventing direct cell contact for 72 h significantly inhibited one third of apoptotic 
cell-induced IL-10 production and 80% IFN-α production by pDCs stimulated with 
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Figure 3.5. PDCs do not respond to necrotic primary cells. 
(A) IFN-α and (B) IL-10 production were measured three days after R848, CpGB, 
and CpGA-stimulated pDCs were co-cultured alone (black bar) and with apoptotic 
(light grey bar), or necrotic (dark grey bar) thymocytes. (C) IL-10 production was 
measured three days after pDCs were co-cultured with R848 and apoptotic (light 
grey bar), or necrotic (dark grey bar) B cells. Data is the mean of three independent 
experiments with error bars representing SEM. Statistical significance was 
determined by one-way ANOVA, comparing cytokine responses by pDCs with and 
without apoptotic cells or necrotic cells. (A) *P=0.0111 and ***P=0.0006; (B) R848 
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Figure 3.6. Direct contact with apoptotic cells induces IL-10 and IFN-α 
secretion by pDCs. 
(A) Representative FACS plots showing the proportion of viable cells, apoptotic 
cells (AC) and bodies (determined by size and granularity, and excluding cell debris) 
remaining in the transwell insert and found in the well below after UV-irradiated 
thymocytes were cultured in the transwell for 24 h. 4x104 pDC were stimulated with 
(B) CpGB and (C) CpGA and cultured with and without 4x106 apoptotic cells (AC) 
in the presence (no contact) or absence (contact) of a transwell insert. After 3 days in 
culture, (B) IL-10 (*P=0.0324) and (C) IFN-α (*P=0.0232) in supernatants was 
measured by ELISA. Results represent mean plus or minus SEM of three 
independent experiments. 
 
 PDCs fail to respond to apoptotic cells in the presence 3.2.4
of virus. 
I wanted to determine if viral antigens mimic the pDC stimuli provided by CpGA 
and subvert apoptotic cell induced IL-10 secretion to stimulate IFN-α secretion. 
However, pDCs were not stimulated to secrete IFN-α following culture with the 
dsDNA virus, murine cytomegalovirus (MCMV) released from infected 3T3 cells, 
even in the presence of apoptotic cells (Figure 3.7.A). The ssRNA influenza A virus 
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also failed to induce IFN-α secretion and the pDCs did not respond to thymocytes 
that had been incubated with influenza for 1 h prior to initiation of apoptosis by UV 
irradiation  (Figure 3.7.Bi). Less than 2% of thymocytes were infected by influenza 
virus, as indicated by surface expression of virus protein markers hemagglutinin 
(HA) and M2280 (Figure 3.7.Bii-iii). Therefore I hypothesised that for pDCs to 
respond, the TLR ligands provided by virus and apoptotic cell nucleic acids need to 
be expressed on the same intact membrane. For that reason, it would be more 
physiological to use cells that were naturally infected by the viruses. 
 
MCMV and influenza virus both successfully infect epithelial cells, but it was 
important to check if apoptotic epithelial cell lines could induce IL-10 regulation 
since I wanted to ask if virus infection subverts IL-10. The C127 (mouse mammary 
epithelial) cell line was induced to undergo apoptosis by UV irradiation and after 6 h 
the majority of non-adherent cells were early apoptotic (AnV+PI-; Figure 3.8.Aii), 
whereas after 18 h incubation most of the non-adherent cells were necrotic (AnV- 
PI+; Figure 3.8.A.iii). Nevertheless, pDCs cultured with apoptotic C127 cells (UV + 
6h) and R848 did not produce IL-10 (Figure 3.8.B). I also found that starvation-
induced apoptotic iBMK cells did not stimulate IL-10-secreting B cells (Figure 
3.8.C). This indicated that apoptotic cell lines do not induce the same regulatory 
phenotype as apoptotic primary cells and could not be used in my assays. 
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Figure 3.7. PDCs were not stimulated to secrete IFN-α when co-cultured with 
virus and apoptotic cells. 
(A) IFN-α in supernatant was measured 24 h after pDCs were cultured without 
apoptotic cells (No AC) and with apoptotic cells (+ AC) in the following conditions: 
with 3T3 cells and CpGA, or 3T3 cells infected overnight with MCMV at a 
multiplicity of infection (MOI) 1, 2, and 5 then freeze-thawed (FT) to release free 
virus. (Bi) pDCs were cultured alone (No Stimulation), with CpGA with and without 
apoptotic cells, and with UV-inactivated influenza virus (MOI 0.1) either directly 
(No AC) or via infected thymocytes induced to become apoptotic cells (+ AC). (Bii-
iii) Influenza virus infection rate was measured by detecting M2 protein using 14C2 
monoclonal antibody (anti-mouse IgG AF647 secondary antibody) and 
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hemagglutinin (HA; anti-mouse IgG AF555 secondary antibody). Results are 
expressed as the mean of (A-Bi) three and (Bii-iii) two independent experiments with 




Figure 3.8. Apoptotic epithelial cell lines do not induce IL-10 secretion 
Representative FACS plots showing the proportion of apoptotic adherent and non-
adherent C127 cells was analysed by annexin V and PI staining of (Ai) untreated 
cells and UV irradiated cells after (Aii) 6 h, and (Aiii) 18 h. (B) IL-10 was measured 
in culture supernatants three days after pDCs were cultured with R848 alone (No 
AC), and with apoptotic thymocytes, or apoptotic C127 cells that had been UV 
irradiated and incubated for 6 h. **P=0.0043; ***P=0.0004. (C) IL-10 was measured 
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and with apoptotic thymocytes, or apoptotic iBMK cells that had been incubated in 
starvation media for 6 h. The results present the mean of three independent 
experiments and SEM. *P=0.412; **P=0.0016. 
 Cytokine production by pDCs is dependent on 3.2.5
apoptotic cell-derived DNA complexes 
Cells that have undergone apoptosis express nuclear DNA-containing chromatin 
complexes on the cell surface membrane and released apoptotic bodies6. It was 
previously shown that apoptotic cell-derived DNA complexes are essential for 
apoptotic cell-mediated induction of IL-10-secreting regulatory B cells55. To 
establish if DNA expressed by apoptotic cells was also important for stimulating IL-
10 secretion from pDCs, DNA was enzymatically removed from the apoptotic cell 
surface using DNase, as previously reported55. This did not affect the proportion of 
thymocytes that became apoptotic (AnV+ PI-) or secondarily necrotic (AnV+ PI+) 
(Figure 3.9.A), and it did not affect binding of CpG to the surface of apoptotic cells 
(Appendix B Figure 2.Aii and Bii). Removing apoptotic DNA complexes abolished 
the production of IL-10 from apoptotic cell/CpGB-stimulated pDCs (by day seven, 
Figure 3.9.B) and apoptotic cell/R848-stimulated pDCs (Figure 3.9.C). It also 
significantly reduced secretion of IL-6 and IFN-γ (Figure 3.9.D-E).  
 
I then asked if removing the DNA complexes that promote IL-10 secretion resulted 
in the pDCs sensing the apoptotic cells as inflammatory. However, IFN-α production 
was not enhanced when R848-stimulated pDCs were co-cultured with DNase-treated 
apoptotic cells (Figure 3.9.F). In fact, IFN-α production by CpGA-stimulated pDCs 
was also inhibited when apoptotic DNA complexes were removed (Figure 3.9.F). 
This confirms the importance of both the apoptotic cell expressed endogenous 
nucleic acid containing complexes on an intact membrane, and the synthetic TLR 
ligand presented to the pDCs. 
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Figure 3.9. CpGB and R848-induced cytokine production by pDCs is 
dependent on apoptotic cell-derived DNA complexes. 
(Ai) Representative FACS plots showing AnV and PI staining of UV-irradiated 
untreated thymocytes and DNase-treated thymocytes. (Aii) The mean proportion of 
apoptotic (AnV+ PI-) and secondarily necrotic (AnV+ PI+) untreated (black bar) and 
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DNase-treated (grey bar) UV-irradiated thymocytes from three independent 
experiments. (B) IL-10 was measured in the cell supernatant three and seven days 
after pDCs were cultured with CpGB alone (No AC, black bar) and with 106 
apoptotic cells (+ AC, light grey bar), or DNase-treated apoptotic cells (+ DNase-
AC, dark grey bar). (C) IL-10, (D) IL-6, and (E) IFN-γ were measured in the cell 
supernatant three and seven days after pDCs were cultured with R848 alone (No AC, 
black bar) and with 106 apoptotic cells (+ AC, light grey bar), or DNase-treated 
apoptotic cells (+ DNase-AC, dark grey bar). (F) IFN-α production was measured 
three days after pDCs were cultured with R848, or CpGA in the presence and 
absence of apoptotic cells (+ AC, light grey bar), or DNase-treated apoptotic cells (+ 
DNase-AC, dark grey bar). Data is shown as the mean of three to eight independent 
experiments, with error bars representing SEM. Statistical significance was 
determined by one-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ns (not 
significant). 
 
 TLR9 expression is required to sustain IL-10 production 3.2.6
by pDCs. 
In addition to stimulating anti-viral immunity, TLR9 ligands also drive pDC 
dependent T cell regulation189. Furthermore, TLR9 expressed by innate-like B cells 
plays an essential tolerogenic role, inducing regulatory B cells in mice and humans, 
in response to apoptotic cell-derived DNA55. Therefore, I was interested to determine 
if apoptotic DNA-dependent induction of IL-10 secretion by pDCs occurred through 
TLR9.   
 
As expected, IL-10 and IFN-α secretion was not detected in TLR9-deficient pDCs 
co-cultured with apoptotic cells and the TLR9 agonists CpGB (Figure 3.10.A) and 
CpGA (Figure 3.10.B), respectively. However following three days of co-culture 
with apoptotic cells and R848, WT and TLR9-deficient pDC secreted equivalent 
amounts of IL-10 (Figure 3.10.C), suggesting that TLR9 stimulation by the apoptotic 
cell expressed chromatin complexes was not required to induce TLR7-stimulated 
pDCs to secrete IL-10 by day three. Whilst WT pDCs had significantly increased the 
production of IL-10 from a mean of 261pg/ml to 394pg/ml by day seven, IL-10 
reduced from a mean of 230pg/ml to 176pg/ml in TLR9-deficient pDCs (Figure 
3.10.C). This indicates that TLR9 signalling was required to augment IL-10 secretion 
induced by R848/apoptotic cells. A similar pattern was also seen for the production 
of IL-6 (Figure 3.10.D) and IFN-γ (Figure 3.10.E) on day three and day seven.  
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Additional support for a regulatory role for TLR signalling is seen in TLR9 deficient 
lupus-prone mice, where despite the reduction in anti-DNA antibody titres, TLR7-
mediated disease is exacerbated; suggesting TLR9 negatively regulates TLR7 
activation191,192,281-283. Hence it may be expected that pDCs activated through TLR7 
(via R848) in the absence of TLR9 would secrete IFN-α when co-cultured with 
apoptotic cells. However, this was not seen (Figure 3.10.F).  
 
I consistently found that after flow sorting spleen, I obtained an average of one third 
of the number of TLR9-deficient pDCs compared to WT pDCs (Figure 3.11.A). 
However, the proportion of pre-sorted splenic pDCs was equivalent in WT and 
TLR9-deficient mice (Figure 3.11.B). Additionally, although there was no significant 
difference in the proportion of T cells (Figure 3.11.B) and whole B cells (Figure 
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Figure 3.10. IL-10 production by pDCs is sustained through TLR9. 
Beginning on the previous page, (A) PDCs isolated from wild type (WT) C57BL/6 
and TLR9-knockout (TLR9 KO) mice were cultured with CpGB alone (No AC, 
black bar) and with apoptotic cells (+ AC, grey bar). IL-10 protein was measured by 
ELISA after three days (D3) and seven days (D7) in culture. (B) WT and TLR9 KO 
pDCs were cultured with CpGA alone and with apoptotic cells. IFN-α protein in 
culture supernatants was measured after three days. (C) IL-10, (D) IL-6, (E) IFN-γ, 
and (F) IFN-α production was measured three and seven days after WT and TLR9 
KO pDCs were cultured with R848 alone and with apoptotic cells. Data is shown as 
the mean of three to eight independent experiments, with error bars representing 
SEM. Statistical significance was determined by t-test. *P < 0.05; **P < 0.01; ***P < 
0.001; ns (not significant). 
 



































Chapter 3: Apoptotic cells induce differential cytokine secretion by pDCs 89 
 
Figure 3.11. Fewer pDCs were purified from TLR9 KO spleen following flow 
sorting. 
(A) The percentage of WT (black bar) and TLR9 KO (grey bar) pDCs isolated 
following flow sorting was calculated as a percentage of the original whole spleen 
cell count. (Bi) Spleens from wild type (WT) and TLR9-deficient (TLR9 KO) mice 
were analysed by flow cytometry to detect T cells (CD3+) and pDCs (B220+ 
PDCA1+ Ly6C+). (Bii) The mean proportion of pDCs (top) and T cells (bottom) in 
WT (black bar) and TLR9 KO (grey bar) spleen. (Ci) Total B cells (CD19+) and 
marginal zone B cells (MZB; CD19+ CD21high CD23low) in WT and TLR9 KO spleen 
were analysed by flow cytometry. (Cii) The mean proportion of total B cells (top) 
and MZB cells (bottom) in WT (black bar) and TLR9 KO (grey bar) spleen. Data is 
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shown as the mean of (A) eight and (B-C) three independent experiments, with error 
bars representing SEM. Statistical significance was determined by t test. *P= (A) 
0.0329; (Cii) 0.0487; ns (not significant). 
 
 Antagonising HMGB1-RAGE interaction did not 3.2.7
significantly inhibit apoptotic cell-induced IFN-α.  
HMGB1 is a non-histone nuclear protein, which functions by binding to and bending 
DNA thereby increasing interactions with transcription factors284. HMGB1 released 
from necrotic cells acts as an alarmin by promoting inflammation104,285. It has also 
been reported that HMGB1 is released from late apoptotic cells286,287 and more 
recently it was shown to be expressed on apoptotic blebs288. Consistent with this, I 
found that HMGB1 expression was highest in late apoptotic/secondarily necrotic 
(82.3% AnV+ PI+) and necrotic (56.6% AnV- PI+) thymocytes, compared to live 
(3.4% AnV- PI-) and early apoptotic cells (9.3% AnV+ PI-) where the plasma 
membrane remained intact (Figure 3.12.A). 
 
PDCs express the HMGB1 receptor, RAGE, but not TLR2 or TLR4206. Following 
interactions with HMGB1, RAGE associates with TLR9, which is important for 
mediating IFN-α production induced by DNA-containing immune complexes from 
SLE patients210. The complex formed by HMGB1 and CpGA also augments IFN-
α production by pDCs through this mechanism210. Therefore, I assessed if HMGB1 
was involved in apoptotic cell-induced IFN-α secretion by CpGA-stimulated pDCs.  
 
IFN-α secretion by pDCs cultured with CpGA was enhanced by a mean of 45% 
when apoptotic cells were added to the culture; but this was limited to a mean of 
13% when binding of HMGB1 to RAGE was inhibited using the non-activating 
antagonist, box A from HMGB1 (Figure 3.12.B). However, the difference in IFN-α 
secretion between untreated and box A-treated cultures did not reach significance. 
Including box A in the culture medium did not inhibit IL-10 production by pDCs co-
cultured for three days with R848 and apoptotic cells (Figure 3.12.C). 
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 Apoptotic cells promote pDC-induced regulation. 3.2.8
PDCs are also known to promote immunological tolerance by inducing IL-10-
secreting Tregs cells via IDO and ICOS-L181-183,185. I repeated preliminary 
experiments generated during my MSc project in the Gray lab, which showed that 
seven days after culture OVA-specific T cells co-cultured with both pDCs and 
apoptotic cells resulted in a significant increase in IL-10 protein to approximately 
6000 pg/ml compared to T cells cultured with pDCs alone (2700 pg/ml) and 
apoptotic cells alone (3700 pg/ml) (Appendix B Figure 4.A). This suggests that the 
interaction of pDC with apoptotic cells may additionally induce IL-10 secretion by T 
cells; however IL-10 secretion was not mediated by IDO expression, as shown by 
using the competitive inhibitor, 1-methyl-DL-tryptophan (1MT) (Appendix B Figure 
4.B). 
 
Using these results, I hypothesised that apoptotic cells would drive TLR7-stimulated 
pDCs to adopt a regulatory phenotype. To test this, I co-cultured apoptotic cells, 
R848 and pDCs with CD4+ T cells for seven days. This resulted in a significant 
increase in IL-10 in the culture medium (3500 pg/ml) compared to T cells co-
cultured with R848 individually with pDCs (710 pg/ml), or apoptotic cells (110 
pg/ml) (Figure 3.13.A).  Using an IL10-secretion assay, I confirmed that this increase 
in IL-10 originated from the T cells, because while R848-activated pDC induced a 
mean of 7% of T cells to secrete IL-10, this was augmented more than 7 fold in the 
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Figure 3.12. Antagonising HMGB1-RAGE interaction did not significantly 
inhibit apoptotic cell-induced IFN-α production. 
(A) UV-irradiated thymocytes, were analysed by flow cytometry to detect anti-
HMGB1 antibody (goat anti-rabbit IgG AF647 secondary antibody) binding to the 
four different AnV and PI populations. (B) The percentage increase in IFN-α 
production induced by co-culture of CpGA-stimulated pDC with apoptotic cells in 
untreated medium (black bar), or medium treated with box A (grey bar). ns (not 
significant). (C) IL-10 production by pDCs cultured with R848, with (grey bar) and 
without (black bar) apoptotic cells in untreated medium (*P=0.0321), or medium 
treated with box A (*P=0.0142). Results are (B) the mean and (C) representative of 
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Figure 3.13. PDCs co-cultured with apoptotic cells induce IL-10 secretion by 
CD4+ T cells. 
(A) CD4+ T cells were cultured with R848 (1µg/ml), pDCs and apoptotic B cells in 
various combinations. After seven days, IL-10 production was measured by ELISA. 
(B) CD4+ T cell IL-10 production was quantified by IL-10 secretion assay. Data is 
shown as the mean of three independent experiments (A) or as a representative plot 
from 1 of 3 independent experiments (B). Statistical significance was determined by 
one-way ANOVA. (A)**P=0.0015; (B) **P=0.0099. 
 
 IL-10 secretion is enhanced in B cells, but not pDCs, 3.2.9
isolated from C1q-deficient mice. 
The lack of complement protein C1q is a major risk factor for developing SLE86, as 
C1q binds directly to the apoptotic cell membranes allowing other complement 
components to bind and mediate clearance by phagocytosis36,37,289. Additionally, C1q 
inhibits CpG and immune complex-mediated IFN-α production by pDCs290-292, and it 
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maintains B cell tolerance to intracellular antigens89. Therefore, because C1q is 
associated with regulating immune responses to apoptotic cells, I was interested to 
assess if the IL-10 response to wild type apoptotic cells was altered when pDCs and 
B cells were generated in a C1q-deficient environment.  
 
All experiments were performed in the absence of serum that would provide C1q. 
Here I show that, although IL-10 secretion by OVA-specific T cells was induced by 
pDCs purified from C1q KO mice and cultured with apoptotic cells and OVA 
peptide, the concentration of IL-10 produced was significantly impaired in 
comparison to co-culture with WT pDC (Figure 3.14.A). However, there was no 
significant difference in CpGB/apoptotic cell-induced IL-10 secretion by pDCs 
purified from WT and C1q KO mice (Figure 3.14.B).  
 
Conversely, apoptotic cells induced the production of more than double the 
concentration of IL-10 by B cells from C1q KO mice that were cultured with the 
TLR9 ligand CpGB, TLR7 ligand R848, TLR2 ligand PGN, and TLR4 ligand LPS 
(Figure 3.14.Ci-iv). IL-10 secretion by the TLR-stimulated B cells isolated from C1q 
KO mice was also significantly enhanced in the absence of apoptotic cells (Figure 
3.14.Ci-iv). To determine if B cells from C1q KO mice responded more greatly to 
apoptotic cells due to a regulatory role played by C1q to dampen BCR activity 
during development, I measured BCR-mediated calcium flux. I observed no 
difference in calcium flux following stimulation of B cells from WT and C1q-
deficient mice with anti-IgM (Figure 3.14.D). 
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Figure 3.14. IL-10 secretion is enhanced in B cells, but not pDCs, isolated from 
C1q-deficient mice. 
On the previous page, (A) IL-10 was measured seven days after OVA-specific T 
cells were cultured with OVA-peptide and pDCs from WT, or C1q KO mice, with 
(grey bar) and without (black bar) WT apoptotic thymocytes. (B) IL-10 was 
measured three days after pDCs purified from WT and C1q KO mice were cultured 
with CpGB alone (black bar) and with WT apoptotic thymocytes (grey bar). (C) IL-
10 was measured three days after CD19+ B cells purified from WT and C1q KO 
mice were cultured without apoptotic cells (black bar), and with WT apoptotic 
thymocytes (grey bar) and (i) CpGB, (ii) R848, (iii) PGN, and (iv) LPS. (D) 
Intracellular calcium flux in B cells isolated from WT and C1q KO mice responding 
to IgM was quantified using a spectrofluorimeter. Results are presented as the mean 
and SEM of three independent experiments. Statistical significance was determined 





Immune complexes composed of autoantibodies and nucleic acids derived from 
apoptotic cells are considered to drive SLE pathogenesis through TLR7/9 mediated 
IFN-α production by pDCs. However, the ability of pDCs from healthy subjects to 
maintain tolerance to apoptotic cells via IL-10, or induce pro-inflammatory IFN-α 
has not been clearly defined. This in vitro study shows that apoptotic cells and 
necrotic debris alone was insufficient to stimulate pDCs. Chromatin complexes 
expressed on the surface of late apoptotic cells, but not nuclear complexes released 
from necrotic cells directly affected pDC function only when they were presented 
with a second signal, provided in this study by ISS-ODNs.  
 
Depending on the TLR ligand used to co-activate the pDCs, IL-10 or IFN-α  was 
produced, demonstrating that the type and the context of cell death influences pDC 
responses. CpGA, which localised to the surface of apoptotic cells, prevented IL-10 
secretion induced by apoptotic DNA. The addition of CpGA may have mimicked the 
response to a virally-infected apoptotic cell, as it is known that infection-induced 
apoptosis results in the arrangement of autoantigens and viral antigens in clusters on 
small apoptotic blebs265.  This might ensure that an adequate anti-viral response is 
induced, as it has been shown that IFN-α secretion by pDCs is enhanced by virus-
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infected myeloid (m)DCs compared to free virus, although this was independent of 
mDC DNA264.  
 
As pDCs did not respond to apoptotic cells in the presence of free virus and they 
required direct contact with apoptotic cells to elicit optimal cytokine responses, it 
suggests that pDCs sample ligands that are co-expressed on an intact (apoptotic) cell 
membrane. Immature pDCs can endocytose and cross-present viral antigens from 
apoptotic cells202,275, therefore they should be able to interact with and endocytose 
chromatin complexes expressed by apoptotic cells or bodies. The RAGE antagonist, 
box A from HMGB1, limited apoptotic cell-induced IFN-α production by pDCs. 
Although the inhibition was not statistically significant, it suggests that activation of 
RAGE is involved in inflammatory pDC recognition of apoptotic cells. 
 
A link to various viruses and autoimmune diseases including SLE, Sjögren’s 
syndrome293 and type I diabetes has been known for some time294. Viral infection has 
been associated with both increased and decreased susceptibility to autoimmunity294. 
Thus CpGB and R848 might mimic viruses that induce IL-10 to inhibit the immune 
system, such as measles virus295 and HIV296. The nature of the apoptotic cell cargo 
may alter the way that self nucleic acids are recognised by pDCs. Consequently, viral 
infection would shape the outcome of the innate and adaptive immune response to 
autoantigens co-expressed on apoptotic cells, by inducing pDCs to secrete either IL-
10 or IFN-α. 
 
It is currently considered that pDCs only respond to apoptotic cell-derived chromatin 
when it is in a complex with IgG autoantibodies and thus delivered to TLR9 through 
receptor-mediated uptake99,100. In comparison, I show that both IL-10 and IFN-α 
cytokine production by pDCs was inhibited when DNA was removed from the 
apoptotic cell membrane. Therefore, pDCs can indeed respond to apoptotic cell 
expressed self-DNA, but only when they receive a second signal provided by the 
TLR ligand. This might demonstrate that only activated pDCs have the capacity to 
take up apoptotic cell material. However, the source of apoptotic cells is likely to be 
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important in determining the response elicited from pDCs. Previous studies show 
enhanced IFN-α when apoptotic or necrotic cells derived from tumour cell lines are 
used100,272, and I found that they failed to promote anti-inflammatory IL-10 secretion 
by pDCs and B cells. This suggests that apoptotic cell lines may be intrinsically pro-
inflammatory. It is also possible that, since pDCs, which have a similar diameter as 
lymphocytes at 8-10µm297, are not classed as professional phagocytic cells they 
might have a limited ability to take up large components, such as apoptotic epithelial 
cells and their apoptotic bodies.  
 
PDCs potentially respond to DNA-containing complexes expressed on apoptotic 
cells rather than DNA per se, as DNase, and freeze-thawing, may break apart 
interactions between DNA and other nuclear components. For example, the DNA-
binding protein HMGB1, which becomes oxidised during apoptosis, has been shown 
to be important for inducing tolerance to apoptotic cells298, in addition to promoting 
IFN-α secretion in response to SLE DNA complexes, or CpGA210. However, 
although inhibiting the HMGB1 receptor RAGE demonstrated that apoptotic cell-
induced IL-10 production occurs independently of RAGE, it is potentially required 
for apoptotic cell-induced IFN-α. Nevertheless, this was not necessarily via HMGB1, 
as RAGE has many ligands including the components important for apoptotic cell 
recognition and uptake, C1q299 and phosphatidylserine300. Therefore, repeating the 
experiments utilising a specific HMGB1 antagonist would distinguish if HMGB1 
plays a role in apoptotic cell recognition, or if further investigation into the other 
RAGE ligands is required.   
 
IL-10 secretion by pDCs occurred within 72 hours of co-culture with apoptotic cells 
and was maintained for up to seven days, provided pDCs also expressed TLR9. In 
the absence of TLR9, long-term (seven days) apoptotic cell-induced IL-10 
production by R848-stimulated pDCs was diminished, indicating that TLR7 
cooperates with TLR9 to maintain the regulatory response. It is possible that 
continuous TLR9 signals by environmental stimuli, such as apoptotic cells, may be 
required to promote cell survival, as fewer TLR9-deficient pDCs were yielded 
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following the harsh process of flow sorting. Furthermore, MZB cells, which express 
high levels of TLR9, were reduced in TLR9-deficient spleen. In support of this, it 
has also been shown that anti-apoptotic gene expression is upregulated at early time 
points (up to 4 h) in CpGB stimulated pDCs301, and in vivo studies have identified 
two temporal and functionally distinct peaks of gene expression in B cells following 
TLR9 stimulation 302. The later peak, which begins five days after stimulation, 
upregulates genes involved in the DNA damage response 302, which will ultimately 
prevent cell death. Further work is required to elucidate the cell death kinetics of 
TLR9-deficient pDCs. 
 
In recent years it has become clear that cytosolic DNA receptors also play an 
important role in stimulating type I IFN production in response to sensing microbial 
DNA and inefficiently cleared apoptotic DNA, with STING being the principal 
adaptor protein in many of these pathways (reviewed303). Additionally, human pDCs 
express MyD88-dependent cytosolic DNA receptors DExD/H-box helicases DHX9 
and DHX36, which specifically sense CpGB and CpGA, respectively, and induce 
cytokine responses akin to TLR9304. Therefore, while CpG/R848 provide a signal 
through TLR9/TLR7, apoptotic DNA may be sensed by cytosolic receptors. It is 
currently not known how the apoptotic cells signal in pDCs to induce IL-10. This 
will be discussed further in chapter six. 
 
It is reported that pDCs do not secrete IL-10 in response to synthetic TLR ligands279 
or apoptotic cells, though these stimuli have been shown to induce IL-10 by 
regulatory B cells in a TLR9 dependent manner55. Again contact with whole 
apoptotic cell membranes was required. Only a small proportion of pDCs were IL-
10-positive following stimulation with R848 and apoptotic cells, which suggests that 
there perhaps a specific subset of pDCs that secrete IL-10 in response to apoptotic 
cells. Similarly, apoptotic cell-induced IL-10-secreting regulatory B cells originate 
from the MZB and B1a B cell subsets55, yet not all of these innate-like B cells 
secrete IL-10. Consequently, regulatory B cells are currently defined by function 
rather than cell surface markers57,305. It is not known from the results in this chapter 
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if the same pDCs that produce IL-10 can then switch to make IFN-α, or if the 
different responses occur in functionally distinct pDC subsets. 
 
PDCs develop from both common myeloid progenitors (CMP) and common 
lymphoid progenitor (CLP) pathways and studies have shown that pDCs derived 
from CLP produce less IFN-α in response to CpGA stimulation compared to pDCs 
from CMP 155,306. However this is likely associated with reduced survival of CLP-
derived pDCs155. Cell surface markers have also been attributed to pDCs with 
distinct functions; CD9posSiglec-Hlow pDCs secrete IFN-α whereas CD9negSiglec-
Hhigh pDCs do not307. Hence pDCs with low IFN-α secreting ability might represent a 
specific subset of regulatory pDCs. Co-staining for intracellular IL-10 and IFN-α 
along with these markers would assess this. 
 
PDCs play an important role in influencing adaptive immune responses and are 
ideally placed to interact with T cells in secondary lymphoid organs. Antigen 
presentation by pDCs is known to be important for reducing the severity of 
autoimmune arthritis, by limiting effector T cell activation186. Human pDCs can also 
ingest microvesicles from apoptotic cells and present the antigen to T cells211. Here I 
showed that pDCs co-cultured with R848 and apoptotic cells induced CD4+ T cells 
to secrete IL-10. Although it remains to be determined if this occurred via secretion 
of IL-10 by the pDC, or through cell-to-cell contact with the T cells, it again 
confirms that TLR7-stimulated pDCs do not automatically induce a pro-
inflammatory response to apoptotic cells.  
 
Apoptotic cell-induced IL-10 secretion by OVA-specific CD4+ T cells, but not by 
TLR9-stimulated pDCs, was reduced when pDCs were isolated from C1q-deficient 
mice. In contrast, I found that B cells derived from C1q-deficient mice were hyper-
responsive to stimulation by TLR ligands and apoptotic cells, as measured by 
increased production of IL-10. Katherine Miles (Gray lab) has now shown a similar 
phenotype in B cells, in particular MZB cells that lack the complement receptor 
CD21 (unpublished data). These results imply that complement proteins function 
during innate-like B cell development to dampen TLR-mediated responses to 
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apoptotic DNA. However, although C1q inhibits TLR7/9-mediated IFN-α production 
by pDCs290-292, it does not appear to influence their regulatory response to apoptotic 
cells. Yet, perhaps signals from C1q-apoptotic cell complexes during the maturation 
of pDCs in vivo alters their function such that they have a greater capacity to induce 
IL-10 secretion by antigen-specific T cells. It has been shown that T cell cytokine 
secretion is enhanced by C1q-primed cDCs308 
 
In summary, this chapter demonstrates that pDCs do not respond to dying cells 
unless they are co-activated by a TLR stimulus, which would be crucial in vivo to 
ensure that pDCs do not respond inappropriately to apoptotic or secondarily necrotic 
cells outwith an inflammatory milieu. The combined TLR/apoptotic cell stimulus 
determines the final pDC response to apoptotic cells, either inducing anti-
inflammatory IL-10 and augmentation of T cell secretion of IL-10, or the production 
of pro-inflammatory IFN-α. The combination of infectious TLR9 ligands that induce 
IFN-α and apoptotic cells may be sufficient to break tolerance to self, leading to 
autoimmunity in genetically susceptible people. Understanding how pDCs respond to 
apoptotic cells could potentially lead to new selective therapeutic targets to reduce 
aberrant inflammation in autoimmune diseases, such as SLE, or promote immune 
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It has been known for many years that peripheral blood lymphocytes from SLE 
patients are more susceptible to undergoing apoptosis (annexin V+)230,309 and have a 
faster rate of apoptosis than healthy donor lymphocytes310. The cause has been 
attributed to increased activation induced cell death of SLE T cells and B cells311-313, 
which potentially explains lymphopenia309, a characteristic used during the 
classification of SLE314. It is unclear how elevated cell death is related to disease 
activity, with some studies reporting a correlation of lymphocyte apoptosis with 
active SLE309,315 and other studies finding no such association230. 
 
It is not clear if accelerated lymphocyte death initiates or perpetuates SLE 
pathogenesis. Secondary necrosis is considered to occur due to impaired removal of 
the apoptotic cells, which subsequently break apart releasing nuclear contents that 
bind to the autoantibodies. There is limited data to suggest that SLE lymphocytes are 
intrinsically susceptible to becoming necrotic. 
 
The current paradigm indicates that in health, pDCs tend to ignore early and late 
apoptotic cells unless the apoptotic nuclear components, such as DNA or RNP, are 
stabilised in immune complexes with auto-IgG, or LL37272,316-318, which are found 
circulating in SLE patient serum. Yet, in chapter three I observed that whole 
apoptotic cells, but not necrotic cells, augmented IFN-α production by mouse pDCs 
co-exposed to CpGA. It is not known if healthy human pDCs also make IFN-α in 
response to activation by CpGA/apoptotic cells and if this response is exacerbated in 
pDCs from SLE patients. Furthermore, it has not been addressed if SLE apoptotic 
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Aims 
In this chapter I hypothesised that in the presence of CpGA, apoptotic cells would 
enhance IFN-α secretion by healthy donor and SLE patient pDCs. It was also 
hypothesised that lymphocytes from SLE patients die abnormally, and this would 
result in the failure of SLE apoptotic cells to promote anti-inflammatory immune 
responses. The following aims were used to test the hypothesis: 
 
• Establish if healthy and SLE pDCs make IFN-α in response to culture with 
CpGA/apoptotic cells. 
• Determine the cell death kinetics of lymphocytes from healthy donors and SLE 
patients.  
• Investigate if apoptotic SLE lymphocytes are efficient at inducing IL-10 
secreting regulatory B cells. 
 
 Results 4.2
 Purifying human pDCs results in reduced CpGA-4.2.1
mediated IFN-α production. 
First I compared CpGA-mediated IFN-α production by pDCs enriched by different 
mechanisms to determine what method gave the best response. PDCs were either 
flow sorted to high purity (>95%, Figure 4.1.A), as described in the materials and 
methods (page 41), or enriched to 44% of the cell population by MACS using 
negative selection (Figure 4.1.B). Additionally, I also looked at pDCs in PBMCs 
since it is reported that CpGA exclusively activates pDCs within the mixed 
population of leukocytes present in PBMCs319. This was confirmed using pDC-
depleted (pDC-ve) PBMCs (Figure 4.1.D). The PBMCs were depleted of CD19+ B 
cells as an additional control to remove the other most common human leukocytes 
that constitutively express TLR9320. I found that pDCs in culture with CD19-depleted 
PBMCs secreted the highest concentration of IFN-α in response to 72 h CpGA 
stimulation compared to pDCs enriched by MACS, and purified by FACS (Figure 
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4.1.D), even though they represent less than 1% of the PBMC population (Figure 
4.1.C). For that reason, I decided to use CD19-negative PBMC in future assays. 
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On the previous page, (A) PBMCs were flow sorted (FACS) to isolate pDCs 
(CD304+) that were more than 95% pure and contained 1.4% contaminating CD14+ 
monocytes. (B) The purity of pDCs (CD304+ CD123high) was assessed by flow 
cytometry following negative selection by magnetic cell sorting (MACS). (C) The 
proportion of pDCs (CD304+ CD123high) in PBMCs that were depleted of CD19+ B 
cells was detected by flow cytometry. (D) IFN-α was measured in culture 
supernatant by ELISA 72 h after 104 pDCs sorted by FACS and MACS, and pDCs 
within 106 CD19-negative PBMCs were cultured alone (no stimulation, black bar) 
and with CpGA (grey bar). 106 pDC-negative PBMCs were cultured in the same 
way. Results are presented as mean with error bars representing SEM of three 
independent experiments. Statistical significance was assessed by t test; **P<0.01. 
 
 Human pDCs stimulated with CpGA respond to whole 4.2.2
apoptotic cells, but not necrotic cells, by secreting IFN-
α  
I wanted to investigate if IFN-α secretion by healthy human pDCs was enhanced by 
co-activation with CpGA and apoptotic cells, as was shown in mouse pDC (chapter 
3, page 74). CD19-negative PBMCs containing pDCs were cultured for 72h in order 
to keep the assays comparable to the mouse pDC cultures in chapter three, and after 
checking that CpGA-induced IFN-α secretion was not significantly elevated at an 
earlier time point (Appendix C Figure 1A). Similar to mouse pDCs, apoptotic cells 
failed to enhance IFN-α production by human pDCs in the absence of additional 
TLR stimulation, or in the presence of CpGB (Figure 4.2.A). Nevertheless, when the 
pDCs were activated with CpGA (3µg/ml chosen after dose response analysis, 
Appendix C Figure 1B), IFN-α secretion was significantly augmented by co-
activation with apoptotic cells (Figure 4.2.A).  
 
Additionally, like mouse pDCs, healthy human pDCs were only stimulated to 
enhance IFN-α production when they were co-cultured with CpGA/apoptotic cells, 
but not by CpGA/necrotic cells generated by breaking apart the membrane of the 
apoptotic cells by freeze-thaw cycles (Figure 4.2.B). 
 
Since the majority of published studies have shown that pDCs only respond to 
necrotic cell material that has formed immune complexes with IgG, or LL37272,316,321, 
I was interested to determine if adding SLE patient anti-DNA and anti-RNP IgG 
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autoantibodies to the culture medium enhanced IFN-α production by pDCs. In 
contrast to previous reports, I found that IgG purified from both healthy donors and 
from SLE patients inhibited CpGA-mediated IFN-α secretion even in the presence of 
apoptotic cells (Figure 4.2.C) and necrotic cells (Figure 4.2.D). Furthermore, SLE 
IgG did not enhance IFN-α production by high purity pDCs co-cultured with CpGA 
and apoptotic cells (Figure 4.2.E). 
 
 
Figure 4.2. Apoptotic cells, but not necrotic cells, or IgG, augment IFN-α 
production by human pDCs.  
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Beginning on the previous page, (A) IFN-α production by CD19-negative PBMCs 
was measured by ELISA 72 h after they were cultured alone () or with 106 UV-
irradiated apoptotic CD4+ T cells ( ) in media alone (no stimulation), and with 
CpGB, or CpGA. n=10 donors. Statistical significance was assessed by t test; 
P=0.0325 (B) IFN-α production by CD19-negative PBMCs was measured by ELISA 
72 h after CD19-negative PBMCs were cultured without stimulation and with CpGA 
either alone (No AC, black bar), with 106 UV-irradiated apoptotic CD4+ T cells 
(light grey bar), or 106 freeze-thawed necrotic CD4+ T cells (dark grey bar). 
Apoptotic cells and necrotic cells were also cultured in the absence of PBMCs. Data 
is represented as the mean with error bars showing SEM of three independent 
experiments. Statistical significance was determined by Student’s t test; **P=0.0099. 
(C) CD19-negative PBMCs were cultured in various combinations with and without 
apoptotic cells, CpGA, and IgG antibodies (10µg/ml) purified from healthy donor 
(HD) or SLE serum. After 72 h, IFN-α in culture supernatants was measured by 
ELISA. Results are from five to eight independent experiments. Statistical 
significance was measured by two-way ANOVA; *P-0.0346; **P=0.0086; ns non-
significant. (D) CD19-negative PBMCs were cultured with CpGA in the presence 
and absence of apoptotic cells (AC), necrotic cells, and SLE patient IgG antibodies 
for 72 h then IFN-α was measured in the culture supernatants. Data is represented as 
the mean with error bars showing SEM of three independent experiments. *P<0.05; 
**P<0.01. (E) Flow sorted pDCs were cultured with CpGA alone, and with apoptotic 
cells (AC) with and without healthy donor (HD), or SLE IgG autoantibodies. Data is 
represented as the mean with error bars showing SEM of three independent 
experiments. 
 
 SLE PBMCs contain fewer pDCs and fail to respond to 4.2.3
CpGA. 
 
I postulated that SLE pDCs would be primed to respond to apoptotic cells by 
secreting a higher concentration of IFN-α than healthy donor pDCs, due to the 
potential increased contact with apoptotic cells in an inflammatory milieu in SLE. 
However, CD19-depleted SLE PBMCs stimulated with CpGA secreted a mean of ten 
times less IFN-α compared to healthy CD19-depleted PBMCs, and this was not 
enhanced by co-culture with apoptotic cells (Figure 4.3.A). Furthermore, I found no 
difference in the concentration of IFN-α in serum (Figure 4.3.B), despite published 
findings that IFN-α is elevated in the serum of SLE patients322. Detection of other 
cytokines revealed that after 72 h stimulation with CpGA, both healthy and SLE 
CD19-depleted PBMCs secreted significant amounts of IL-6 (Figure 4.3.C), but not 
IL-12 (Figure 4.3.D), TNF-α (Figure 4.3.E), or IL-1β (Figure 4.3.F). 
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Since I was using CD19-depleted PBMCs in the assays I wanted to check that I was 
stimulating an equivalent number of healthy and SLE pDCs in the culture wells. 
Flow cytometry analysis revealed that SLE PBMC contained a significantly lower 
proportion of pDCs (CD304+ CD123high; mean 0.2%) compared to healthy PBMC 
(mean 0.5%; Figure 4.3.Gi-ii). Nevertheless, there was no significant correlation 
(Spearman) between the proportion of pDCs in SLE PBMCs and the concentration of 
IFN-α secreted in response to CpGA (Figure 4.3.Giii). The proportion of pDCs in 
healthy donor PBMCs also did not correlate with IFN-α (Figure 4.3.Giv). HCQ, a 
DMARD commonly used to treat SLE, is reported to work by interacting with DNA 
and RNA, which subsequently prevents them from binding to TLR9 and TLR7, 
respectively323. Therefore, as an additional control, non-SLE patients who were on 
HCQ therapy were included in the control group. Furthermore, half of the SLE 
PBMCs used for IFN-α analysis were from patients that were not receiving HCQ 
therapy at the time of blood donation, including the outlier in the SLE group (Patient 
Number 6) who had a high proportion of pDCs, but low IFN-α secretion.  
 
In chapter three I showed fewer flow-sorted pDCs were yielded from TLR9-deficient 
spleen (Figure 3.11 Page 89) suggesting a link between TLR9 expression and pDC 
numbers. Therefore, I was interested to assess TLR9 expression by SLE pDCs. 
Using intracellular staining, I found that the proportion of pDCs expressing TLR9 
(Figure 4.4.A-Bi) and the intensity of TLR9 staining (Figure 4.4.Bii) was the same in 
SLE as in health. As a negative control, I confirmed that the pDC-negative 
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Figure 4.3. SLE patients have a lower proportion of peripheral pDCs and make 
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On the previous page, (A) IFN-α in culture supernatant was measured 72 h after 
CD19-depleted PBMCs from healthy donors and SLE patients were cultured with 
CpGA alone (No AC, ), or with apoptotic CD4+ T cells (+ AC, ). n = 10 (healthy) 
and 12 (SLE) (B) The concentration of IFN-α in healthy donor and SLE patient 
serum was quantified by ELISA. n = 10 (healthy) and 21 (SLE). (C) IL-6, (D) IL-
12p70, (E) TNF-α, and (F) IL-1β was measured by the CBA inflammatory human 
(), cytokine kit 72 h after healthy and SLE PBMC were cultured without stimulation 
or with CpGA ( ). (C-D) n = 5 (healthy) and 10 (SLE). (Gi) Representative flow 
cytometry plot and (Gii) quantification of the proportion of pDCs (CD123high 
CD304+) in healthy and SLE PBMCs. n = 9 (healthy) and 17 (SLE). IFN-α 
concentration secreted by (Giii) SLE (n = 13) and (Giv) healthy (n = 6) PBMCs 
after 72 h CpGA stimulation plotted against the proportion of pDCs within the 
PBMCs. Each data point represents one donor. Statistical significance was 
determined by (B) paired t-test; *P = 0.015; **P = 0.009, and (Gii) unpaired t-test; 
***P = 0.0008. Spearman correlation co-efficient, (Giii) r = 0.3702; P = 0.2140, (Giv) 
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Figure 4.4. SLE and control pDCs express TLR9. 
Beginning on the previous page, (A) Intracellular TLR9 expression in peripheral 
pDCs (Lineage- HLA-DR+ CD123high) and pDC-negatives (Lineage- HLA-DR- 
CD123+) was assessed by flow cytometry of (i) control PBMCs and (ii) SLE 
PBMCs. (iii) The TLR9 isotype control antibody was used to set the gates. (B) 
Intracellular TLR9 expression in pDCs was quantified as (i) the proportion of TLR9-
positive pDCs and (ii) as the MFI of TLR9-PE. There was no significant difference 
between control and SLE as determined by unpaired t test. n = 12 (control) and 11 
(SLE).  
 
 SLE B cells make IL-10 in response to CpGB. 4.2.4
 
Since SLE pDCs did not respond well to TLR9 stimulation by CpGA, I was 
interested to determine if TLR9 stimulation was also affected in B cells. I stimulated 
B cells for 72 h with CpGB (2µM chosen following dose response; Appendix C 
Figure 1C) and found that, compared to unstimulated B cells, IL-10 secretion was 
enhanced by more that 100% in SLE CD19+ B cells and a mean of 87% control 
CD19+ B cells (Figure 4.5.A). The difference between IL-10 secretion by SLE and 
control B cells was not statistically significant. In addition, TLR9 stimulation of 
whole PBMCs that contained SLE B cells also resulted in increased IL-10 secretion 
(Figure 4.5.B). However, co-culturing CpGB-stimulated SLE PBMCs with apoptotic 
cells further augmented IL-10 secretion by a mean of only 8% compared to a mean 
of 44% increase in control PBMCs (Figure 4.5.C).  
 
I next wanted to determine if the limited apoptotic cell-mediated IL-10 response by 
SLE PBMC occurred due to differences in the B cell populations in SLE, compared 
to controls (healthy donors and non-SLE patients). Consistent with the published 
literature324, I found that the CD24hiCD38hi ‘transitional’ B cell population was 
increased in SLE patients compared to controls (Figure 4.6.A-C), although the 
difference did not reach statistical significance. Whereas, the IgD+ CD27- ‘naïve, 
IgD- CD27+ ‘switched memory’, and IgDlowCD27+ CD1c+ IgM+ ‘marginal zone’ B 
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There was no significant difference in the percentage of CD20+ and CD19+ B cells 
(Figure 4.6.Di and 4.6.Dii, respectively) in the control and SLE lymphocyte 
populations. However, SLE lymphocytes contained a lower proportion of CD3+ T 
cells (mean 52%) compared to healthy lymphocytes (mean 70%; Figure 4.7.B). The 
expression of both CD3+ CD4+ T cells and CD3+ CD8+ T cells were significantly 
reduced in SLE by 51% and 45%, respectively (Figure 4.7.C). This is in contrast to 
published data that showed SLE patients had the same percentage of CD4+ and CD8+ 
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Figure 4.5. SLE B cells make IL-10 in response to TLR9 stimulation by CpGB, 
but not apoptotic cells. 
(A) Control and SLE CD19+ B cells were cultured (), or with without stimulation 
TLR9 stimulation by CpGB ( 72 h (i) IL-10 concentration in supernatant ). After 
was measured and (ii) the percentage increase in IL-10 secretion following TLR9 
stimulation was determined. n = 3 (control) and 4 (SLE). (B) Control and SLE 
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( 72 h (i) IL-10 concentration in supernatant was measured and (ii) the ). After 
percentage increase in IL-10 secretion following TLR9 stimulation was determined. 
n = 7 (control) and 13 (SLE). (C) Control and SLE PBMCs were cultured with 
CpGB alone (No AC, ), or with apoptotic CD4+ T cells (+ AC, 72 h (i) IL-). After 
10 concentration in supernatant was measured and (ii) the percentage increase in IL-
10 secretion following co-culture with apoptotic cells was determined. n = 4 
(control) and 6 (SLE). Statistical significance of the difference in the percentage 
increase in IL-10 secretion by control and SLE cells was analysed by unpaired t-test; 
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Figure 4.6. SLE patients have a lower proportion of naïve, switched memory, 
and marginal zone B cells. 
The proportion of (A) control and (B) SLE CD20+ B cells that were transitional 
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marginal zone (MZB, IgDlow CD27+ IgM+ CD1c+) was assessed by flow cytometry 
and (C) quantified. (D) The percentage of (i) CD20+ and (ii) CD19+ control and SLE 
lymphocytes. Each data point represents one donor; (C) n = 25 (control) and 19 
(SLE) (Di) n = 9 (control) and 19 (SLE); (Dii) n = 7 (control) and 7 (SLE). 
Statistical significance was determined by unpaired t-test; no significance (ns); **P < 
0.01; ***P < 0.0001. 
 
Figure 4.7. SLE patients have a lower proportion of CD4+ and CD8+ T cells. 
(A) CD3, CD4, and CD8 expressing (i) healthy and (ii) SLE lymphocytes were 
analysed by flow cytometry. (B) The percentage of CD3-positive healthy and SLE 
lymphocytes was quantified. n = 7 (healthy) and 10 (SLE). *P = 0.0109. (C) The 
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CD8+ T cells (n = 5 (healthy) and 8 (SLE); ***P = 0.003) in healthy () and SLE (u) 
lymphocytes was quantified. Statistical significance was determined by unpaired t-
test. 
 SLE lymphocytes are more susceptible to dying 4.2.5
following initiation of apoptosis. 
 
As discussed at the beginning of this chapter, lymphopenia in SLE patients may be 
caused by the lymphocytes becoming apoptotic at a faster rate than lymphocytes 
from healthy donors. I wanted to further assess cell death, but due to the low 
numbers of leukocytes obtained from SLE patient blood I decided to look at the 
whole lymphocyte population obtained in the non-adherent cell fraction after 
adhering the monocytes to plastic. This did not affect the proportion of T cells and B 
cells within the lymphocyte population (Appendix C Figure 2). However, it should 
be noted that the non-adherent population that I have called lymphocytes in this 
chapter and in chapter five likely contains contaminating monocytes due to the 
impaired ability of SLE monocytes to adhere to plastic78. 
 
I measured apoptosis by flow cytometry using AnV and propidium iodide (PI), 
which were gated as shown by the representative FACS plots (Figure 4.8.Ai-ii). AnV 
is a phospholipid binding protein that identifies cells in the early stage of apoptosis 
when PS is transferred from the inner leaflet to the outside of the plasma membrane. 
Late apoptotic/necrotic cells are detected by co-staining with cell membrane 
impermeable DNA-intercalating dyes, such as PI, which are excluded from early 
apoptotic cells due to an intact cell membrane.  
 
Here I found that SLE lymphocytes were already dying immediately following 
isolation from the blood. At this stage (0 h) a mean of 19% of SLE lymphocytes 
were AnV single positive (Figure 4.8.Bi) and 7% were double positive for AnV and 
PI, indicating secondary necrosis (Figure 4.8.Bii). Consistent with published reports, 
SLE lymphocytes were induced to become apoptotic at an accelerated rate. A mean 
of 23% SLE lymphocytes were AnV single positive 2 h following initiation of the 
intrinsic apoptotic pathway by UV irradiation and this was enhanced to 40% after 4 
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h, compared to 14% (2 h) and 24% (4 h) of healthy control lymphocytes (Figure 
4.8.Bi). Activating the extrinsic apoptotic pathway by Fas ligation with anti-CD95 
antibody (also known as Fas) for 4 h also resulted in a mean of 40% SLE 
lymphocytes and 25% healthy lymphocytes becoming AnV single positive (Figure 
4.8.Bi). Healthy donor lymphocytes did not progress to secondary necrosis 4 h after 
induction of apoptosis with UV (4%) or anti-CD95 antibody (4%) (Figure 4.8.Bii), 
as expected. However, a mean of 22% UV irradiated, and 13% anti-CD95 antibody 
treated SLE lymphocytes were AnV and PI double positive after 4 h (Figure 4.8.Bii). 
 
The surface of lymphocytes was assessed using scanning electron microscopy to 
quantify cells that were designated as looking viable, apoptotic (indicated by the 
protrusion of apoptotic bodies), and necrotic (indicated by the appearance of a 
compromised membrane) (Figure 4.8.Ci-ii).  Immediately following isolation, 40% 
of 50 SLE lymphocytes counted per sample were in a necrotic state, whereas less 
than 20% of healthy lymphocytes were necrotic or apoptotic (Figure 4.8.Di). After 4 
h of apoptosis induction using anti-CD95, 50% of healthy lymphocytes had started to 
generate apoptotic bodies, with only 10% showing necrotic cell phenotype (Figure 
4.8.Dii). Conversely, more than half of SLE lymphocytes plasma membrane 
appeared necrotic following 4h anti-CD95 treatment, while 28% remained viable and 
18% had the appearance of apoptotic bodies (Figure 4.8.Dii). 
 Apoptosis is not accelerated in SLE neutrophils. 4.2.6
 
It is also known that an increase in circulating apoptotic neutrophils77,325 and 
neutropenia are commonly associated with SLE326. Therefore, I asked if SLE 
neutrophils, like lymphocytes, were also dying at an accelerated rate. Neutrophils 
have a short lifespan and naturally die rapidly in culture327. Peripheral human 
neutrophils isolated from blood by a percoll gradient can be sorted to high purity 
using their size (FSC) and granularity (SSC)328. I analysed neutrophils by flow 
cytometry using FSC/SSC gating to determine the rate of spontaneous cell death 
after 2 h, 4 h, and 12 h in culture, which revealed that a similar proportion of SLE 
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neutrophils were AnV-positive at these time points compared to healthy neutrophils 
(Figure 4.9).  
 
 
Figure 4.8. SLE lymphocytes are more susceptible to becoming secondarily 
necrotic.  
(Continued overleaf) 
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Figure 4.8. SLE lymphocytes are more susceptible to becoming secondarily 
necrotic. 
On the previous page, (A) Representative flow cytometry plot showing the gating 
strategy for measuring apoptosis by AnV and PI staining of (i) healthy and (ii) SLE 
lymphocytes. (B) The percentage of healthy () and SLE (u) lymphocytes that were 
(i) early apoptotic (AnV+ PI-) and (ii) secondarily necrotic (AnV+ PI+) at 0 h, 2 h and 
4 h post-UV irradiation, and 4 h after anti-CD95 treatment. n = 5-10 (healthy) and 5-
17 (SLE). (C) Representative scanning electron microscopy images showing (i) 
healthy and (ii) SLE lymphocytes that were classified as viable, apoptotic, and 
necrotic. (D) The proportion of healthy and SLE lymphocytes that looked viable, 
apoptotic, and necrotic was quantified at (i) 0 h and (ii) 4 h after anti-CD95 
treatment. n = 2. Statistical significance was quantified by unpaired t-test; no 
significance (ns); *P < 0.05; **P < 0.01; ***P < 0.0001. 
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Figure 4.9. SLE neutrophils die spontaneously at the same rate as healthy 
neutrophils. 
(A) Representative flow cytometry plots showing the gating strategy for measuring 
apoptosis by AnV staining of healthy and SLE neutrophils that were cultured for (i) 0 
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h, (ii) 2 h, (iii) 4 h, and (iv) 12 h. (B) The percentage of the healthy () and SLE (u) 
neutrophil population that was AnV-positive at 0 h, 2 h, 4 h, and 12 h was quantified. 
Each data point represents the mean of four donors with error bars showing SEM. 
 
 Caspase-activated DNA fragmentation is impaired in 4.2.7
apoptotic SLE lymphocytes. 
 
I measured activation of the apoptosis executioner caspases to determine if the high 
proportion of necrotic SLE lymphocytes (AnV+ PI+; Figure 4.8.Bii) was caused by 
activation of the apoptotic cell death pathway. This was achieved using a 
fluorescence assay to detect the conversion of pro-caspases 3 and 7 in to active 
caspases 3 and 7 (optimisation Appendix C Figure 3), which confirmed that SLE 
lymphocyte cell death did indeed occur in response to normal activation of caspases 
(Figure 4.10). 
 
The effector caspases trigger processes required for chromatin condensation and 
DNA fragmentation329. I assessed DNA fragmentation in untreated (Figure 4.11.A) 
and anti-CD95 treated lymphocytes (Figure 4.11.B) by confocal microscopy and 
found that the mean fluorescence intensity of TUNEL-positive nuclei was 
significantly lower in the SLE lymphocytes (Figure 4.11.D). 
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Figure 4.10. Caspase 3 and 7 are activated in healthy and SLE lymphocytes 
after UV irradiation. 
(A) Representative histograms showing the gating strategy of activated caspase 3/7-
positive lymphocytes using untreated healthy lymphocytes as a negative control. (B) 
The proportion of caspase 3/7-positive healthy and SLE lymphocytes was quantified 
after UV irradiation to induce apoptosis. n = 10 (healthy) and 12 (SLE). Statistical 
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Figure 4.11. The fluorescent intensity of TUNEL-positive nuclei in SLE 
lymphocytes was reduced compared to healthy lymphocytes. 
Beginning on the previous page, (A) Untreated and (B) 4 h anti-CD95 treated (i) 
healthy and (ii) SLE lymphocytes were fixed and stained using the TUNEL assay to 
detect DNA fragmentation (green) and DNA (DAPI, blue) then assessed by confocal 
microscopy. (C) Non-specific fluorescence of DAPI into TUNEL-positive channel 
was assessed. Scale bar: (Ai) 7.5µm; (Aii-Bii) 5µm; (C) 25µm. (D) The mean 
fluorescence intensity of TUNEL-positive nuclei in anti-CD95 treated lymphocytes 
from three independent donors was measured in at least 30 fields of view (per donor) 
using ImageJ software. Statistical significance was determined by unpaired t-test. 
***P = 0.0004. 
 
 SLE lymphocytes have an excess of mitochondria. 4.2.8
 
I next assessed mitochondria, since they play a central role in the apoptosis pathway. 
Cardiolipin is an important lipid component of the inner mitochondrial membrane. 
Apoptotic stimuli triggers elevated ROS resulting in the oxidation of cardiolipin, 
which then accumulates on the outer mitochondrial membrane and permits the 
formation of membrane pores330. The subsequent release of cytochrome c induces the 
apoptotic caspase cascade5. NAO is a fluorescent marker that binds to non-oxidised 
cardiolipin, and consequently was originally used to determine mitochondrial 
mass331. However, NAO fluorescence is reduced when cardiolipin is oxidised, 
therefore it is now also used to detect loss of mitochondrial membrane integrity, 
which occurs during the very early stages of apoptosis initiation332.  
 
The proportion of cells that had lost NAO fluorescence after 4 h culture in media 
alone (untreated), or following apoptosis induction by UV irradiation, or anti-CD95 
was measured by flow cytometry (Figure 4.12.Ai). Compared to healthy 
lymphocytes, approximately double the proportion of SLE lymphocytes was NAO-
negative 4 h after culture in media alone and after UV-irradiation (Figure 4.12.Aii). 4 
h anti-CD95 treatment resulted in the greatest difference between healthy and SLE 
lymphocytes, with a mean of three times more NAO-negative SLE lymphocytes 
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Transmission electron microscopy of CD19+ B cells and CD4+ T cells fixed 
immediately following isolation from the blood showed an accumulation of 
structures that resemble mitochondria in cells derived from SLE patients (Figure 
4.12.Bi and Ci). Healthy donor B cells contained a mean of 1.4 mitochondria 
whereas SLE B cells had a mean of 6.4 mitochondria (Figure 4.12.Bii). Similarly, 
healthy T cells contained a mean of 2.1 mitochondria and SLE T cells had a mean of 
5.9 mitochondria (Figure 4.12.Cii). 
 Apoptotic SLE lymphocytes have an impaired ability to 4.2.9
induce regulatory B cells. 
 
Apoptotic cells normally instruct the immune system to prevent inflammation. For 
example, dying cells regulate immunity through apoptotic DNA-dependent induction 
of IL10-secreting regulatory B cells55,56. I hypothesised that, because AnV single 
positive early apoptotic cells were more numerous in SLE lymphocytes following 
UV irradiation (Figure 4.8.Bi), they should be able to enhance IL-10 secretion by 
CpGB-stimulated healthy donor B cells. However, compared to the response induced 
by healthy apoptotic lymphocytes (mean 1,312 pg/ml), IL-10 secretion was 
significantly impaired when B cells were co-cultured with apoptotic SLE 
lymphocytes (mean 728 pg/ml; Figure 4.13A). IL-6 production was also limited, 
although this was not statistically significant (Figure 4.13B). I was also surprised to 
find that apoptotic lymphocytes from SLE patients failed to augment CpGA-induced 
IFN-α production by healthy pDCs, although this did not reach statistical 
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Figure 4.12. SLE lymphocyte mitochondria lose membrane integrity more 
rapidly and are in higher abundance than healthy lymphocyte mitochondria. 
(Ai) Representative flow cytometry plots showing the selection of the NAO negative 
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become apoptotic (untreated), as a negative control. (Aii) The percentage of NAO-
negative healthy (black bar, n = 5) and SLE (grey bar, n = 5) lymphocytes 4 h after 
culture in media (4 h untreated), following UV irradiation (4 h UV), and after anti-
CD95 antibody treatment (4 h anti-CD95). (Bi) Untreated healthy and SLE CD19+ B 
cells were imaged by transmission electron microscopy. (ii) The mean number of 
mitochondria (indicated by the red arrow head) per B cell was quantified. (Ci) 
Untreated CD4+ T cells were imaged by transmission electron microscopy. (ii) The 
mean number of mitochondria (indicated by the red arrow head) per T cell was 
quantified. Scale bar: 1µm Statistical significance was determined by unpaired t-test; 




Figure 4.13. Apoptotic SLE lymphocytes have an impaired ability to induce 
cytokine secretion by healthy B cells and pDCs. 
(A) IL-10 and (B) IL-6 production was quantified by ELISA 72 h after healthy B 
cells were cultured with CpGB alone, and CpGB plus 0.5x106 healthy donor 
apoptotic lymphocytes (B + HD-AC), or 0.5x106 SLE apoptotic lymphocytes (B + 
SLE-AC). Healthy and SLE apoptotic cells were cultured with CpGB alone as a 
negative control. (C) IFN-α production was quantified 72 h after CD19-negative 
healthy PBMCs were cultured with CpGA alone (No AC), and with 106 healthy 
donor apoptotic lymphocytes (+ HD-AC), or 106 SLE apoptotic lymphocytes (+ 
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SLE-AC). Graphs are the mean of (A-B) nine and (C) three independent experiments 
with error representing SEM. The significant difference in cytokine production 
induced by healthy apoptotic lymphocytes compared to SLE apoptotic lymphocytes 
was analysed by t-test; *P = 0.0346.  
 
 Discussion 4.3
In this chapter I set out to investigate if healthy human pDCs respond to apoptotic 
cells in a similar way to mouse pDCs and if SLE lymphocytes die abnormally. I have 
revealed that, in the absence of SLE IgG autoantibodies, apoptotic cells augment 
CpGA-induced IFN-α secretion by healthy human pDCs, but IFN-α production in 
response to TLR9 stimulation was impaired in SLE pDCs. I also found that SLE 
lymphocytes had a high propensity to becoming secondarily necrotic. Furthermore, 
apoptotic SLE lymphocytes had a reduced ability to modulate responses by healthy B 
cells and pDCs. These findings are important when considering the role of pDCs and 
apoptotic cells in SLE pathogenesis. 
 
I was interested to find that apoptotic cells, but not necrotic cells, induced healthy 
donor pDCs to secrete IFN-α only when they were co-exposed to CpGA, which is 
consistent with the mouse pDC data presented in chapter three. This novel finding 
increases our understanding of how human pDCs respond to apoptotic cells in an 
inflammatory environment. It expands our view that pDCs ‘ignore’ apoptotic cell-
derived nucleic acids in homeostatic conditions, but this is disrupted by an 
intervening inflammatory stimulus, such as FcγRIIa activation by immune 
complexes101,272, or TLR9 activation by CpGA.  
 
It has been published that small DNA-containing membrane microparticles (DNA-
MMP) released from apoptotic cells, but not necrotic cells, were endocytosed by 
healthy human pDCs independently of FcγRII and induced TLR9-dependent IFN-α 
secretion333. This study supports my finding of antibody-independent uptake and 
stimulation of human pDCs by self-apoptotic cell components. However, the authors 
reported IFN-α production using apoptotic MMPs alone, which contradicts my need 
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to co-activate the pDCs with a synthetic TLR9 ligand in order for whole apoptotic 
cells to augment IFN-α secretion.  
 
The accepted paradigm is that pDCs only respond to late apoptotic/necrotic cells 
following a two-signal stimulation: 1) IgG autoantibodies engaging FcγRIIa 
followed by, 2) entry of immune complexes in to pDCs and engaging 
TLR7/9100,101,272. I also had to provide a second signal (CpGA activation of TLR9) in 
order for primary apoptotic cells to become immunogenic. Yet, in contrast to the 
published findings using late apoptotic/necrotic cell lines, I found that IFN-α  
secretion was inhibited by IgG purified from anti-DNA+ RNP+ SLE patient serum 
even in the presence of free DNA/RNA released from necrotic primary cells. This 
again highlights the difference between apoptotic cell lines and primary cells, as 
discussed in chapter three. 
 
However, studies have shown that monocytes regulate immune complex and 
bacterial DNA-induced IFN-α production by human pDCs in PBMC cultures321,334. 
Therefore, it is important to take in to consideration the regulatory network of cells 
that pDCs will encounter in vivo.  Nevertheless, I did not see an IgG-mediated 
increase when the pDCs were purified from PBMCs; although they potentially had 
not survived in culture long enough to respond. FcγRIIa is also a negative regulator 
of CpGA-induced IFN-α production when it is triggered in the absence of immune 
complexes by high concentrations (>5mg/ml) of ‘free’ IgG100. Therefore, although I 
only used 10µg/ml of IgG antibodies in the assays (in accordance to previous 
studies93), it is possible that the SLE IgG autoantibodies failed to form a complex 
with healthy donor apoptotic and necrotic DNA/RNA thus they acted by directly 
inhibiting pDC IFN-α through FcγRIIa. 
 
The number of pDCs found circulating in SLE patients has not been consistently 
reported. It is now known that the human pDC marker BDCA-2 that was used in 
previous studies to show a reduction in peripheral pDCs in SLE335,336 is 
downregulated following TLR7/9 activation337. Therefore it is not clear if the 
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perceived reduction was due to the SLE pDCs being activated. In this chapter I 
confirmed that pDCs were reduced in SLE PBMCs using the markers CD304 and 
CD123. Conversely, it has also been reported that the percentage of BDCA-4 
(CD304)+ peripheral blood pDCs in SLE patients was not significantly different336 or 
higher than healthy donors338.  
 
Despite being reduced, perhaps due to mobilisation to sites of inflammation339, SLE 
pDCs were not completely depleted (>0.1%) and they expressed normal levels of 
TLR9 protein. Nevertheless, SLE PBMCs failed to make a good IFN-α response to 
CpGA even in the presence of apoptotic cells. This complements published findings 
that SLE PBMC made less IFN-α in response to DNA-containing immune 
complexes, or HSV-1336. It could be considered that SLE pDCs were potentially 
hyporesponsive to TLR9 stimulation in vitro due to the induction of TLR9 tolerance 
by immune complexes during circulation, which has been described in lupus-
susceptible mice340. Addtionally, the SLE pDCs might not have survived the in vitro 
cell culture. 
 
While I saw low IFN-α production by SLE PBMCs, it was apparent that not all 
responses to TLR9 activation were defective, as demonstrated by equivalent CpGA-
induced IL-6 secretion by both healthy and SLE PBMCs. IL-6 and IFN-α secreted by 
pDCs along with ‘help’ via CD40 signalling induce the differentiation of virus-
specific and autoreactive antibody secreting plasma cells119,341. Like IFN-α, IL-6 is 
elevated in SLE serum and it is emerging as a new potential therapeutic target for 
treating SLE patients, as discussed in chapter one and reviewed in reference126 
 
PDCs are associated with SLE pathogenesis due to their natural ability to make IFN-
α in response to nucleic acids. Although it is not known how SLE pDCs respond to 
TLR9 and apoptotic cells within patients, the lack of an increase of IFN-α in this in 
vitro study questions the significance of pDC activity in SLE. Additionally, IRF5 
SNPs, which are related to the IFN-α pathway and are associated with SLE 
susceptibility342 actually reduce the ability of pDCs to secrete IFN-α in response to 
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RNA immune complexes, or CpGA343 even though IFNα-induced gene upregulation 
was elevated by serum from patients with these SNPs344. Specific depletion of pDCs 
in the BXSB lupus mouse model indicate that pDCs are necessary for initiating 
disease through activation of T cells, B cells and mDCs, and autoantibody 
production, but the IFN-α signature in blood was not affected345. Other cells, in 
particular neutrophils in circulation and bone marrow are emerging as an additional 
source of IFN-α production in SLE346,347.  
 
In the second part of this chapter I confirmed that SLE lymphocytes (enriched from 
PBMCs by adhering monocytes to culture wells) were more susceptible to becoming 
apoptotic, but I also found that they became significantly more secondarily necrotic 
at an early time point. The lack of the appearance of apoptotic bodies imaged by 
scanning electron microscopy and less intense, more diffuse DNA fragmentation 
suggests that SLE lymphocytes were dying abnormally even though the apoptotic 
effector caspases 3 and 7 were activated. Intriguingly, chromatin fragmentation in 
apoptotic renal cells is reduced in lupus-prone mouse models348, and caspase-
activated DNase-deficiency, which results in the inability to correctly fragment 
nuclear DNA during apoptosis, leads to increased anti-DNA/chromatin antibodies349. 
I speculate that the apoptosis pathway is initiated, but it is unable to successfully 
proceed; therefore the dying cells break apart instead. Pharmacological caspase 
inhibitors, such as zVAD-fmk, would confirm if the apoptotic caspase cascade 
elicited the increased number of necrotic SLE lymphocytes, or if this occurred 
independently of the effector caspases.  
 
Although enhanced Fas-expression due to lymphocyte activation might explain why 
Fas-mediated apoptosis was enhanced using anti-CD95 (Fas) antibody in SLE 
lymphocytes, I found that rapid cell death was also induced by activation of the 
intrinsic death pathway by UV irradiation. This suggests that SLE lymphocytes are 
intrinsically susceptible to becoming secondarily necrotic. Using NAO fluorescence, 
I observed that a higher proportion of SLE lymphocytes had disrupted mitochondrial 
integrity, which complements reports that SLE T cells have increased mitochondrial 
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membrane polarisation and less ATP350,351. Furthermore, mouse B cells co-
stimulated through the BCR and TLR7 have depleted ATP, loss of mitochondrial 
membrane potential and showed necrotic morphology352. It was discovered many 
years ago that when intracellular ATP concentration is low, apoptosis switches to 
necrosis, although this did not result in externalisation of PS2 3. Therefore, 
malfunctioning mitochondria might be key to explaining why SLE lymphocytes do 
not survive. 
 
In addition, dynamin-related protein 1 (Drp1) expression is reduced in SLE T 
cells353. Drp1 is required for mitochondrial fission and mitophagy, an autophagy 
process first termed a decade ago354, which is essential for regulating mitochondrial 
quality. Mitochondrial mass is increased in autophagy-deficient peripheral T cells 
and this is associated with elevated apoptosis355. I hypothesise that dysfunctional 
mitophagy might be associated with the abnormal accumulation of structures 
resembling mitochondria I observed in SLE T and B cells. Whether SLE 
mitochondria are inflammatory is not known and this will be discussed in more detail 
in chapter six in the context of the other work reported in this thesis. 
 
Enriched SLE apoptotic lymphocytes were impaired at regulating both anti-
inflammatory IL-10 secretion by B cells and pro-inflammatory IFN-α secretion by 
pDCs; further supporting the hypothesis that apoptosis is abnormal is SLE 
lymphocytes. To induce these immune responses it is essential that healthy B cells 
and pDCs recognise apoptotic DNA/chromatin expressed on intact apoptotic cell 
membranes55 (chapter 3 page 84). Human pDCs are unable to phagocytose large 
components, such as whole apoptotic cells356, but they can internalise apoptotic 
bodies211, which express the DNA and chromatin357. However, the membrane of 
apoptotic SLE lymphocytes rapidly breaks apart and apoptotic bodies are less 
frequent. These novel findings indicate that apoptotic DNA/chromatin from SLE 
patients may not be presented, or recognised in the same way as in health. Whilst 
pDCs recognised healthy apoptotic lymphocytes independently of SLE IgG, it 
remains to be investigated if it is required for the recognition of SLE apoptotic 
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lymphocytes. The potential role of SLE DNA in disease pathogenesis will be 
discussed in chapter six. 
 
Looking from the other perspective, I showed that healthy apoptotic cells failed to 
augment IL-10 secretion by SLE B cells (within PBMCs) even though they 
responded well to TLR9 stimulation by CpGB. This was potentially due to SLE 
patients expressing fewer peripheral MZB cells, which play an important role in 
regulating tolerance to self-DNA/chromatin complexes expressed on apoptotic 
cells55,57. Immature transitional B cells were higher in SLE patient blood, as 
previously reported324,358, but they have reduced IL-10 production and immune 
regulatory function in response to CD40 stimulation324. More recently, another 
immature B cell population (CD27-CD38intIgD+) from SLE patients has been 
reported to have impaired CD40-induced IL-10 secretion and regulation of T cells359. 
Therefore, the combination of both dysfunctional B cells and abnormal apoptotic 
cells may contribute to impaired immune regulation in SLE.  
 
In summary, the findings of this chapter demonstrate that we may need to re-assess 
how healthy pDCs respond to apoptotic cells and the role of pDC-derived IFN-α in 
SLE pathogenesis. It also suggests that, in addition to activation-induced cell death, 
the elevated number of apoptotic lymphocytes found circulating in SLE is likely 
caused by an intrinsic abnormality, which predisposes them to dying abnormally. 
The inability of SLE lymphocytes to survive and induce immune regulation is further 
investigated in chapter five.  
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Chapter 5 The role of autophagy in apoptosis 
and SLE 
 Introduction 5.1
The rapid removal of apoptotic cells by neighbouring cells and professional 
phagocytes is vital for maintaining homeostasis33. It is widely accepted that 
inefficient clearance of apoptotic cells is central to driving inflammation in SLE 
patients due to an accumulation of secondarily necrotic cells and the abnormal 
exposure of apoptotic chromatin. The impaired removal of apoptotic cells has been 
attributed to intrinsic defects in the phagocytic function of SLE macrophages77,78, 
which might be caused by reduced Fc-receptor mediated uptake360. Additionally, 
C1q deficiency is a very strong risk factor for developing SLE, which is believed to 
be due to the loss of apoptotic cell opsonisation and subsequent phagocytosis361.  
 
However the nuclear antigens associated with SLE are normally expressed on the 
surface of apoptotic cells and smaller apoptotic bodies362,363. Membrane-bound 
apoptotic bodies contain nuclear antigens, such as DNA, that are safely packaged and 
more easily phagocytosed. They promote immune regulation, such as stimulating the 
generation of IL10-secreting regulatory B cells55,364 and pDCs (chapter 3). Yet the 
accumulation of apoptotic cells cannot be the only explanation for an increased 
tendency towards autoimmunity. For example, mice deficient in the apoptotic “eat-
me” signals mannose-binding lectin365 and CD14106 do not develop autoimmunity, 
despite an accumulation of apoptotic cells. However, SLE lymphocytes are more 
susceptible to apoptosis and do so at an accelerated rate (chapter 4), which indicates 
that there is additional intrinsic defect in the apoptotic cells that triggers 
inflammation in SLE patients. 
 
A number of recent studies have identified an important role for autophagy proteins 
in the heterophagy of apoptotic corpses by phagocytes247-249. Autophagy proteins, 
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such as ATG5, ATG7, and LC3-II, are required to mediate the lysosomal 
degradation, but not uptake, of apoptotic cells in the non-canonical autophagy 
mechanism, LAP247,250. The activation of autophagy prior to apoptotic cell death is 
also important for the release of “find me” signals to recruit phagocytes, such as LPC 
and ATP246. Additionally, although autophagy has largely been seen as a survival 
mechanism by cells to avoid cellular apoptosis, it is now clear that the autophagy and 
apoptosis pathways share many regulatory elements (discussed in chapter 1 section 
1.4.3). For example, Bcl-2 not only functions as an anti-apoptotic protein, but also 
prevents autophagy via its inhibitory interaction with Beclin-1 238, whereas calpain-
cleaved ATG5 translocates to the mitochondria, where it induces apoptosis through 
inhibition of anti-apoptotic BCL-XL243. 
  
Variants in the autophagy-related genes ATG567,231 and DRAM-1 233, are associated 
with SLE, but the function of autophagy in the pathogenesis of SLE is unclear. On 
one hand the induction of autophagy has been reported to be defective in SLE CD4+ 
T cells 230,366. Conversely, in comparison to healthy control cells, SLE T cells have 
been shown to contain more vacuoles228 and LC3+ punctae, which are also increased 
in SLE B cells 229. Nevertheless, it has not been investigated if autophagy defects in 
SLE patients cause accelerated apoptosis, or impaired phagocytosis. 
 
I hypothesised that the reduced ability of SLE lymphocytes to survive and to 




The focus of this chapter was to evaluate the link between autophagy and aberrant 
apoptosis in SLE using the following aims: 
• Establish if autophagy proteins are defective in SLE lymphocytes. 
• Assess if autophagy defects are associated with known SNPs. 
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• Analyse the response of macrophages to apoptotic SLE lymphocytes compared to 
apoptotic healthy lymphocytes.  
 
 Results 5.2
 The Atg5-/- iBMK cell line undergoes accelerated 5.2.1
secondary necrosis. 
I was interested to determine if autophagy proteins, in particular ATG5, play a role in 
controlling apoptotic cell death, since it is known that autophagy is associated with 
SLE susceptibility67,231,232 and SLE lymphocytes become apoptotic at an accelerated 
rate, rapidly progressing to secondary necrosis (Chapter 4 Figure 4.8). Therefore, I 
examined the death kinetics of Atg5-/- iBMKs compared to wild type (Atg5+/+) 
iBMKs over 6 h, following the induction of apoptosis with UV irradiation. 
 
The adherent cells were viable, indicated by AnV and PI staining, thus only the non-
adherent cells at each time point were collected, counted, and analysed by flow 
cytometry. While deficiency of ATG5 protein (Figure 5.2.A) did not affect the 
proportion of Atg5-/- iBMKs that were early apoptotic (AnV+ PI-) compared to 
Atg5+/+ iBMKs (Figure 5.2.B), it did result in approximately double of the Atg5-/- 
iBMKs becoming secondarily necrotic (AnV+ PI+) at 6 h following UV treatment 
(Figure 5.2.B). Although the result did not reach statistical significance, this implies 
that ATG5, which is required for functional autophagosome formation, is necessary 
to control the rate that cells die by apoptosis.  
 
It is still unknown why autophagy should continue to function in cells committed to 
apoptosis (reviewed in367); it is mostly considered that autophagy is inhibited 
following caspase-mediated cleavage and inactivation of autophagy proteins240-242, 
which would disregard a crucial role. Nevertheless, I still see ATG5 protein 
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Figure 5.1 Atg5-/- iBMK cells become more secondarily necrotic than WT iBMK 
cells after UV irradiation.  
(A) Western blot to show that Atg5-/- iBMK cells have less 55kDa ATG5-ATG12 
protein complex compared to WT (Atg5+/+) iBMK cells. β-actin was probed as a 
loading control. (Bi) Representative FACS plots of Atg5+/+ (top) and Atg5-/- (bottom) 
iBMK cells to show annexin V (AnV) and propidium iodide (PI) staining after the 
induction of apoptosis with UV irradiation. (Bii) The mean percentages of AnV+ PI- 
(top) and AnV+ PI+ (bottom) Atg5+/+ (black bar) and Atg5-/- (grey bar) iBMKs at 0 h, 
4 h, and 6 h after UV irradiation pooled from three independent experiments. Error 
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 ATG5 protein expression is reduced in SLE 5.2.2
lymphocytes 
Despite the association of ATG5 SNPs with SLE, the role of autophagy in the 
pathogenesis of SLE is unclear. Furthermore, it is not established how, or if, the 
expression and function of the ATG5 protein is altered in lymphocytes from SLE 
patients. For that reason, I measured ATG5 protein in lymphocytes isolated from 
controls (healthy donors and non-SLE patients) and SLE patients. ATG5 
constitutively forms a complex with ATG12, which is irreversible due to the 
isopeptide bond368. Therefore, the anti-ATG5 antibody detects the 55kDa ATG5-
ATG12 complex, with very little 33 kDa ‘free’ ATG5 found.  
 
Western blotting revealed a two-fold reduction of ATG5-ATG12 protein expression 
in untreated SLE lymphocytes compared to controls (Figure 5.2.Ai), which was more 
clearly seen when ATG5 protein density was normalised to β-actin (Figure 5.2.Aii) 
The ubiquitin protein ligase (E3)-like enzyme activity of ATG5-ATG12 is exerted 
through the association with and activation of ATG3223. Therefore, I was interested 
to determine if expression of ATG3 protein was also reduced in SLE lymphocytes. 
However, there was no significant difference in protein expression of ATG3 in SLE 
patient lymphocytes compared to control lymphocytes (Figure 5.2.B). I also found no 
significant difference in ATG5-ATG12 protein expression in untreated monocyte-
derived macrophages from healthy donors and SLE patients (Figure 5.2.C). Both the 
lymphocytes and macrophages are not highly pure populations due to the adherence 
method used to enrich for them. 
 
Analysis of the expression of other upstream autophagy proteins was not possible 
due to the limited amount of protein lysate generated from the number of SLE 
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Figure 5.2. ATG5-ATG12 protein expression is reduced in SLE lymphocytes. 
Beginning on the previous page, (Ai) Western blot showing less 55kDa ATG5-
ATG12 protein expression in SLE lymphocytes compared to healthy donor (HD) 
lymphocytes that were untreated (UT) and treated with anti-CD95 for 4 h. β-actin 
was probed as a loading control. (Aii) The ATG5-ATG12 band density was 
normalised to β-actin band density using ImageJ software. ** P = 0.0038. (Bi) 
Western blot to show that there is no difference in ATG3 protein expression in HD 
and SLE lymphocytes. β-actin was probed as a loading control. (Bii) ATG3 band 
density was normalised to β-actin band density using ImageJ software. There was no 
statistically significant difference (ns) between controls and SLE. (Ci) Western blot 
to show that there is no difference in ATG5-ATG12 protein expression in HD and 
SLE human monocyte derived macrophages (HMDM). β-actin was probed as a 
loading control. (Cii) The ATG5-ATG12 band density was normalised to β-actin 
band density using ImageJ software. There was no statistically significant difference 
(ns) between controls and SLE. The difference in the protein ladder markers is 
because (Ai) is a pre-cast gel (Novex® Life Technologies), whereas (Bi) is a gel 
made in the lab. Each point is one control sample () and one SLE sample (w). 
Sample numbers: (A) n = 16 (control) and 20 (SLE), (B) n = 5 (control) and 7 (SLE), 
(C) n = 3 (control) and 5 (SLE). 
 
 Autophagic flux is impaired in SLE lymphocytes. 5.2.3
The final stage of autophagosome formation requires LC3-II to integrate in the 
membrane for closure of the double membrane. Since the ATG5-ATG12 protein 
complex is essential for LC3-I conversion to LC3-II, I hypothesised that the low 
expression of this autophagy protein in SLE lymphocytes would ultimately result in 
the dysfunctional formation of autophagosomes.  
 
The autophagosome-specific dye Cyto-ID® can be used to label and quantify 
autophagic vacuoles in live cells369. As a positive control, I serum-starved healthy 
donor lymphocytes for 4 h to induce autophagy and treated the cells with the 
lysosomal protease inhibitors E64d and pepstatin A for the final 2 h to inhibit 
autophagosome degradation by lysosomes. This allowed the build up of autophagic 
vacuoles, as can be seen by increased Cyto-ID staining (Figure 5.3.Ai). I then 
confirmed that baseline autophagy was reduced in SLE lymphocytes (Cyto-ID mean 
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The amount of LC3-II is correlated with the number of autophagosomes370. 
Therefore, I measured the conversion of LC3-I to LC3-II to determine if the reduced 
presence of autophagosomes in SLE lymphocytes occurred due to impaired 
autophagic flux. E64D and pepstatin A were added to the lymphocytes for the final 2 
h of the 4 h culture to prevent the degradation of LC3-II on the inner autophagosome 
membrane and I found by western blotting that LC3-I failed to convert to LC3-II in 
the SLE lymphocytes (Figure 5.3.Bi). This is more clearly seen when the ratio of 
LC3-II to LC3-I band densities were quantified using ImageJ software (Figure 
5.3.Bii).  
 Atg5 gene expression in SLE lymphocytes is normal. 5.2.4
Since ATG5-ATG12 protein was reduced in SLE lymphocytes, I analysed Atg5 gene 
expression to ask if less mRNA was transcribed. The results from qPCR showed no 
significant difference in Atg5 mRNA between SLE and healthy lymphocytes (Figure 
5.4.A). As expected, Atg3 gene expression in SLE lymphocytes compared to healthy 
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Figure 5.3. LC3-I conversion to LC3-II is impaired in SLE lymphocytes. 
(Ai) FACS plot of healthy control lymphocytes that were cultured in starvation 
media for 4 h with (grey line) and without (black line) 2 h treatment with E-64d and 
pepstatin A (+ E/P) and then stained with Cyto-ID to detect autophagosomes. 
Untreated and unstained lymphocytes were used as a negative control (grey dashed 
line). (Aii) Representative histograms of control and SLE lymphocytes that were 
cultured for 4 h then stained with Cyto-ID. (Aiii) The mean fluorescence intensity 
(MFI) of Cyto-ID staining was significantly higher in control lymphocytes compared 
to SLE lymphocytes (* P = 0.0342). Each point is one control sample () and one 
SLE sample (w). n = 9 (control) and 11 (SLE). (Bi) Western blot to show LC3B-I 
(~16 kDa) is not converted to LC3B-II (~18 kDa) when lysosomal proteases are 
inhibited for 2 h in SLE lymphocytes (+ E/P).  β-actin was probed as a loading 
control. (Bii) After normalisation to β-actin, the ratio of the LC3-II density to LC3-I 

















































































Chapter 5: The role of autophagy in apoptosis and SLE 144 
density was measured in control and SLE lymphocytes without (w/o, ) and with (+, 
) lysosomal inhibitors. n = 6 (control) and 6 (SLE). 
 
Figure 5.4. Atg5 and Atg3 gene expression in SLE lymphocytes is normal 
compared to control lymphocytes. 
(A) Atg5 and (B) Atg3 mRNA in control (black bar) and SLE (grey bar) 
lymphocytes was analysed by real-time PCR and normalised to the house-keeping 
gene 18S ribosomal RNA. The relative expression in control and SLE samples 
compared to a control sample that was run on every PCR plate was not statistically 
significant (ns). Sample numbers: (A) n = 18 (control) and 19 (SLE), (B) n = 12 
(control) and 12 (SLE). 
 
 SNPs in and near the Atg5 gene are not associated with 5.2.5
the cohort of SLE samples. 
I was interested to determine if variations of SNPs in or near autophagy-related 
genes differed between controls and the cohort of SLE patients used in this thesis. A 
total of four SNPs were selected for this analysis. Three SNPs were selected from 
previous studies showing an association with SLE (ATG5 rs57377567; PRDM1-
ATG5 rs656843167,231; DRAM-1 rs4622329233). The fourth SNP (ATG16L1 
rs2241880), was selected as a negative control since it is associated with the chronic 
inflammatory disorder, Crohn’s disease371, but has not been linked to SLE. 
 
Before performing the SNP genotyping assay, the quality of the samples was 
assessed using a 2% agarose gel to check the DNA integrity. The absence of ladders 
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The genotype frequencies of rs573775, rs6568431, and rs4622329 in the control 
samples did not deviate significantly from the expected frequencies calculated using 
the Hardy-Weinberg equation, p2 + 2pq + q2 = 1, where p represents allele 1 and q 
represents allele 2 (Table 5.1). However, SNP rs2241880 genotype frequencies in the 
control samples were significantly different from the expected frequencies calculated 
using the Hardy-Weinberg equation; therefore this SNP was excluded from further 
analysis (Table 5.1). Furthermore, the allele clusters generated for rs4622329 were 
not optimally separated (Figure 5.5.Biv) and for that reason this SNP was also 
excluded from further analysis.  
 
Using statistical analysis described in the materials and methods, I found that there 
was no significant difference between the control group and SLE patients in the 
allele frequency (Table 5.2) and genotype frequency (Table 5.3) of ATG5 (rs573775) 
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Locus SNP Allele p (1) Allele q (2) Control p2 q2 2pq χ2 P-value
0.126025 0.416025 0.45795
Expected ratio 12.6 41.6 45.8
Actual ratio 7.9 36.8 55.3
0.164025 0.354025 0.48195
Expected ratio 16.4 35.4 48.2
Actual ratio 13.5 32.4 54
0.175561 0.337561 0.486878
Expected ratio 17.6 33.8 48.7
Actual ratio 32.4 48.6 18.9
0.152881 0.370881 0.476238
Expected ratio 15.3 37.1 47.6





























Table 5.1. Expected genotype frequencies according to the Hardy-Weinberg equation.
Table 5.2. Allele frequencies of SNPs rs573775 and rs6568431 in control and SLE samples.
Table 5.3. Genotype frequencies of SNPs rs573775 and rs6568431 in control and SLE samples.
















Chapter 5: The role of autophagy in apoptosis and SLE 147 
 
Figure 5.5. SNPs in and near the Atg5 gene are not associated with the cohort 




































Chapter 5: The role of autophagy in apoptosis and SLE 148 
(A) 2% agarose gel to assess integrity of the control (C) and SLE (S) DNA samples. 
Allelic discrimination plots showing the clustering of homozygotes for allele 1 (red), 
allele 2 (blue) and heterozygotes (green) for SNPs (Bi) rs573775, (Bii) rs6568431, 
(Biii) rs2241880, and (Biv) rs4622329 in control (left) and SLE (right) DNA 
samples. Non-template controls are shown in (Bi) yellow and (Bii-iv) turquoise. 
 
 Inhibiting calpain did not significantly restore ATG5-5.2.6
ATG12 protein. 
Since SNPs in and near ATG5 were not significantly associated with the SLE patient 
samples and Atg5 mRNA expression was normal, I wanted to determine if low 
ATG5-ATG12 protein was caused by rapid degradation of ATG5 in the cytosol. Free 
ATG5 protein can be cleaved by the non-lysosomal proteases, calpain 1 and calpain 
2, following induction of apoptosis in cell types including neutrophils and Jurkat T 
cells243. The 24 kDa cleavage product is translocated to mitochondria, where it 
further drives apoptotic cell death through inhibition of the anti-apoptotic Bcl-xL and 
release of cytochrome c243. Therefore, I assessed if calpain activity was responsible 
for the reduced expression of the ATG5-ATG12 complex and the enhanced 
apoptosis seen in SLE lymphocytes.  
 
There was no significant difference in calpain 1 and calpain 2 mRNA expression in 
SLE lymphocytes compared to control lymphocytes (Figure 5.6.A). Following 4 h 
treatment of control and SLE lymphocytes with the calpain-specific inhibitor, 
calpastatin, ATG5 protein was detected by western blotting. When the ATG5 protein 
band was analysed by ImageJ software there was a modest increase in ATG5-ATG12 
expression when calpain was inhibited, however this did not reach statistical 
significance (Figure 5.6.Bii). The lymphocytes were also treated with the lysosomal 
inhibitor HCQ to detect autophagic flux, but even in the presence of calpastatin, 
LC3-I conversion to LC3-II remained impaired in SLE lymphocytes (Figure 5.6.Bi). 
Furthermore, the proportion of SLE lymphocytes that became apoptotic (AnV+ PI-) 
and secondarily necrotic (AnV+ PI+) following 6 h anti-CD95 treatment was not 




Chapter 5: The role of autophagy in apoptosis and SLE 149 
These findings imply that the calpain-mediated cleavage pathway may not be 
associated with reduced ATG5-ATG12 in SLE lymphocytes. Nevertheless, it is still 
possible that ATG5 is proteolytically degraded since treating cells for 2 h with E-64d 
and pepstatin A resulted in a significant increase in ATG5-ATG12 protein 
expression in SLE lymphocytes (Figure 5.6D), although it did not restore LC3-I 
conversion to LC3-II (Figure 5.3.B). In addition to inhibiting calpain, E-64d also 
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Figure 5.6. Inhibiting calpain did not significantly restore ATG5-ATG12 
protein. 
There was no significant difference (ns) in (Ai) calpain 1 and (Aii) calpain 2 gene 
expression in control (black bar) and SLE (grey bar) lymphocytes, which were 
analysed by real-time PCR and normalised to the house-keeping gene 18S ribosomal 
RNA. (Bi) Western blot to show that ATG5-ATG12 protein complex was not 
enhanced and LC3-I did not convert to LC3-II in SLE lymphocytes treated for 4 h 
with calpastatin (+) and 2 h with HCQ. Healthy donor (HD) lymphocytes were used 
as a control. (Bii) ATG5-ATG12 band density was normalised to β-actin band 
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dead cells were gated on FACS plots and the proportion of apoptotic (AnV+ PI-) and 
secondarily necrotic (AnV+ PI+) cells was analysed in 6 h anti-CD95 SLE samples 
that had been cultured for 18 h with (n) and without w/o () calpastatin. (D) 
Following western blotting the band density of ATG5-ATG12 was normalised to β-
actin in control and SLE lymphocytes cultured without E-64d and pepstatin A (w/o 
E/P, black line) and with E-64d and pepstatin A (+ E/P, grey line). n = 4 (control) 
and 7 (SLE). Statistical significance was determined by paired t-test; *P=0.0286. 
 
 Phagocytosis of apoptotic SLE lymphocytes is 5.2.7
impaired. 
The increased number of apoptotic cells progressing to secondary necrotic cells seen 
in patients with SLE is attributed to inefficient phagocytosis caused by lack of 
opsonisation, such as complement deficiency361 and reduced phagocytic function of 
SLE macrophages77,78. However, in the absence of SLE serum-influencing factors 
(such as complement and autoantibodies), I found no significant difference in the 
mean phagocytic index of monocyte-derived macrophages from controls (mean 
phagocytic index 64) and SLE patients (mean phagocytic index 54) following 1 h co-
culture with UV-irradiated healthy donor apoptotic lymphocytes (Figure 5.7.Ai, Bi, 
C). This complements previous findings, which used the Jurkat cell line as the 
apoptotic cell feed372. Nevertheless, the phagocytic index of the healthy macrophages 
responding to healthy apoptotic cells was split into two distinct populations based on 
the age group of the donors. Macrophages derived from donors that were 25 years 
old or younger had a higher phagocytic index compared to macrophages from donors 
that were 30 to 55 years old. It has previously been reported that ageing impairs the 
phagocytic ability of macrophages (reviewed in reference373). 
 
Interestingly, in comparison to healthy apoptotic lymphocytes, when the same 
number of SLE apoptotic lymphocytes were used the phagocytic index was reduced 
in both control macrophages (mean phagocytic index 37) and SLE macrophages 
(mean phagocytic index 26) (Figure 5.7.Aii, Bii, C). This novel finding indicates that 
SLE macrophages are equally able to phagocytose healthy apoptotic cells. However, 
like healthy macrophages they are impaired in their ability to ingest apoptotic cells 
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derived from SLE lymphocytes. This suggests that the apoptotic SLE lymphocytes 
lack an intrinsic “eat-me” signal.  
 
To further examine if macrophages preferentially engulf healthy apoptotic cells, CM-
orange labelled healthy lymphocytes and CM-green labelled SLE lymphocytes 
induced to die by UV irradiation were co-incubated with control macrophages. After 
1 h uptake was measured by flow cytometry, which showed that a mean of 24% 
macrophages had phagocytosed apoptotic healthy lymphocytes, whereas only 11% 
and 7% of macrophages were positive for apoptotic SLE lymphocytes or both 
healthy and SLE lymphocytes, respectively (Figure 5.8).  
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Figure 5.7. Phagocytosis of apoptotic SLE lymphocytes is impaired. 
Beginning on the previous page, confocal microscopy images of (A) healthy donor 
macrophages (HD Mϕ) and (B) SLE patient macrophages (SLE Mϕ) that were co-
cultured for 1 h with 106 CM-green labelled UV-irradiated (i) healthy donor 
apoptotic lymphocytes (HD-AC, top row) and (ii) SLE apoptotic lymphocytes (SLE-
AC, bottom row). (C) The number of CM-green apoptotic cells (AC) found in 
macrophages (depicted by brightfield) was counted, whereas cells lying outside 
macrophages were ignored. HD Mϕ + HD-AC (, n = 9); HD Mϕ + SLE-AC ( , n = 
8); SLE Mϕ + HD-AC (n, n = 17); SLE Mϕ + SLE-AC ( , n = 5). Scale bar: 25µm. 
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Figure 5.8. Healthy macrophages preferentially phagocytose apoptotic healthy 
lymphocytes compared to apoptotic SLE lymphocytes. 
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On the previous page, (A) Gates were set on FACS plots using CD14+ macrophages 
that were cultured alone. (B) Representative FACS plots showing CD14+ healthy 
donor macrophages (HD Mϕ) following 1 h culture with 106 CM-orange labelled 
UV-irradiated healthy donor apoptotic lymphocytes (HD-AC) and 106 CM-green 
labelled UV-irradiated SLE apoptotic lymphocytes (SLE-AC). (C) The proportion of 
macrophages that had taken up HD AC (CD14+ CM-orange+), SLE AC (CD14+ CM-
green+), and both HD and SLE AC (CD14+ CM-orange+ CM-green+). n = 6. 
Statisitcal significance was assessed by one-way ANOVA. *P = 0.0204 and **P = 
0.0037. 
 
 Atg5 deficiency does not affect phagocytic uptake of 5.2.8
apoptotic cells.  
I was interested to determine if low ATG5 protein expression in SLE lymphocytes 
caused their impaired uptake by asking if autophagy proteins in apoptotic cells are 
important for their recognition by phagocytes. It was previously considered that 
autophagy was required for expression of the “eat-me” signal PS on apoptotic 
embryonic stem (ES) cells246. However, the same group have recently published a 
contradictory report, stating that PS exposure was normal in autophagy-deficient 
apoptotic cells248. Additionally, there is normal PS exposure on apoptotic Atg5-/- 
iBMKs (Figure 5.1) and SLE lymphocytes (Chapter 4), as indicated by positive AnV 
binding.  
 
To examine the role of ATG5 in apoptotic cell uptake, mouse BMDMs were cultured 
with CM-green labelled Atg5+/+ or Atg5-/- iBMK cells that were induced to become 
apoptotic by UV irradiation followed by 6 h incubation. Flow cytometry revealed 
that Atg5-deficiency did not significantly affect phagocytic uptake of apoptotic 
iBMK cells (Figure 5.9.A), with an average of 50% and 45% of macrophages 
positive for Atg5+/+ iBMKs and Atg5-/- iBMKs, respectively (Figure 5.9.B).   
 Apoptotic SLE lymphocytes are pro-inflammatory to 5.2.9
macrophages. 
Apoptotic cells are known to inhibit TLR-stimulated pro-inflammatory cytokine 
production by macrophages45,374, which is reported to require cell contact and is 
independent of phagocytosis43. Therefore, although fewer apoptotic SLE 
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lymphocytes were phagocytosed by macrophages, I was interested to determine if 
they could still bestow anti-inflammatory actions on the macrophages.  
 
Monocyte-derived macrophages were stimulated with 5ng/ml LPS, as this 
concentration induced the most TNF-α production (Appendix D Figure 3A). As 
expected, I saw a reduction in LPS-induced TNF-α production from healthy donor 
macrophages when they were co-cultured with healthy donor apoptotic lymphocytes 
(Figure 5.10.Ai). Conversely, apoptotic SLE lymphocytes significantly enhanced 
TNF-α production by LPS-stimulated healthy control macrophages (Figure 5.10.Ai). 
Furthermore, apoptotic SLE lymphocytes augmented secretion of the pro-
inflammatory cytokine IL-1β by an average of 13-fold (Figure 5.10.Aii), although 
this was not statistically significant compared to healthy apoptotic lymphocytes. 
However, apoptotic SLE lymphocytes did not affect IL-18 (Figure 5.10.C) or IFN-α 
(Figure 5.10.Ei).   
 
To assess if the increased number of necrotic cells in the SLE lymphocytes were 
responsible for the increased pro-inflammatory cytokine secretion, LPS-stimulated 
healthy control macrophages were cultured with healthy donor and SLE patient 
apoptotic lymphocytes that were made necrotic by freeze-thawing. I was surprised to 
find that the necrotic cells inhibited LPS-induced TNF-α and IL-1β secretion (Figure 
5.10.Bi-ii).  
 
SLE macrophages responded to healthy apoptotic cells in a phlogistic manner, as 
apoptotic healthy control lymphocytes failed to inhibit TNF-α production by LPS-
stimulated macrophages from SLE patients and induced more than double the 
concentration of TNF-α (Figure 5.10.D). In contrast, IL-1β (Figure 5.10.D) and IFN-
α (Figure 5.10.Eii) secretion by SLE macrophages was not enhanced by apoptotic 
healthy control lymphocytes. 
 
Although I have found no difference in the rate of apoptotic cell death of neutrophils 
from healthy donors and SLE patients (Chapter 4 Figure 4.9) I was interested to ask 
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if dying neutrophils from SLE patients were also pro-inflammatory to macrophages 
since they are associated with inflammation in SLE93,148,273. LPS-stimulated control 
macrophages were co-cultured with neutrophils, which had been induced to die by 
overnight culture in serum-free conditions. Here I found that apoptotic SLE 
neutrophils were not pro-inflammatory, as they inhibited LPS-induced TNF-α 
production by macrophages (Figure 5.11). 
 
 
Figure 5.9. Atg5-/- iBMK cells were efficiently phagocytosed by macrophages. 
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On the previous page, (Ai) Gates were set on FACS plots using F4/80+ macrophages 
that were cultured alone. Representative FACS plots of F4/80+ mouse macrophages 
following 1 h culture with CM-green labelled (Aii) Atg5+/+ and (Aiii) Atg5-/- iBMK 
cells. (B) The mean proportion of macrophages from three independent experiments 
that had phagocytosed apoptotic Atg5+/+ (black bar) and Atg5-/- (grey bar) iBMK cells 
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Figure 5.10. Apoptotic SLE lymphocytes induce pro-inflammatory cytokine 
secretion by control macrophages. 
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Control macrophages were stimulated with LPS (5ng/ml) and cultured alone and 
with 106 UV-irradiated apoptotic lymphocytes from healthy donors (HD-AC) and 
SLE patients (SLE-AC). After 18 h, the fold change in (Ai) TNF-α (n = 4 (healthy) 
and 3 (SLE)) and (Aii) IL-1β (n = 5 (healthy) and 6 (SLE)) were measured in the cell 
supernatant. (B) Control macrophages were stimulated with LPS (5ng/ml) and 
cultured alone and with 106 UV-irradiated apoptotic lymphocytes that were made 
necrotic by freezing and thawing (FT) from healthy donors (HD-FT) and SLE 
patients (SLE-FT). After 18 h, the fold change in (Bi) TNF-α (n = 3 (healthy) and 3 
(SLE)) and (Bii) IL-1β (n = 3 (healthy) and 3 (SLE)) were measured. (C) IL-18 was 
measured in cell supernatants after control macrophages were stimulated with LPS 
(5ng/ml) and cultured for 18 h alone (No AC, black bar), and with 106 control, or 106 
SLE apoptotic lymphocytes (+ AC, grey bar). (D) TNF-α (n = 9) and IL-1β (n = 11) 
secretion by SLE macrophages was quantified after 18 h stimulation with LPS 
(5ng/ml) and culture alone ( No AC) and with 106 UV-irradiated apoptotic healthy 
donor lymphocytes ( + AC). IFN-α secretion by (Ei) control and (Eii) SLE 
macrophages was measured in the supernatant following culture as described in A 
and B. Statistical significance was determined by t-test. * P = 0.0312; **P=0.0077; *** 





Figure 5.11. Apoptotic SLE neutrophils inhibit LPS-induced TNF-α production 
by control macrophages. 
(A) SLE neutrophils were stained for annexin V (AnV) and propidium iodide (PI) 
after 18 h culture in serum-free media. (B) TNF-α was measured in the supernatant 
of control macrophages that were cultured for 18h with no stimulation () and LPS 
(n) without SLE neutrophils (n = 3) and with apoptotic SLE neutrophils (n = 6). 
Statistical significance was determined by paired t-test; * P = 0.0121. 
 
 LC3-associated phagocytosis (LAP) is functional 5.2.10
in SLE macrophages. 
There was no significant functional defect in the ability of SLE macrophages to 
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did not determine if they could correctly digest their phagocytic cargo. If apoptotic 
cells are not efficiently degraded in the phagocyte’s lysosomes this can stimulate the 
production of pro-inflammatory cytokines, including TNF-α375. Therefore, since 
healthy apoptotic lymphocytes enhanced LPS-stimulated TNF-α secretion by SLE 
macrophages, I hypothesised that SLE macrophages are unable to digest apoptotic 
cells in the phagolysosome. 
 
Professor Doug Green’s lab have shown that LAP is important for the degradation, 
but not uptake, of apoptotic cells and in the absence of LAP the undigested 
phagocytic cargo can stimulate pro-inflammatory cytokine release247,250. As part of a 
collaboration with Professor Doug Green and Dr Jennifer Martinez, I co-cultured 
three-day matured peripheral blood monocytes from healthy controls and SLE 
patients with Zymosan A (S. cerevisiae) bioparticles conjugated to AF594, or CM-
green labelled apoptotic healthy donor CD4+ T cells, as described in the materials 
and methods (page 64). After 1 h, free apoptotic cells were removed, the 
macrophages were fixed and the phagocytic index was calculated.  This confirmed 
that, compared to healthy macrophages, SLE macrophages are not impaired in their 
capacity to take up apoptotic cells (Figure 5.13.A-B). Additionally, SLE 
macrophages and control healthy macrophages had the same ability to engulf killed 
yeast, with a mean of 4 and 4.5 zymosan bioparticles engulfed per macrophage, 
respectively (Figure 5.12.A-B). At the same time, the number of apoptotic cells and 
zymosan bioparticles that were surrounded by a LC3+ phagosome were enumerated. 
The mean percentage of zymosan bioparticles that were contained within LC3+ 
phagosomes in control macrophages was half of that counted in SLE macrophages; 
however this result was not statistically significant possibly due to the spread of the 
data (Figure 5.12.C). There was also no difference in the percentage of apoptotic T 
cells that were within LC3+ phagosomes in healthy and SLE macrophages (Figure 
5.13.C). These findings suggest that LAP is functioning in SLE macrophages. 
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Figure 5.12. SLE macrophages efficiently phagocytose Zymosan A (S. 
cerevisiae) bioparticles by LAP. 
Confocal microscopy images of (Ai) healthy donor macrophages (HD Mϕ) and (Aii) 
SLE patient macrophages (SLE Mϕ) that were co-cultured for 1 h with zymosan 
bioparticles conjugated to AF594 (red) at a ratio of 8:1 (8 particles: 1 macrophage). 
Macrophages were fixed and stained for LC3-associated phagosomes (green) and 
DNA (DAPI, blue). Green arrows indicate zymosan bioparticles surrounded by LC3+ 
phagosome and white arrows show zymosan bioparticles that were not enclosed 
within LC3. The red boxes indicate cells that were zoomed in on. Scale bars: 25µm 
and 5µm. (Aiii) Non-specific fluorescence of the secondary antibody goat anti-rabbit 
AF488 in cells not stained with primary antibody. (B) Quantification of the mean 
number of zymosan bioparticles counted per healthy (, n = 6) and SLE (n, n = 7) 
macrophages. (C) The mean proportion of zymosan bioparticles that were 
surrounded by LC3 in healthy (, n = 6) and SLE (n, n = 7) macrophages. No 
significant difference (ns). 
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Figure 5.13. SLE macrophages efficiciently phagocytose apoptotic healthy 
CD4+ T cells by LAP. 
Beginning on the previous page, confocal microscopy images of (Ai) healthy donor 
macrophages (HD Mϕ) and (Aii) SLE patient macrophages (SLE Mϕ) that were co-
cultured for 1 h with 106 CM-green labelled UV-irradiated healthy donor apoptotic 
CD4+ T cells (CM-green AC). Macrophages were fixed and stained for LC3-
associated phagosomes (red) and DNA (DAPI, blue). Red arrows indicate apoptotic 
cells surrounded by LC3+ phagosome and white arrows show apoptotic cells that 
were not enclosed within LC3. The red boxes indicate cells that were zoomed in on. 
Scale bars: main images 25µm and zoomed images (Ai) 7.5µm and (Aii) 5µm. (Aiii) 
Non-specific fluorescence of the secondary antibody goat anti-rabbit AF647 in cells 
not stained with primary antibody. (B) The mean phagocytic index of healthy (, n = 
6) and SLE (n, n = 7) macrophages that had engulfed apoptotic cells. (C) The mean 
proportion of apoptotic cells that were surrounded by LC3 in healthy (, n = 6) and 
SLE (n, n = 7) macrophages. No significant difference (ns). 
 
 Discussion 5.3
Autophagy defects are associated with SLE67,228-231,366, but it is not clear if autophagy 
proteins played a role in the aberrant apoptosis and impaired phagocytosis seen in 
SLE. In this chapter I have presented data to show that SLE lymphocytes have a 
reduced expression of the ATG5-ATG12 protein complex and defective autophagic 
flux. Following programmed cell death, apoptotic SLE lymphocytes also underwent 
more rapid secondary necrosis. Selective ATG5-deficiency in iBMK apoptotic cells 
also led to enhanced secondary necrosis, yet it did not affect their subsequent uptake 
by macrophages. In contrast, apoptotic SLE lymphocytes were not efficiently 
phagocytosed by healthy or SLE macrophages, and they induced phlogistic cytokine 
responses in these cells. Unexpectedly, SLE macrophages were not impaired in their 
ability to phagocytose healthy apoptotic cells. Hence the defect in phagocytosis lies 
not with the SLE macrophage but with an intrinsic defect in apoptotic SLE 
lymphocytes themselves.  
 
The safe packaging of nuclear constituents in membrane-enclosed apoptotic bodies is 
essential for promoting anti-inflammatory immune responses. In chapter four it was 
shown that apoptotic SLE lymphocytes rapidly lost cell membrane integrity 
compared to healthy donor lymphocytes. In the present chapter I show that SLE 
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lymphocytes have low ATG5-ATG12 protein expression and similarly to the SLE 
lymphocytes, a higher proportion of Atg5-deficient iBMK cells became secondarily 
necrotic following UV irradiation compared to WT iBMK cells. This indicates that 
functioning autophagy may regulate apoptotic cell membrane integrity, perhaps 
through the correct formation of apoptotic bodies.  
 
Reduced ATG5-ATG12 protein expression in SLE lymphocytes compared to healthy 
lymphocytes is a novel finding. Consequently LC3-I failed to convert to LC3-II, 
which complements previous studies230,366, but contradicts other published reports 
that show increased autophagosomes in SLE B cells229 and an over abundance of 
autophagic vacuoles in SLE T cells228. In the latter study, the number of autophagic 
vacuoles was potentially overrepresented as they included single-membrane vesicles, 
whereas autophagic vacuoles are characterised by a double membrane. However, the 
contrasting findings may be caused by the heterogeneity and disease activity of SLE 
patients, which emphasises the need for large sample sizes. 
 
SNPs in and near the Atg5 gene have been associated with SLE patients67,231, yet I 
found no statistically significant evidence for an association of the ATG5 SNP 
rs573775 and PRDM1-ATG5 SNP rs6568431 in the SLE patients studied in this 
thesis. Further analysis of additional SNPs is required to rule out the association of 
other autophagy-related SNPs. For example, it has been shown that Atg5 gene 
expression was increased in EBV-transformed B-lymphoblastoid cell lines 
expressing the PRDM1-ATG5 SNPs rs548234 and rs6937876232.  
 
SLE lymphocytes are more susceptible to undergoing apoptosis and this is likely 
caused by their lack of crucial autophagy proteins. Converting LC3I to LC3II is 
essential to stabilise the autophagosome, yet this process was defective in SLE 
lymphocytes. Therefore, autophagy cannot occur and the cell cannot survive stress, 
such as UV irradiation. It was interesting that, despite low ATG5-ATG12 protein, 
ATG5 mRNA in SLE lymphocytes was comparable to healthy lymphocytes. This 
suggests that either the mRNA failed to be translated in to protein, or the protein was 
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rapidly degraded post-translation. The findings using the protease inhibitors 
calpastatin and E-64d suggest that ATG5 may be targeted for degradation in SLE 
lymphocytes, which could be clarified utilising a time course of protease inhibition. 
Pulse-chase experiments with radioactive methionine, followed by 
immunoprecipitation of ATG5 and SDS-PAGE analysis376 would also confirm if 
ATG5 protein turnover is increased in SLE lymphocytes.  
 
Protein degradation is unlikely to occur after ATG5 has conjugated to ATG12 since 
there is no known enzyme that can break apart the isopeptide bond377. ATG7368 and 
ATG10378 are required for the attachment of ATG12 to ATG5. ATG5 also interacts 
with ATG16 via a non-covalent bond, forming the ATG12-ATG5.ATG16 complex, 
which localises to the autophagosome outer membrane379. Analysing the expression 
of these other autophagy proteins would determine if it is specifically ATG5 protein 
that is reduced in SLE lymphocytes. It should be considered that ATG5 might be 
degraded in SLE lymphocytes if it is not stabilised by ATG12 or ATG16.  
 
Apoptotic SLE lymphocytes and Atg5-/- iBMK cells both expressed the “eat-me” 
signal PS; hence autophagy machinery is not essential for PS exposure on dying 
cells. Despite this, apoptotic SLE lymphocytes were not efficiently phagocytosed by 
healthy or SLE macrophages. In contrast, apoptotic Atg5-/- iBMKs were effectively 
taken up by mouse macrophages, which supports published data showing PS 
exposure and uptake of apoptotic corpses in developing C. elegans is independent of 
autophagy protein expression in the apoptotic cell248. I have not recapitulated the 
phagocytosis defect using apoptotic Atg5-/- iBMK cells hence it is likely to be more 
complicated than reduced ATG5 expression in SLE lymphocytes. 
 
Nevertheless, dysfunctional phagocytosis does seem to be associated with a defect in 
the dying cell rather than the macrophage, as I found SLE macrophages had the same 
ability as healthy macrophages to phagocytose apoptotic lymphocytes and zymosan 
bioparticles. It could be postulated that impaired phagocytosis of SLE lymphocytes 
was caused by a higher proportion of secondarily necrotic cells; however there was 
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also 1.5-times more early apoptotic (AnV+ PI-) SLE cells compared to the healthy 
apoptotic cell feed (Chapter 4 Figure 4.8). Furthermore, it is reported that necrotic 
cells are phagocytosed by macrophages 380,381. 
 
The uptake of apoptotic SLE lymphocytes was reduced, rather than completely 
inhibited; therefore it would be interesting to investigate if the apoptotic SLE 
lymphocytes that were successfully phagocytosed released a component that 
switched off additional uptake. It cannot be concluded from my flow cytometry data 
if apoptotic SLE lymphocytes limited the uptake of apoptotic healthy lymphocytes 
when they were co-incubated with macrophages, as I did not have a positive control 
where apoptotic healthy lymphocytes were fed alone. Measuring phagocytic uptake 
of healthy apoptotic cells, or zymosan bioparticles, by macrophages in the presence 
and absence of supernatant collected from apoptotic SLE lymphocytes would assess 
if they secrete an inhibitory factor. Future work to determine why apoptotic SLE 
lymphocytes are not eaten is discussed more in chapter six. 
 
Despite the reduced uptake of apoptotic SLE lymphocytes, they induced LPS-
stimulated macrophages to secrete pro-inflammatory IL-1β. Unlike monocytes, 
macrophages require two signals to release IL-1β: the first signal (TLR activation) 
stimulates the production of the IL-1β precursor and the second signal (such as ATP, 
or LL37) activates the cleavage of pro-IL-1β to make active IL-1β141. The cleavage 
of pro-IL-1β into mature IL-1β is mediated by inflammasome-activated caspase-1 
activation142. Activated inflammasomes also processes pro-IL-18 to active pro-
inflammatory IL-18, but I did not see macrophage production of IL-18 in response to 
apoptotic SLE lymphocytes. Caspase-1 activity in the macrophages should therefore 
be measured to confirm if apoptotic SLE lymphocytes activated the inflammasome. 
It would also be interesting to determine if only the macrophages that have taken up 
apoptotic SLE lymphocytes secrete the IL-1β. This could be assessed by intracellular 
IL-1β staining and correlating it with the presence of apoptotic SLE lymphocytes 
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The inflammasome is associated with SLE pathogenesis. For example, lupus-like 
disease is reduced in mouse models deficient in caspase-1 149 and IL-1β150. 
Additionally, healthy monocytes are stimulated to produce IL-1β in response to 
NLRP3 inflammasome activation by nuclear constituents, including U1-small 
nuclear ribonucleoprotein146 and self-DNA147, which form immune complexes with 
antibodies. Apoptotic cells normally inhibit pro-inflammatory cytokine production 
and inflammasome activation382 to prevent inflammation, yet I show that apoptotic 
SLE cells provided a second (danger) signal. Again this may be attributed to the 
presence of secondarily necrotic cells. However, apoptotic healthy and SLE 
lymphocytes that were broken apart by freeze-thawing did not induce pro-
inflammatory cytokine production. Additionally, late apoptotic (secondarily necrotic) 
cells induce the same signalling pathway in macrophages as early apoptotic cells107. 
This implies that dying SLE lymphocytes are sensed by the immune system in a 
different way to healthy apoptotic cells.  
 
It has been shown that increased damaged mitochondrial ROS resulting from 
autophagy inhibition activates the NLRP3 inflammasome and IL-1β production in 
THP1 macrophages383. Therefore, I hypothesise that the autophagy defect in SLE 
lymphocytes causes impaired removal of damaged mitochondria (indicated in 
Chapter 4) and the subsequent ROS production triggers the inflammasome in 
macrophages that engulf them. Repeating these experiments with primary 
lymphocytes from autophagy-deficient mice might begin to address this. The 
potential role of inflammasomes in SLE will be discussed further in chapter six 
(section 6.1.2). 
 
Healthy apoptotic cells enhanced TNF-α production by LPS-stimulated SLE 
macrophages, which complements previous findings showing apoptotic cell-derived 
nucleic acids induced TNF-α secretion by SLE monocytes384. Phagosome-lysosome 
fusion appears normal, as indicated by LC3 association with apoptotic cell-
containing phagosomes. This is consistent with a study that recently reported an 
increase in LC3 mRNA in SLE monocyte-derived macrophages phagocytosing 
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apoptotic neutrophils385. Furthermore, if the SLE macrophages were unable to 
degrade the apoptotic cell cargo I would expect to see increased IL-1β247. Therefore, 
SLE macrophages appear primed to be pro-inflammatory, even though they express 
the same amount of TLR4 on their surface as controls386. However, SLE monocyte-
derived macrophages increase their expression of mRNA for the receptor CD93 
following phagocytosis of apoptotic cells, which enhances macrophage sensitivity to 
TLR stimulation385. This susceptibility to being pro-inflammatory would further 
augment inflammation in patients with SLE. 
 
In summary, this chapter has shown that autophagy is defective in SLE lymphocytes 
due to reduced expression of the ATG5-ATG12 complex. ATG5-deficiency results 
in increased secondary necrosis in cells dying by apoptosis. Furthermore, inefficient 
clearance of apoptotic SLE cells is caused by a defect in the apoptotic cell, rather 
than the phagocytic cell, and SLE apoptotic lymphocytes are intrinsically pro-
inflammatory to macrophages. With these novel findings it may be possible to 
develop treatments to rectify the defect in leukocyte autophagy, subsequently 
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Chapter 6 Overall Discussion 
Apoptotic cells in health induce anti-inflammatory immune regulation, even though 
they express on their surface the autoantigens, DNA, Ro, and RNP, which are 
associated with SLE6,73. The current paradigm of SLE indicates that tolerance is lost 
to apoptotic cells due to dysfunctional phagocytes and/or loss of opsonisation factors, 
which allows the progression to secondary necrosis and formation of immune 
complexes with autoantibodies. However, late apoptotic/secondarily necrotic cells 
may actually never be inflammatory in a healthy immune system50,105,387. Hence, this 
raises the question, is there something intrinsically different about apoptotic SLE 
cells that causes inflammation? Chronic inflammation in SLE is associated with IFN-
α, and pDCs responding to immune complexes are considered to be the main source 
due to their specialised ability to secrete this cytokine in response to TLR7 and TLR9 
stimulation by nucleic acids. It is now established that pDCs have heterogeneous 
functions, including an important role in maintaining tolerance through the induction 
of Tregs. Additionally, TLR9 can no longer simply be viewed as an inflammatory 
virus receptor, as it protects lupus-prone mice from TLR7-mediated disease191,192 and 
also mediates IL-10 secretion by regulatory B cells responding to self-DNA 
expressed on apoptotic cells55. This leads to a second question; do pDCs in health 
respond to apoptotic cell-derived DNA in a tolerogenic way? 
  
These unresolved questions formed the basis of the main hypothesis of this thesis, 
that apoptotic cells induce regulation through pDCs in health and an intrinsic defect 
in SLE apoptotic cells contributes to inflammation. I addressed the hypothesis by 
studying pDC responses to apoptotic cells in healthy subjects, analysing the cell 
death kinetics of lymphocytes from SLE patients, and evaluating how B cells and 
macrophages respond to apoptotic SLE lymphocytes. The following key findings of 
this study contribute to existing knowledge: 
 
1. In healthy subjects, DNA expressed on apoptotic cells induces anti-inflammatory 
pDCs, unless they are co-stimulated with a viral mimetic (Chapter 3). 
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2. Peripheral lymphocytes from SLE patients are susceptible to becoming secondarily 
necrotic and fail to enhance IL-10 secretion by regulatory B cells (Chapter 4). 
3. There is an autophagy defect and an “eat-me” defect in SLE lymphocytes, which 
are intrinsically pro-inflammatory to macrophages (Chapter 5).  
 
It is important to maintain tolerance to self, in particular apoptotic self, and this is 
achieved by the well-known anti-inflammatory reactions from professional 
phagocytes, and regulatory T cells and B cells, discussed in chapter one (section 
1.1.3). Here I show for the first time that in health, apoptotic cells control both 
regulatory and pro-inflammatory responses of pDCs depending on the co-activating 
TLR stimulus. This confirms that pDCs have heterogeneous functions depending on 
the microenvironment. This new regulatory function of pDCs may be relevant at 
homeostatic sites of apoptosis, such as in the thymus, where pDCs are already known 
to contribute to central tolerance176-178.  
 
I hypothesised that, like B cells, pDCs are stimulated to make IL-10 by apoptotic 
DNA/chromatin signalling through TLR9. I confirmed that IL-10 production is 
dependent on apoptotic DNA/chromatin (Figure 3.9 page 84), but I was surprised to 
find that the initial secretion of IL-10 is mediated in a TLR9-independent manner 
(Figure 3.10 page 87). Therefore, against the current thinking, I report that apoptotic 
cells can induce activated pDCs to secrete IL-10 and promote IL-10-secreting T 
cells. However, these results do not go as far as to contradict the general consensus 
that self-DNA is excluded from TLR9 compartments in health to maintain 
tolerance161. The extracellular or intracellular pDC receptor that recognised apoptotic 
DNA/chromatin is not defined in my study. 
 
For the first time I also demonstrate that apoptotic cells enhance IFN-α production by 
healthy mouse and human pDCs in the absence of SLE-associated immune 
complexes (Figures 3.3 page 74; Figure 4.2 page 106). Again this depends on 
apoptotic DNA/chromatin, and only occurs when pDCs are co-activated with the 
virus mimetic, CpGA. Therefore, due to the requirement of TLR9 stimulation by 
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CpGA I was unable to confirm that the apoptotic DNA was sensed by TLR9. A 
different explanation could be that apoptotic cell DNA enhanced IFN-α produced in 
the presence of CpGA as a result of entry of more CpGA into the pDC, rather than 
priming of the cell by the TLR as I suggest. However, this is unlikely since I found 
that the CpG ODNs still co-localised with the surface of apoptotic cells following the 
removal of apoptotic DNA (Appendix B Figure 2), and CpG enters pDCs easily102. 
The combination of mammalian DNA and CpGA might form a large complex that 
gets held up for longer in early endosomes hence results in enhanced IRF7 activation 
and IFN-α production. 
 
A virus-infected host may benefit from sensing self-DNA in a way that induces IFN-
α rather than inducing tolerance, since the local induction of an anti-inflammatory 
immune response can delay virus clearance388. The elevated level of extracellular 
IFN-α can feedback to augment additional pDC production of IFN-α through the 
IFNAR389, thus enhancing anti-viral immunity. It has been shown that cDCs 
phagocytosing pathogens and apoptotic cells at the same time discriminate between 
phagosomes containing microbial PAMPs from those containing apoptotic cells390. 
Consequently, cDCs respond to infected apoptotic cells by making TGF-β and IL-6, 
which together promote a protective Th17 response391. However, since virus-infected 
apoptotic cells cluster self and virus nucleic acids on apoptotic bodies265, I postulate 
that they are processed together in pDCs and once the virus particles are no longer 
co-expressed on apoptotic cells the response by pDCs ceases. This response might 
trigger autoimmunity in genetically susceptible individuals, as virus infections are 
associated with SLE64.  
 
A limitation of the present study is that I did not fully establish how apoptotic cells 
engage pDCs; although it is likely via interactions with RAGE, the significance of 
this is still unclear (Figure 3.12 page 92). In pDCs, conventional autophagy is 
essential for the recognition of ssRNA viruses253, whereas LAP is required for IRF7 
activation in response to DNA-containing immune complexes254. Furthermore, the 
production of IFN-α, but not other inflammatory cytokines, in response to DNA 
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viruses or CpGA is reduced in mouse pDCs deficient in the essential autophagy 
proteins ATG5253 and ATG7254. Therefore, in the presence of CpGA, apoptotic cell-
derived DNA may be trafficked to TLR9 in autophagosomes. In chapter four I found 
that SLE pDCs did not make IFN-α in response to co-culture with apoptotic cells and 
CpGA despite not being completely absent within PBMCs (Figure 4.3 page 109). In 
chapter five I reported that the essential autophagy protein complex ATG5-ATG12 is 
reduced in SLE lymphocytes and LC3-I fails to convert to LC3-II (Figure 5.2 page 
140; Figure 5.3 page 143). From these results, I hypothesise that, since pDCs can 
originate from lymphoid progenitors, autophagy is also defective in SLE pDCs, 
hence IFN-α secretion is reduced and they have an inability to survive. However, 
diminished numbers of circulating pDCs may indeed be caused by their recruitment 
to inflammatory sites in the SLE patients339.  
 
My data provides further evidence to support the literature that reports the non-
phlogistic nature of late apoptotic/secondary necrotic cells105, even when they are left 
lingering due to deficient phagocytic removal106. So could the current paradigm of 
SLE macrophages being unable to keep up with the number of apoptotic cells thus 
allowing them to become necrotic and consequently inflammatory be too simple? 
Indeed in this study I found that, against the existing view, defective phagocytosis is 
caused by the apoptotic SLE lymphocytes rather than SLE macrophages, which were 
fully functioning phagocytic cells (Figure 5.7 page 152; Figure 5.13 page 163). 
Therefore perhaps we need to look at the paradigm of SLE from a different angle; 
taking into account that impaired uptake of apoptotic lymphocytes is caused by an 
intrinsic defect in the dying cell. It was suggested many years ago that inflammation 
observed in phagocyte receptor-deficient mice might not occur as a result of the 
apoptotic cells progressing to secondary necrosis387. Instead, inflammation may 
reflect the presence of late apoptotic cells in the absence of anti-inflammatory 
induction through these receptors387. Additionally, the autoimmune effect of 
defective phagocytosis appears to be cell type specific, as C1q-deficient mice 
develop glomerulonephritis84, but the removal of apoptotic keratinocytes following 
UV irradiation is unaffected392. It is conceivable that C1q-deficient mice and humans 
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develop SLE due to downstream effects of the failed clearance of specific apoptotic 
cells, such as the increased exposure of innate like B cells to apoptotic cell 
autoantigens in bone marrow. This enhances IgM production by positively selected 
B1 cells89 and is supported by my results showing enhanced TLR- and apoptotic cell-
induced IL-10 production by B cells isolated from C1q-deficient mice (Figure 3.14 
page 95). It is postulated that increased IgM binding to apoptotic cells prevents the 
exposure of autoantigens that would otherwise induce negative selection of 
conventional B cells; thus autoreactive B cells escape into the periphery89. 
 
Despite the contradictory finding, the downstream effect of impaired waste disposal 
will undoubtedly still be the same, with rapid cell death increasing the availability of 
autoantigens and cell death-inducing factors provoking flares of disease symptoms. 
Combined with the fact that apoptotic SLE lymphocytes are inflammatory to 
macrophages, and they fail to induce immune regulation by B cells, it is not 
surprising that chronic systemic inflammation occurs. While I found no obvious 
defect in autophagy proteins, or LAP in SLE monocyte-derived macrophages, they 
clearly also have an unrelated defect in the handling of phagocytosed apoptotic cells, 
as indicated by elevated TNF-α (Figure 5.10 page 159). This complements a report 
that SLE monocyte-derived macrophages upregulate and downregulate different 
genes compared to healthy macrophages following the phagocytosis of apoptotic 
cells, although this study used neutrophils as the apoptotic cell feed385. 
 
Mouse and human pDCs are non-responsive to apoptotic cells that are broken apart 
by freezing and thawing (Figures 3.5 page 78; figure 4.2 page 106), which I postulate 
disrupts membrane interactions that are important for recognising DNA/chromatin. 
Expressing DNA on membrane bound apoptotic bodies is likely a mechanism used 
by the dying cells to regulate immunity, as apoptotic DNA binds complement393 
hence mediates phagocytosis, and it induces IL-10 secreting B cells55 and pDCs 
(chapter 3). Intriguingly, pDCs and B cells make a similar response to apoptotic SLE 
lymphocytes, as DNase-treated and freeze-thawed healthy apoptotic cells (Figure 
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4.13 page 128), suggesting that the presentation of apoptotic DNA has gone wrong in 
SLE.  
 
It is not clearly understood how apoptotic cells create apoptotic bodies. The current 
assumption is that, as caspase-activated ROCK1 induces the breaking apart of the 
nucleus, DNA/chromatin passively arrives at the blebbing cell membrane where it is 
subsequently released as an apoptotic body16. Yet, the fundamental process is not 
known. Our lab has observed that apoptotic Atg5-/- iBMK and MEF cell lines fail to 
form apoptotic bodies and subsequently break apart (K. Miles, K. Phadwal, J. 
Simpson and M. Gray, unpublished data), indicating that autophagy proteins are 
essential for generating apoptotic bodies. The low expression of ATG5-ATG12 in 
SLE lymphocytes may limit their capacity to make bodies and thus reduce the 
presentation of membrane-associated DNA. Interestingly, scanning electron 
microscopy detected fewer bodies in the apoptotic SLE lymphocytes (Figure 4.8 
page 120), though it is possible that they were missed due to the cells rapidly 
progressing through the stages of apoptosis.  
 Future work 6.1
The results presented in this thesis have, to a certain extent, answered my initial 
questions, by showing that pDCs do respond to apoptotic cells in health and 
apoptotic SLE lymphocytes are intrinsically pro-inflammatory. My findings have 
raised additional interesting questions, which will be investigated in the future.  
 The role of apoptotic cell-induced regulatory pDCs in 6.1.1
vivo 
One of the limitations of this thesis is that I did not establish how significant the IL-
10 produced by pDCs is, as opposed to apoptotic cell-induced IL-10 made by other 
cells. I reported that pDCs co-cultured with apoptotic cells induce IL-10 secreting T 
cells in vitro, indicating that it is likely that pDCs are important for maintaining 
regulation to apoptotic cells. The rarity of pDCs means it is difficult to examine 
pDC-specific responses to apoptotic cells in vivo without other immune cells, such as 
B cells, masking the effect. Therefore, I am commencing a study to determine if 
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IL10-secreting T cells that are induced by pDCs and apoptotic cells in vitro have a 
regulatory function in vivo. This will be achieved using the OVA-peptide system to 
assess if pDC/apoptotic cell primed T cells, when injected in to mice, suppress 
antigen-specific T cell proliferation and secretion of pro-inflammatory cytokines. 
 
Additionally, it requires further work to elucidate the signals induced by apoptotic 
cells that stimulates pDCs to make IL-10. Since the literature states that pDCs do not 
secrete IL-10 in response to TLR7/9 stimulation due to low ERK1/ERK2 
expression279 and I show that TLR9 is not essential for the initial production of 
apoptotic cell-induced IL-10 (Figure 3.10 page 87) it suggests that another pathway 
is triggered within the pDCs. The activation state of pDCs depends accordingly on 
the TLR ligand used to stimulate them. It is reported that CpGB activates p38 
expression by pDCs, whereas IFNα-inducing influenza PR/8 does not394. 
Furthermore, apoptotic cells stimulate IL-10 production in macrophages through p38 
and apoptotic cell response elements (ACRE)395. It may be that the combined p38-
mediated signaling induced by TLR stimulation and apoptotic cells is adequate to 
induce detectable IL-10 from pDCs.  
 The inflammasome and SLE 6.1.2
In chapter five I discussed the potential role for apoptotic SLE lymphocytes to 
stimulate the inflammasome in healthy macrophages since I found enhanced IL-1β 
secretion. Further work is required to elucidate how apoptotic SLE lymphocytes 
might activate inflammasomes. It is considered that immunogenic cell death cannot 
occur in the absence of autophagy due to lack of ATP release396. However, here I 
hypothesise that it is SLE DNA that is inflammatory. Oxidised mitochondrial 
(mt)DNA released following apoptosis induction activates IL-1β through the NLRP3 
inflammasome397. mtDNA damage is associated with SLE398,399, and I found that 
SLE lymphocytes contained an abnormal accumulation of mitochondria (Figure 4.12 
page 127), indicating that mtDNA may be inflammatory in SLE. However, I also 
saw dim TUNEL staining (Figure 4.11 page 124), which implies that nuclear DNA is 
incompletely fragmented. It is unclear if autophagy is required to regulate DNA 
fragmentation in mammalian cells, but in Drosophila autophagy degrades the 
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inhibitor of apoptosis, dBruce, thus permitting CAD-mediated DNA 
fragmentation400. Additionally, the autophagy pathway has recently been reported to 
play an important role in the degradation of damaged autosomal nuclear DNA partly 
through the lysosomal nuclease DNase-II401. In the absence of autophagy, damaged 
nuclear DNA initiates inflammation via STING-dependent mechanisms401. Impaired 
DNA degradation is associated with SLE, as indicated by the development of lupus-
like disease in DNase-I-/- mice402. Yet, the role of autophagy and/or the 
inflammasome in this process in SLE has not been investigated. Repeating the 
experiments with DNase added to culture medium to remove SLE DNA would 
initially determine if this is the inflammatory component. 
 Apoptotic SLE lymphocytes lack an “eat-me” signal 6.1.3
Fewer SLE apoptotic lymphocytes are phagocytosed compared to healthy apoptotic 
lymphocytes, but there is no clearance defect observed using apoptotic Atg5-/- iBMK 
cells (Figure 5.9 page 157). Therefore, although ATG5-ATG12 expression is low 
and autophagy is defective in SLE lymphocytes, the “eat-me” defect appears to be 
more complex than simply abnormal autophagy. This is supported by the fact that 
Atg5-/- mice do not develop SLE. We need to find out what is different about the 
SLE apoptotic cells that prevent them from being removed by macrophages. We 
know that PS is expressed, but although this is necessary, it is not sufficient for 
phagocytic uptake of apoptotic cells387, indicating that other “eat-me” factors are 
missing. For example, the surface expression of apoptotic DNA acts to stimulate 
phagocytosis of apoptotic cells (reviewed in reference403), but as previously 
discussed in this chapter, the correct presentation of apoptotic DNA may not occur 
on apoptotic SLE lymphocytes. Therefore the importance of DNA presentation for 
the uptake of apoptotic cells remains to be investigated. Retaining surface expression 
of a “don’t eat-me” signal, such as CD47, or CD31, would also prevent the apoptotic 
cells from being phagocytosed7. This will be explored further using the relevant 
antibodies to detect surface expression of “eat-me” and “don’t eat me” factors. 
Additionally, it still has to be investigated whether complement proteins, such as C1q 
and C3b, actually bind to the surface of apoptotic SLE lymphocytes to opsonise 
them. It should also be considered that it is not the effect of a surface receptor, but 
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the release a factor from apoptotic lymphocytes that inhibits uptake, as discussed in 
chapter five.  
 
I do not know if the “eat-me” defect is specific to SLE lymphocytes. Exposure to 
sunlight triggers a photosensitive rash and disease flares in SLE patients; so are non-
immune skin epithelial cells keratinocytes that are exposed to UV also 
unsuccessfully phagocytosed and pro-inflammatory? C1q-deficient mouse studies 
imply that disposal of apoptotic keratinocytes involves distinct uptake mechanisms 
compared to other organs, such as the kidneys392. The damaging response generated 
by UV irradiation results in the recruitment of lymphocytes339, therefore 
inflammation in the skin might be exemplified when the recruited SLE lymphocytes 
undergo abnormal apoptosis in situ. 
 Are SLE apoptotic cells intrinsically pro-inflammatory in 6.1.4
vivo?  
I have clearly shown that apoptotic lymphocytes derived from SLE patients exhibit 
pro-inflammatory actions on macrophages in vitro. It is not known though if 
apoptotic SLE lymphocytes are pro-inflammatory in vivo. This could be established 
by asking if they can confer protection against autoimmunity using in vivo mouse 
models of MS and arthritis, which has been published for healthy apoptotic cells55,56. 
It would also be interesting to determine if the pro-inflammatory effects induced by 
SLE lymphocytes are resultant from their defect in autophagy. If this were the case 
then I would expect that autophagy-deficient primary apoptotic cells would not 
protect mice from in vivo autoimmune disease.  
 Wider implications 6.2
Until now, I have focused on interpreting the meaning of my findings with regards to 
health and SLE. However, the results presented in this thesis may also have wider 
implications in other fields, such as tumours and atherosclerosis. 
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 Tumour immunity 6.2.1
PDCs infiltrate many solid tumours, such as melanoma404, breast cancer405, ovarian 
carcinoma406, and head and neck cancer407. The recruitment of pDCs is likely 
mediated by tumour-derived chemokine signals CXCL12 and CCL20, which are 
recognised by pDC-expressed receptors CXCR4 and CCR6, respectively408. It might 
be expected that pDCs would be detrimental to the tumours that they infiltrate since 
they are potent producers of IFN-α, which is key in controlling the development of 
cancer. For example, IFN-α prevents the development of tumour-associated 
macrophages (TAMs)409, augments tumour-directed NK cell cytotoxicity, and 
inhibits the proliferation of tumour cells410. However, several studies have reported 
that the presence of pDCs in tumours is associated with enhanced tumour 
progression and a negative patient prognosis405,406,411. This occurs due to the 
suppressive tumour microenvironment, which actually prevents IFN-α production by 
mechanisms including immunosuppressive cytokines TGF-β and IL-10, or ligation 
of the inhibitory receptor ILT7 by tumour cell-expressed BST2412. Consequently, 
tumour-associated pDCs are tolerogenic and secrete IDO, or express ICOS-L thus 
inducing IL-10 secreting Tregs182,185.  
 
Tumour growth, such as B cell (Burkitt’s) lymphoma and melanoma, is also 
accelerated by apoptotic tumour cells, due to the differentiation of TAMs with a pro-
angiogenic and matrix remodelling phenotype58,413. It could be postulated from the 
data I presented in chapter three, that tumour-infiltrating pDCs would contribute to 
the immunosuppressive environment by secreting IL-10 in response to tumour 
apoptotic cells. Although I failed to induce IL-10 responses using tumour cell lines 
(Figure 3.8 page 82), pDCs might be stimulated by other infiltrating immune cells 
that subsequently die in situ. My finding that apoptotic tumour cells are not 
recognised in the same way as healthy apoptotic cells is supported by the report that 
macrophages develop a distinct phenotype after phagocytosing malignant apoptotic 
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Nevertheless, after anti-cancer chemotherapy and radiotherapy, it is vital to prevent 
the repopulation of cancer cells, which is dependent on the correct balance between 
anti-tumour immunity and the immunosuppressive microenvironment generated by 
apoptotic tumour cells after therapy396. IFN-α is ideal for this due to its anti-
neoplastic properties. It is important to target IFN-α to the tumour site rather than 
systemic administration, which comes with adverse effects including depression, 
fatigue410, and in certain patients the development of lupus-like disease110. Therefore, 
utilising pDCs as endogenous sources of IFN-α for anti-tumour therapy has recently 
gained interest408,412. Imiquimod, a synthetic TLR7/8 agonist, is already used 
topically to treat skin cancers. In mice it is reported to work by TLR7-mediated 
activation of dermal mast cells, which secrete CCL2 to recruit pDCs that are 
subsequently stimulated through TLR7 to produce IFN-α414. The recruitment of 
peripheral pDCs overcomes the problem that TLR7/9-mediated IFN-α secretion is 
dysfunctional in pDCs conditioned by the tumour microenvironment. This may also 
be achieved by combining therapy with inhibitors that restore pDC function410. 
Inducing potent anti-tumour IFN-α secretion by pDCs using CpG ODN nanorings 
has showed promise in mice415. Therefore, my finding that apoptotic cells 
significantly enhance IFN-α production by pDCs compared to stimulation by CpGA 
alone could be applied to maximise anti-cancer therapy. Exploiting immune cells as 
Trojan horses to carry cancer cell-specific lytic virus has proved successful at 
preventing tumour regrowth after therapy in a mouse model of prostate cancer416. 
Using the same principle, viruses that induce apoptosis of the immune cell at the 
tumour site would potentially induce effective IFN-α production by pDCs, if I prove 
the hypothesis that CpGA mimics the co-expression of virus particles on apoptotic 
bodies with host DNA. 
 Atherosclerosis 6.2.2
Atherosclerosis describes the accumulation of fatty deposits called plaques that build 
up inside arteries eventually leading to them becoming hard and narrow417. 
Atherosclerosis is the major cause of death in developed countries resulting from 
myocardial infarction or stroke due to advanced atherosclerotic plaque rupture and 
thrombosis417. The inflammatory immune response to fatty deposits on the arterial 
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wall involves the infiltration of neutrophils and recruitment of lymphocytes and 
inflammatory monocytes, which develop into foam macrophages following the 
engulfment of fat and cholesterol. Macrophages within plaque lesions become 
apoptotic due to oxidative stress and ER stress triggered by high levels of free 
cholesterol418. As atherosclerosis progresses, inflammation fails to resolve due to the 
inefficient removal and subsequent accumulation of apoptotic plaque 
macrophages419. Consequently, the apoptotic macrophages progress to secondary 
necrosis, resulting in the development of a necrotic core that renders the plaque 
vulnerable to rupturing419.  
 
Intriguingly, SLE is associated with an increased risk of accelerated 
atherosclerosis420. This may reflect that both diseases share impaired disposal of 
dying cells. Indeed, C1q-deficiency in low density lipoprotein receptor (Ldlr)-/- mice 
causes an accumulation of apoptotic cells in early atherosclerotic plaques421. It has 
also recently been demonstrated using a combined model of SLE and atherosclerosis 
(Sle16.Ldlr-/- mice) that both nephritis and atherosclerosis are accelerated422. This 
was attributed to hyperlipidaemia-mediated elevated pathogenic C3 deposition in the 
kidneys, resulting in the depletion of protective C3 from atherosclerotic plaques, 
where complement proteins are important for removing apoptotic cells422. Therefore 
SLE potentially accelerates atherosclerosis by increased complement consumption. 
 
Furthermore, a different study published in the same year reported that defective 
autophagy may play a role in inefficient removal of apoptotic cells in advanced 
plaques423. A fully functional autophagy pathway is required to protect macrophages 
from NADPH oxidase-induced oxidative stress and apoptosis, but autophagy activity 
is reduced in advanced plaques423. ATG5-deficient mice had elevated plaque 
necrosis, but this was not caused by a defect in the phagocytic function of 
macrophages423. Instead, the study reported that the absence of the essential 
autophagy protein ATG5 in apoptotic macrophages prevented them from being 
eaten, even though there was no defect in the expression of PS423. It is not 
understood if the reduced autophagy in advanced atherosclerotic plaques is caused 
 
	  
Chapter 6: Overall Discussion 182 
by an intrinsic defect in the macrophages, or as a result of chronic inflammation and 
this requires further investigation. Nevertheless, the data presented in this thesis 
using SLE lymphocytes supports the hypothesis generated in this published study on 
macrophages, that autophagy protects cells from apoptosis-inducing stress and if this 
fails then autophagy acts to ensure the anti-inflammatory disposal of the dead cells. 
 
Based on the results I present in this thesis, the intrinsic defect in autophagy and 
reduced ability of apoptotic SLE lymphocytes to be phagocytosed also potentially 
contribute to accelerated atherosclerosis in SLE patients. It would be interesting to 
investigate if, like apoptotic SLE lymphocytes, reduced autophagy in atherosclerotic 
apoptotic cells induces pro-inflammatory responses by macrophages. This might 
define new inflammatory mechanisms involved in atherosclerosis that are synergistic 
with SLE. 
 Summary and conclusion 6.3
It is vital to maintain homeostasis in response to apoptotic cells to prevent 
autoimmunity. This thesis describes a previously unidentified role for pDCs in 
contributing to immune tolerance to apoptotic cells in health. It is considered that 
pDCs only respond to self nucleic acids in SLE due to the formation of immune 
complexes. However, in this thesis I report that in healthy subjects apoptotic cells 
boost pro-inflammatory IFN-α in the presence of a virus mimetic. In addition to the 
novel responses by pDCs, I have found that SLE lymphocytes have reduced 
expression of the essential autophagy proteins ATG5-ATG12 and consequently 
cannot convert LC3-I to LC3-II. Therefore, in the absence of functioning autophagy, 
SLE lymphocytes have a reduced ability to cope with stress, such as UV irradiation, 
and are subsequently prone to dying by secondary necrosis. SLE is associated with 
an eating defect, but I propose that this is caused by the apoptotic SLE lymphocytes 
rather than dysfunctional macrophages. Apoptotic SLE lymphocytes augment 
inflammatory cytokine production by LPS-stimulated macrophages, and they have a 
reduced capacity to induce anti-inflammatory cytokine production by B cells. I 
propose an update to the current paradigm of SLE to include the intrinsic pro-
inflammatory role of apoptotic SLE cells (Figure 6.1 and 6.2). In conclusion, the 
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results presented in this thesis suggest that an intrinsic defect in apoptotic SLE 
lymphocytes drives inflammation. If we could understand what was causing the 
lymphocytes to become a danger signal we might have a better handle on new 




Figure 6.1. An intrinsic defect in SLE apoptotic cells drives inflammation  
From the data generated in this thesis my updated hypothesis is that inflammation in 
SLE is caused by the intrinsic autophagy pathway defect in SLE lymphocytes (1) 
that leads to their reduced ability to survive stress therefore they are more susceptible 
to dying (2). I further hypothesise that the incorrect execution of the apoptosis 
pathway, inefficient uptake by macrophages (3), and induction of pro-inflammatory 
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Figure 6.2. The upated paradigm of Systemic Lupus Erythematosus 
The paradigm of SLE described in Figure 1.3 can be updated to include the data 
generated in this thesis (depicted by the blue dashed lines). Whole apoptotic cells are 
recognised by plasmacytoid DCs in the absence of autoantibody immune complexes 
(A). Plasmacytoid DCs co-exposed to CpGB/R848 and apoptotic cell-derived DNA 
are stimulated to secrete IL-10 (B). Lymphocytes from SLE patients are predisposed 
to becoming apoptotic and rapidly progress to necrosis (C).
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12 F 19  ND Normal ANA HCQ 
Figure 
4.3A-F 
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14 F 65  
Anti-Ro 
Anti-La 
Normal ANA HCQ, Mtx 
Figure 
4.3G 
15 F 51  
Anit-Sm 
Anti-RNP 
Normal Arthritis, ANA HCQ Figure 4.5 




17 F 58  
Anti-Ro 
Anti-La 





18 F 55  ND ND ANA HCQ, Mtx 
Figure 4.4, 
4.5 
19 F 22  ND Low ANA HCQ 
Figure 4.4, 
4.5 








Low ANA HCQ 
Figure 4.4, 
4.5 
22 F 65  
Anti-Ro 
Anti-La 
Normal ANA HCQ, Mtx 
Figure 4.4, 
4.5 




24 F 25  Anti-RNP   HCQ Figure 4.4 






Class III Lupus 
Nephritis, ANA 
Nil Figure 4.6 
26 F 59 1 Anti-Ro Normal  HCQ, Mtx Figure 4.6 





HCQ, Aza Figure 4.6 







29 F 22 12 Anti-dsDNA Normal 
Lupus 
Nephritis 
HCQ, Aza Figure 4.6 
30 F 20 5 
Anti-Sm 
Anti-RNP 
Normal  HCQ Figure 4.6 





ND ANA Pred, Mtx Figure 4.6 




ND ANA Aza Figure 4.6 
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33 F 66 2 Anti-dsDNA Normal ANA HCQ, MMF Figure 4.6 






Normal ANA HCQ Figure 4.6 
35 F 37 10 ND Low ANA HCQ, MMF Figure 4.6 




Normal  Mtx 
Figure 4.6, 
5.7 









Low ANA HCQ Figure 4.6 
39 F 51  
Anti-Ro 
Anti-La 




40 F 64  
Anti-dsDNA 
Anti-Ro 
Normal ANA Nil 
Figure 4.6, 
5.5 
41 F 43  Anti-Ro Normal ANA Pred Figure 4.6 
























45 F 63  ND Normal  Nil 
Figure 
4.8A-B 
46 F 36  ND Normal Alopecia Nil 
Figure 
4.8A-B 
47 F 56  ND Normal Polyarthritis HCQ 
Figure 
4.8A-B 
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51 F 66  
Anti-Ro 
Anti-La 



































56 F 62  ND ND   
Figure 
4.8A-B 
57 F 41 14 
Anti-dsDNA 
Anti-Ro 
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69 F 54  Anti-dsDNA ND   
Figure 
4.12A, 5.5 
70 F 58  Anti-Ro Normal ANA Nil 
Figure 
4.12A, 5.5 
71 F 50  Anti-Ro Normal ANA Aza 
Figure 
4.12A 












Normal  HCQ, MMF 
Figure 
4.12A 



















76 M 38  
Anti-Ro 
Anti-La 
ND   
Figure 4.9, 
5.6A 
77 F 64  
Anti-Ro 
Anti-La 
  Nil Figure 4.9 
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 ANA Nil Figure 4.9 








81 F 33  
Anti-Ro 
Anti-La 
Low Raynaud’s Nil 
Figure 
4.10, 5.4 
82 F 20  Anti-dsDNA ND Arthritis, ANA Nil 
Figure 
5.2A 
83 F 73  Anti-dsDNA ND  HCQ 
Figure 
5.2A, 5.3B 













































































Table A.1. SLE patient characteristics 










92 F 55  
Anti-Ro 
Anti-La 












95 F 37  ND ND  Nil 
Figure 
5.2A, 5.5 





Low  MMF, Pred 
Figure 
5.2A, 5.5 




98 M 22  Anti-Ro Normal  HCQ, Pred 
Figure 
5.2A, 5.5 
99 F 47  
Anti-dsDNA 
Anti-Ro 
Normal  HCQ 
Figure 
5.2A, 5.5 
100 F 35  
Anti-dsDNA 
Anti-RNP 




101 F 28  
Anti-Ro 
Anti-La 




102 F 66  Anti-dsDNA    
Figure 5.4, 
5.5 
103 F 54  Anti-RNP  Arthritis, ANA Pred, MMF 
Figure 5.4, 
5.5 
104 F 51  
Anti-Ro 
Anti-La 
 ANA Nil Figure 5.4 
105 F 37  
Anti-dsDNA 
Anti-RNP 
Low ANA HCQ 
Figure 5.4, 
5.5 
106 M 50  Anti-dsDNA  Arthritis  
Figure 5.4, 
5.5 
107 F 35  
Anti-dsDNA 
Anti-Sm 
 ANA Nil 
Figure 5.4, 
5.5, 5.6A 
108 F 77  
Anti-Ro 
Anti-La 
Normal ANA  
Figure 
5.6A 
109 F 53  
Anti-Ro 
Anti-La 
 Arthritis  
Figure 5.5, 
5.6B 
110 F 46 6  Low Renal MMF Figure 
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111 M 52 13 Anti-dsDNA Normal  Nil 
Figure 
5.10A 
112 F 75 3 Anti-dsDNA Normal ANA HCQ 
Figure 
4.13 

















115 F 34  Anti-dsDNA Low  HCQ 
Figure 
5.6C, 5.7 









117 F 42  
Anti-dsDNA 
Anti-Ro 
Normal  HCQ 
Figure 
5.6C 
118 F 67      
Figure 
5.6C 
119 F 38 4  Low Arthritis, ANA HCQ, Aza Figure 5.8 





Nil Figure 5.8 




























124 F 28 4 Anti-dsDNA Normal Rash, ANA Mtx, Pred 
Figure 
5.10A 
125 F 29      
Figure 
5.10B-C 
126 F 55      
Figure 
5.10B-C 
127 F 55      Figure 
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128 F 37  
Anti-dsDNA 
Anti-Ro 
  HCQ 
Figure 
5.11, 5.12 
129 F 45  
Anti-Ro 
Anti-RNP 
  Nil 
Figure 
5.11, 5.12 
130 F 62  Anti-dsDNA Normal  HCQ 
Figure 
5.11, 5.12 




 ANA Nil 
Figure 
5.11, 5.12 
132 F 56  Anti-dsDNA Normal ANA HCQ 
Figure 
5.11, 5.12 
133 F 48 6 
Anti-dsDNA 
Anti-Ro 
Normal ANA HCQ 
Figure 
5.11, 5.12 
134 F 24 3 Anti-dsDNA Normal  HCQ, Aza 
Figure 
5.11, 5.12 




















137 F 68 14 Anti-dsDNA Low 
Arthritis, renal, 
Raynaud’s 
MMF Figure 5.7 







139 F 77  Anti-dsDNA Normal Arthritis HCQ Figure 5.7 
140 F 64  Anti-dsDNA Normal ANA Nil Figure 5.7 




Low Arthritis HCQ, SSZ 
Figure 5.5, 
5.7 
142 F 53      Figure 5.5 








Nil Figure 5.5 
144 F 37  Anti-dsDNA   Nil Figure 5.5 
145 F 45     Nil Figure 5.5 
146 F 71  Anti-dsDNA Low Arthritis, ANA Pred Figure 5.5 





Normal Renal, ANA Pred, MMF Figure 5.5 
Table A.1. SLE patient characteristics 
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Abbreviations: ANA – antinuclear autoantibodies; Aza – azathioprine; CNS – 
central nervous system; HCQ – hydroxychloroquine; MMF – micophenolate mofetil; 
Mtx – methotrexate; ND – not done; Pred – prednisolone; SSZ – sulphasalazine. 
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Sex Age Disease Medication Figures 
1 F 47 Fibromyalgia Nil 
Figure 4.3A-F, 
4.4 
2 F 64 Rheumatoid arthritis Nil 
Figure 4.3A-F, 
4.4 
3 F 56 Rheumatoid arthritis HCQ Figure 4.5, 4.3 
4 F 19 Undifferentiated CTD Mtx Figure 4.5 
5 F 64 Rheumatoid arthritis Nil Figure 4.5 
6 F 19 Fibromyalgia, ANA HCQ Figure 4.4, 4.3 
7 F 25 Fibromyalgia Nil Figure 4.4 
8 F 49 Raynaud’s Nil 
Figure 4.8A-B, 
4.10, 5.2A-B 






10 M 46 
Severe pulmonary 
fibrosis 
 Figure 5.2A 
11 F 57  HCQ Figure 5.2A 
12 F 53 Fibromyalgia, dry eyes  
Figure 5.2A, 
5.3 
13 F 35 Rheumatoid arthritis Pre-biologic therapy Figure 4.13C 
14 F 49 Rheumatoid arthritis Biological resistant Figure 5.4 
15 F 56 Rheumatoid arthritis  Figure 5.4 
16 F 57  HCQ Figure 5.4, 5.5 
17 F 36 Fatigue Nil Figure 5.4, 5.5 
18 F 54 Rheumatoid arthritis  Figure 5.4, 5.5 
19 F 53 Fibromyalgia  
Figure 5.4, 
5.5, 5.6 
20 M 66   Figure 5.4, 5.5 
21 F 77   Figure 5.4, 5.5 
22 M 69 Wegener’s disease  Figure 5.4 
23 F 52 Arthritis HCQ, Pred Figure 5.4 
24 F 66 Rheumatoid arthritis Biologic therapy Figure 5.6, 5.8 
25 F 54 Rheumatoid arthritis Nil Figure 5.8 
26 F 43 Systemic sclerosis  Figure 5.5 
27 F 57 Systemic sclerosis  Figure 5.5 
28 F 69   Figure 5.5 
29 M 64 Swollen joints Nil Figure 5.5 
30 F 61 Osteoarthritis  Figure 5.5 
31 F 45 
Undifferentiated CTD, 
cerebral vasculitis 
 Figure 5.5 
32 F 72   Figure 5.5 
Abbreviations: CTD – connective tissue disease; HCQ – hydroxychloroquine; Mtx 
– methotrexate; Pred – prednisolone.
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Figure 1. Highly purified mouse pDCs were flow sorted from CD19-negative 
spleen. 
(A) The purity of splenocytes was assessed following the removal of CD19+ B cells 
by positive bead selection. (B) CD19- splenocytes were flow sorted by first selecting 
the CD11b- and CD3- population to remove monocytes and T cells. The PDCA-1+ 
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Figure 2. CpG associates with the surface of apoptotic cells. 
(Ai) UV-irradiated apoptotic thymocytes and (Aii) DNase-treated apoptotic 
thymocytes were cultured for 2 h with CpGB directly conjugated to AF488 (Green). 
The cells were co-stained for apoptotic DNA and chromatin using the mouse 3H9 
antibody and rabbit anti-mouse AF555 (red) and nuclear DNA using DAPI (Blue). 
(Bi) Untreated apoptotic cells and (Bii) DNase-treated apoptotic cells were cultured 
with CpGA-AF488, as described for (A). Freshly isolated live thymocytes were 
cultured with (Ci) CpGB-AF488 and (Cii) CpGA-AF488, as described in (A). 
Apoptotic cells were cultured with (Di) CpGB-AF488 and (Dii) CpGA-AF488 then 
stained with goat anti-mouse AF555 to detect non-specific binding of the secondary 
antibody. Images are representative of three independent experiments and were 
acquired on a Leica TCS SP5 (Leica Microsystems) confocal laser scanning 
microscope with a fixed stage inverted microscope DMI6000CS, equipped with a 
HCX PL APO 63x/1.33 NA oil immersion objective. Images were acquired using 
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Figure 3. Optimising pDC stimulation by synthetic TLR agonists. 
(Ai) PDCs were cultured with CpGB (10µg/ml) in the presence (grey bar) and 









Appendix B 200 
after 24 h, 48 h, and 72 h in culture. (Aii) IL-10 in culture supernatants was 
measured 72 h after pDCs were cultured with apoptotic thymocytes and CpGB at the 
following concentrations: 1, 3, 5, 10, and 20 µg/ml. (Bi) PDCs were cultured with 
CpGA (20µg/ml) in the presence (grey bar) and absence (black bar) of apoptotic 
thymocytes. IFN-α was measured in supernatants after 24 h, 48 h, 72 h, and 7 days in 
culture. (Bii) IFN-α in culture supernatants was measured 72 h after pDCs were 
cultured with apoptotic thymocytes and CpGA at the following concentrations: 1, 3, 
10, and 20 µg/ml. PDCs were cultured with R848 (1µg/ml), with (grey bar) and 
without (black bar) (Ci) apoptotic thymocytes and (Cii) apoptotic B cells. IL-10 was 
measured in the culture supernatants at the time points stated. (D) IL-10 production 
by pDCs was measured 72 h after culture with CpGB and apoptotic thymocytes (AC) 
are the following pDC:AC ratios: 1:1, 1:10, 1:25, 1:50, and 1:100. Results are 






Figure 4. pDCs co-cultured with apoptotic cells induce IL10-secreting OVA 
peptide-specific T cells independent of IDO. 
(A) IL-10 protein in cell supernatants was quantified by ELISA three days (D3) and 
seven days (D7) after DO11.10 OVA-specific T cells (1x105 /well) and OVA-peptide 
(2µg/ml) were cultured with BALB/c pDC (black bar), pDC and apoptotic cells (light 
grey bar), and apoptotic cells (dark grey bar). Results are mean plus or minus SEM 
of at least four independent experiments.  (B) OVA-specific T cells were cultured 
with pDCs, apoptotic cells and OVA-peptide in untreated media, or media treated 
with 1-methyl-D-tryptophan (1MT 200µM) to inhibit IDO activity. Results are mean 
plus or minus SEM of three independent experiments. Statistical significance was 
determined by one-way ANOVA.  **P < 0.01; ns (not significant). 
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Figure 1. Optimising human CpG stimulation. 
(A) Healthy PBMCs were cultured alone (No Stimulation) and with CpGA for 24 h, 
48 h, and 72 h. IFN-α production was measured by ELISA. (B) IFN-α was measured 
72 h after healthy PBMCs were cultured with and without apoptotic CD4+ T cells 
and CpGA at concentrations 0, 1, and 3 µg/ml. (C) Healthy B cells were cultured 
with and without apoptotic CD4+ T cells and CpGB at concentrations 0, 2, and 4 µM. 
After 72 h IL-10 in culture supernatant was measured by ELISA. Results are 
presented as mean and SEM of two independent experiments. 
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Figure 2. T cell and B cell proportions after adhering monocytes to plastic. 
(A) CD3+CD4+ T and CD19+ B lymphocytes were assessed by flow cytometry in (i) 
whole PBMCs and (ii) in the non-adherent cell population 1 h after incubation in 24-
well culture plates. (B) The mean proportion of T and B lymphocytes from four 




Figure 3. Optimising FAM-FLICA Caspase 3/7 activation kit. 
Flow cytometry analysis to assess the proportion of lymphocytes that were positive 
for active caspases 3 and 7 after FAM-FLICA staining (A) untreated cells, and 
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Figure 1. Late apoptotic/secondarily necrotic cells express ATG5-ATG12.  
(A) Western blot gel showing 55 kDa ATG5-ATG12 protein expression in untreated 
and anti-CD95 treated apoptotic Jurkat cells. β-actin was used as the loading control. 
(B) Representative FACS histograms from 1 of 2 independent experiments of 






Figure 2. Optimising TLR-stimulation of healthy macrophages. 
Control macrophages were culture with no stimulation (No stim) and with LPS 
(1ng/ml, 5ng/ml, and 10ng/ml), or R848 (0.1µg/ml and 1µg/ml). TNF-α in the cell 
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